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Abstract
Germ cell tumours (GeTs)affect both paediatric and adult populations, and can
occur either in gonadal or extragonadal regions along the body's ventral midline. These
tumours can be broadly categorized into two subgroups, seminomatous (SEM) or non-
seminomatous (N-SEM). The latter can be further subcategorized into embryonal
carcinoma (EC), teratoma, yolk sac tumour (VST)and choriocarcinoma (eC) according
to their differentiation. As in many other tumours, DNA methylation has been
proposed to be involved in GCTdevelopment. However to date, most studies were
performed using adult testicular GCTs. Furthermore, these studies only include a
handful of genes in their analysis. Thus, the roles of DNAmethylation in paediatric and
extragonadal GeTs have not been explored. Therefore, this project attempted to fill
this gap in knowledge by performing methylation analysis in a cohort of paediatric GCT
samples and GCTcell lines.
Although paediatric GCTsmostly consist of teratomas, seminomas or VSTs,only
the latter two were included in the methylation analysis as they were the only samples
in the available tumour bank. Using the methylation level of L1NE-l repeat elements as
a measurement of global genome methylation, we found that both paediatric
seminoma and VSTsamples displayed global hypomethylation as compared to somatic
controls. However, when methylation at gene promoter regions was investigated using
Illumina Golden Gate methylation arrays, seminoma and VSTexhibited very different
methylation features. VSTswere found to be highly methylated at many of the sites
investigated. Surprlslnglv, we found that the methylation features in seminoma were
similar to the somatic controls. From this analysis, we identified 85 genes that were
differentially methylated in the VSTs.However, by correlating our methylation data
with the expression array data performed by our collaborators on the same samples,
only eight of these genes (PYCARO, CASPB, C02, HOAC9, TFAP2C, ETV1, EV/2A, HLA-F)
were differentially expressed.
As in previous GCTstudies, our analysis was focused on the methylation at epG
islands. During the course of this project technological advancement led to the
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creation of new methylation arrays that offer wider genome coverage. One example is
the Infinium Methylation 450K array that covers more than 450,000 CpG sites and
includes regions flanking the CpG islands such as the CpG shores and CpG shelves.
Since no previous GCT studies have attempted to investigate methylation in those
regions, we utilized this methylation array on four GCTcell lines; TCAM2 (seminoma),
NT2Dl (teratocarcinoma), GCT27(embryonal carcinoma) and GCT44(yolk sac tumour).
Similar to previous GCT studies, we found that nonseminomatous GCT cell lines
displayed higher methylation at the CpG islands as compared to the seminoma cell
lines. Strikingly, expanding our analysis to other regions (CpG shores and shelves etc.)
revealed that each GCTsubtype exhibited distinct methylation features. Both ECand
teratoma cell lines displayed higher methylation than the seminoma and VSTcell lines
at all regions. Interestingly, the VSTcell line only showed higher methylation than the
seminoma cell line at the CpG islands and to a lesser extent at the CpG shores while
the seminoma cell line exhibited higher methylation at the CpG shelves as compared
to the VSTcell line. This is the first time such features have been reported for GCTs.
From this Infinium methylation data, we have also identified a high number of
hypermethylated genes including those that are uniquely methylated for each cell line.
By correlating this methylation data with Affymetrix gene expression data, 98 genes
that were differentially methylated and differentially expressed in the VST cell line
have been identified. However, further analysis needs to be performed to understand
the role of these genes in VSTdevelopment.
As in other types of tumour, the hypermethylation observed in the VSTcell line
might be caused by many epigenetic modifiers. Using real-time RT-PCRon three
epigenetic modifiers (DNMT38, EZH2, SUZ12), we found that DNMT38 was highly
expressed in the VSTsamples and cell line as compared to the seminoma samples and
cell line. This suggests that DNMT38 might contribute to VST hypermethylation and
resulting differences in their biology. However, knockdown of DNA methyltransferases
(DNMTs) and DNMT38 using 5-azadeoxycytidine and microRNA-29b respectively, did
not seem to have any effect on the response of all four GCTcell lines towards cisplatin.
On the other hand, both knockdowns only caused little effect on cell migration;
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affecting only the seminoma and YSTcell lines. Nonetheless, further analysis is still
needed to fully assessthe role of DNAmethylation in regulating cell behaviour.
In summary, paediatric YSTs displayed hypermethylation at many promoter
regions as compared to seminomas. Meanwhile, methylation analysis at regions
outside of CpG islands in GCTcell lines revealed unique methylation features for each
GCT subtype which might indicate different underlying mechanisms in their
development. Further analysis on genes found to be differentially methylated and
differentially expressed in both paediatric and GCTcell lines are now needed to fully
establish their role in GCTdevelopment.
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1. Introduction
DNA methylation is an epigenetic mechanism known to playa major role in
normal development such as in establishing genomic imprinting, X-chromosome
inactivation and retrotransposon silencing. However, many cancer studies have
revealed simultaneous presence of global hypomethylation and gene promoter
hypermethylation. This suggests that DNA methylation might also have a role in
tumour development.
Germ cell tumours (GeTs) are a rare tumour that can affect both children and
adults, and occur in both gonadal and extragonadal regions. Hlstologlcallv they can be
categorized into two large groups; seminomatous and non-seminomatous GeTs. In
addition to that, non-seminomatous GCTs could be further subdivided into four
subtypes according to their differentiation; teratoma, embryonal carcinoma, yolk sac
tumour and choriocarcinoma. Despite many studies conducted, the aetiology of GeTs
is still not fully understood.
As in other tumours, methylation studies performed in GeTs also revealed
similar global hypomethylation and gene promoter hypermethylation, with non-
seminomatous GeTs exhibited higher degree of hypermethylation than the
seminomatous GeTs. This implies DNA methylation involvement in GeT development.
However, these studies were quite restricted in terms of samples, which consisted only
of adult testicular GCTs,and the few genes that have been analysed. Therefore, the
role of DNA methylation in the paediatric population and extragonadal GeTs remains
to be determined. In this thesis I attempt to begin to fill in this gap in our knowledge.
1.1. Epigenetics
There is still no clear definition of the term 'epigenetics', but most researchers
would agree it involves heritable changes in gene expression and chromatin
organization without altering the DNA sequence itself (Jiang et al., 2008, Sawan et al.,
2008). The two most we" studied epigenetic processes are DNA methylation and
histone modification. At the moment only DNA methylation appears to fulfil the
epigenetic definition in terms of being heritable. The inclusion of histone modification
as an epigenetic process is still questionable as at the moment only methylation of
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lysine at histone H3 has been found to be heritable (Hansen and Helin, 2009). For the
purpose of this thesis, most of the content will revolve around DNA methylation.
However, since the histone modifications have also been linked with DNA methylation
in regulating gene expression, it will also be briefly discussed here.
1.1.1. Histone Modifications
Histone modifications refer to modifications at the N-terminal tail of the core
histones (Hl, H2, H3 and H4) in the nucleosome. These modifications could be
methylation, acetylation, phosphorylation, ubiquitylation and many others (Margueron
and Reinberg, 2010) (Figure 1.1). These modifications will then either cause 'loosening'
or 'tightening' of the chromatin by modulating nucleosome contacts to each other or
the modifications could also recruit other proteins which have enzymatic activities
that will further modify the chromatin. Two of the best studied histone modifications
are acetylation and methylation, both of which will be briefly discussed here.
Acetylation of a histone's lysine residues is believed to neutralize the residue's
positive charge, prevent chromatin compaction and reduce the interaction between
histone tails and the DNA (Shahbazian and Grunstein, 2007). This leads to more open
chromatin and promotes gene transcription. Indeed, histone acetylation can often be
found at the transcribed region of active genes and has been associated with gene
activation (Wang et al., 2008). This dynamic process is governed by two type of
enzymes; histone acetyltransferases (HATs) and histone deacetylases (HOACs). HATs
act by transferring an acetyl group from acetyl-CoA onto the E-amino group of the
lysine residues of the histone tail. Based on sequence similarities, there are three large
families of HATs. These are GCNS-related N-acetyltransferase (GNAT), p300/CBP-
associated factor (PCAF) and the MYST family. Wang et al.(2008) in their histone
profiling in human C04+T cells identified three patterns of histone acetylation. They
could be highly elevated at the transcription start site (TSS)but low at the transcribed
regions. The second pattern showed similar elevation at the TSS but gradually
decreasing across the transcribed regions and lastly both TSS and the transcribed
regions showed elevation of acetylation. The authors suggested that the first pattern
was involved in transcription initiation while the last two were involved in transcription
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elongation, since the last two patterns depended upon PCAFthat is usually associated
with the elongating form of RNAPolIl.
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Figure 1.1: Diagram showing the modification at the histone cores. These modifications could be
methylation (M), acetylation (A), phosphorylation (P), ubiquitination (U). Diagrams was taken from
Portela and Esteller (2010).
On the other hand, HDACsremove the acetyl marks from histones and restore
lysine's positive charge causing condensation of the chromation which leads to
transcriptional inactivation. Again based on the sequence homology, HDACscan be
categorized into four classes; HDACclass I (HDAC 1, 2, 3 and 8), HDACclass II (HDAC4,
5, 6, 7, 9, 10), HDACclass III (also referred to as sirtuins) and HDACclass IV (HDAC11).
It is still not clear if each HDAC has specific substrates to bind to as most of the time
they act in the form of complexes. For example HDAC1 and HDAC2 form a complex
with NuRD,SIN3A (Peinado et al., 2004) or Co-REST(You et al., 2001) while HDAC3and
HDAC4form a complex with SMRT/N-CoRfor gene repression (Fischle et al., 2002).
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Histone methylation can occur either at lysine or arginine residues. For the
purpose of this thesis only methylation at the lysine will be covered since they are
among the most widely studied modification. Unlike acetylation, histone methylation
does not have any profound effect on the residue's charge. Histone methylation can
cause gene repression or activation depending on which residue is modified and the
number of methyl groups involved (Wilting and Dannenberg, 2012). In the case of
lysine for example, monomethylation of lysine 9 on histone H3 (H3K9me) and
trimethylation of lysine 4 (H3K4me3) are associated with active transcription while
trimethylation at lysine 9 or 27 (H3K9me3 or H3K27me3) relates to transcriptional
repression (Barskl et al., 2007). This process involves the transfer of a methyl group
from S-adenosyl-l-methionine (Ado-Met) to the amino residue of the histone by
histone methyltransferases (HMTs). There are two categories of HMTs; the first
contains SET-domains (also called SET-domain protein methyltransferase family) and
the other is the DOTl family which does not have any SETdomain.
The SET-domain methyltransferase family consists of seven protein subfamilies
which Include SUV39,SETl, SET2,EZ,RIZ,SMYDand SUV4-20. Unlike HATs,each of this
SET-domain family seems to have a preference for which lysine to methylate. The
human SUV39hl from SUV39 family for instance was found to be H3K9 specific (Reaet
al., 2000) while the SETl family methylates lysine 4 on histone H3 (H3K4). On the other
hand, EZH2 from the EZ family methylates lYSine 27 on histone 3 (H3K27) and the
SUV4-20 family specifically methylates lysine 20 on histone 4 (H4K20). In contrast, the
DOTll family, which does not have any SET domain, was found to selectively
methylate lysine 79 on histone 3 (H3K79). Other histone methyltransferase family
members and their target residues are illustrated in Figure 1.2.
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Figure 1.2: Diagram showing lysine methyltransferases grouped according to the lysine residue
targeted for modification. The globular domains (histone 3 and histone 4) are shown as ovals and the
straight line represents the histone tail. Diagram taken from Martin and Zhang (2005)
Attachment of a methyl group at a lysine residue is removed by two classes of
histone demethylases (HDMs). The first known HDMs are the LSDl classwhich consists
of LSDl and LSD2 (Shi et al., 2004). Through an amine oxidase reaction, LSDl can
demethylate mono- and dimethylated H3K4 (Shi et al., 2004). Although generally
associated with gene repression, LSDl is also involved in gene activation. Formation of
a complex between LSDl and the androgen receptor has been found to be able to
demethylate the repressive mark of H3K9me2 and leads to activation of androgen
receptor target genes (Metzger et al., 2005). Meanwhile, the second class of HDMs is
proteins that contain Jumonji C domains (JmjC). Currently, 27 different JmjC domain
proteins have been identified in the human genome (Agger et al., 2008). Unlike LSD1,
they can also demethylate trimethylated H3K4 in addition to mono- and dimethylated
H3K4 (Christensen et al., 2007). Methylation at other lysine positions has also been
demonstrated; for example the UTX member of JmjC was observed to be able to
demethylate di- and trimethylated H3K27 (Lee et al., 2007).
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1.1.2. DNA Methylation
In mammalian cells, DNA methylation involves a methyl group being added to a
cytosine residue at a CpGdinucleotide site (Figure 1.3). This process is catalyzed by an
enzyme called DNA Methyltransferases (DNMT) using a methyl group donated by S-
adenosyl-L-methionine (AdoMet) (Hermann et al., 2004, Bestor, 2000). There are five
known types of DNMTs, namely DNMTl, 2, 3a, 3b and 3L, which are briefly discussed
below.
DNMT
S-adenosyl-L-methionine
Cytosine 5-methylcytosine
Figure 1.3: Diagram showing the process of adding a methyl-group to a cytosine base by a DNA
methyltransferase (DNMT). S-adenosyl-L-methionine acts as the methyl-donor in this process. Diagram
was taken from Daniel et 01.(2011).
In normal genomes, CpG methylation is found to be distributed in a unique
pattern whereby some sites display high CpGmethylation while others show low CpG
methylation. Sites with high CpG methylation correspond to pericentromeric regions,
imprinted genes and genes on the inactive X chromosome while gene promoter
regions are usually hypomethylated (Daniel et al., 2011). The function of CpG
methylation on these sites will be discussed further in this chapter.Recently,
methylation at sites other than a CpG has been reported in mouse and human
embryonic stem cells, but this non-CpG methylation level was found to be low and
variable (Ziller et al., 2011, Dodge et al., 2002, Ramsahoye et al., 2000).
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1.1.2.1. DNA Methyltrans!erases (DNMTs)
DNMTs contain two important domains (Figure 1.4); a C-terminal (also called
catalytic) domain and an N-terminal (also called regulatory) domain (Margot et al.,
2003). For DNMTl, these two domains are linked by GlyLys dipeptides. Although the
DNMTl C-terminal domain contains a motif for active methyltransferase activity, it is
not capable of any enzymatic activity on its own (Margot et al., '2000) but needs to be
activated by the N-terminal domain (Margot et al., 2003). Abundant DNMTl is
targeted to replication foci (Daniel et al., 2011) and this is believed to be due to the
presence of a DNA binding region in its N-terminal domain (Leonhardt et al., 1992). In
addition to this, a preference of DNMT1 towards hemimethylated CpGs suggests its
involvement in maintaining the DNA methylation pattern (Bacolla et al., 2001).
Furthermore, the presence of a proliferating cell nuclear antigen (PCNA) binding
domain (Leonhardt et al., 1992) and polybromo homology domain in DNMT1 (Liu et al.,
1998) (Figure1.4) implies that it has the ability to bind to newly replicated DNA, thus
supporting its role in maintaining methylation patterns. Mutation of Dnmtl in EScells
produced cells with a severely demethylated genome (Li et al., 1992) with high
frequencies of deletions and rearrangements (Chen et al., 1998). This mutation also
proved to be lethal in mouse embryos which showed biallelic expression of imprinted
genes and activation of Xist gene on X chromosomes (Beard et al., 1995, LI et al.,
1992).
Unlike DNMTl, both DNMT3A and DNMT3B show a lack of interaction between
the C-terminal and the N-terminal domains with the C-terminal domains being
catalytically active alone (Gowher and Jeltsch, 2002, Margot et al., 2003). Meanwhile, a
PWWP domain in the N-terminal domain has been shown to be essential for DNMT3A
and DNMT3B localization and directing methylation at major satellite repeats in the
pericentromeric region (Chen et al., 2004). Both DNMT3A and DNMT3B also showed
no preference towards hemimethylated CpGs and are scattered throughout the
nucleus (Daniel et al., 2011, Margot et al., 2001). This has earned them the title of 'de
novo methyltransferases' believed to function in setting up methylation patterns in
previously unmethylated DNA. However, such titles are not exclusive as in vitroanalysis
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shows that DNMTl can also act as a de novo methyltransferase (Hsieh,
200S).Homozygous mutation of either Dnmt3a or Dnmt3b proved to be fatal in mice
(Okano et al., 1999) while heterozygous mutation of the C-terminal domain of
DNMT3B resulted in demethylation of satellite sequences and has been linked to the
development of immunodeficiency, centromeric instability and facial anomaly (ICF)
syndromes (Xu et al., 1999).
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Figure1.4: Structure of DNA methyltransferases.Among the domains and motifs found at the N-
terminus of DNMTl are PCNA binding domain (PBD), a targeting sequence (TS), a cysteine-rich region
(C), and a polybromo homology domain (PBHD). Among the shared motifs in DNMTl and DNMT3 are
tryptophan-rich region (PWWP) and another cysteine-rich region (e-rich). At the C-terminus, all the
highly conserved motifs are represented by a vertical bars although here only motifs I, IV and X are
labelled. Diagram was taken from Margot et 01.(2003).
Unlike the DNMTs described above, DNMT2 does not show any enzymatic
activity even though it has an apparent active methyltransferase motif in its C-terminal
domain (Margot et al., 2003). In line with this, genome methylation was found to be
unaffected in Dnmt2 mutant mice (Okano et al., 1998). DNMT3L was also found to be
catalytically inactive believed to result from the lack of a required domain for DNA
methyltransferase activity (Cheng and Blumenthal, 2008). However unlike DNMT2,
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Dnmt31 has been found to aid Dnmt3a in establishing methylation of maternally
imprinted genes in mice (Hata et al., 2002, Kaneda et al., 2004).
1.1.3. Links between Histone modifications and DNA methylation
DNA methylation and histone repressive marks are commonly observed in
compacted chromation while chromatin with unmethylated DNA usually displays a
high level of acetylated histone, an active histone mark. This suggests an intricate link
between these two epigenetic modifiers in gene regulation. However, which one acts
as an initiator in this process is still unresolved.
DNA methylation can directly regulate gene transcription by resisting the
binding of transcription factors (Mulero-Navarro et al., 2006, Kulak et al., 2012).
However, links between DNA methylation and histone modification can occur
mediated by methyl-binding proteins (MBPs). MBPs are characterized by a methyl-CpG
binding domain (MBD) and all MBP members (MBDl-4, MeCP2) except MBD3 show
preferential binding to methylated CpGs (Fraga et al., 2003). In contrast, another MBP
called Kaiso does not have the same methyl-CpG binding domain but still preferentially
binds to methylated CpGs via zinc finger domain recognition (Prokhortchouk et al.,
2001).
MBD1 has been suggested to participate in dissemination of the H3K9
methylation histone modification in a new DNA strand by recruiting the H3K9
methyltransferase, SElDB1 (Sarraf and Stancheva, 2004). Only during DNA replication,
they form a complex with the chromatin assembly factor, CAFplSO. This complex was
further found to interact with PCNA, which is known to bind to DNMTl during
replication (Figure 1.5). It is believed that this process leads to heritably maintained
H3K9 methylation marks on the new strand since knockdown of MBD1 using siRNA
resulted in loss of H3K9methylation at multiple loci.
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Figure 1.5: Maintenance of histone methylation mark by MBD. a) MBDl recruits SETDBl and
established H3K9 methylation marks, b) during replication phase, DNMTl forms a complex with
proliferating cell nuclear antigen (peNA) at the replication fork. At the same time, MBDl and SETOBl
form a complex with CAFp150 and facilitates the establishment of H3K9 marks at the newly replicated
methylated DNA, c) newly establish H3K9 methylation marks on the new DNA strand. Figures taken from
Klose and Bird (2006)
Another MBP protein, MeCP2, has been associated with the histone
methyltransferase that is specific to lysine 9 (H3K9) (Fuks et al., 2003). The
differentially methylated domain (DMD) of the H19 gene, which is a MeCP2 regulated
gene, was found to have a high level of H3K9 methylation when the MeCP2 level was
high. However, in a Tet-Off MeCP2 cell line where the MeCP2 level was decreased by
the addition of tetracycline, this reduction correlated with a low level of H3K9
methylation at H19 DMD. This suggests that H3K9 methylation at H19 DMD is
regulated by MeCP2. Beside this, MeCP2 has also been found to associate with the
mSin3A-HDAC co-repressor complex to repress Bdnf gene transcription (Chen et al.,
2003).
On the other hand, Okamoto et al. (2004) observed that during the mouse
embryo X-inactivation process, H3K27 and H3K9 methylation occurred at very early
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stage even before de novo DNA methylation occured. Furthermore, in an experiment
performed in Neurospora crass a, mutation of H3K9 by changing the lysine residue to
leucine or arginine caused an abolishment of almost all DNA methylation (Tamaru and
Selker, 2001). This suggests that histone modification might have some Influence over
DNA methylation.
Based on the finding that DNMT3L can interact with unmethylated H3K4 (Ooi et
al., 2007), a model has been proposed for how H3K4 methylation might be involved in
establishing DNA methylation in early development (Cedar and Bergman, 2009)(Figure
1.6). During this period, H3K4 methyltransferase is believed to be recruited by RNA
Polymerase II, which is abundantly found at CpG islands. Therefore at this region, H3K4
residues are methylated while at other regions they are unmethylated. Meanwhile, de
novo methylation was carried out by DNMT3A and DNMT3B which formed a complex
with DNMT3L. Since DNMT3L can only bind to unmethylated H3K4, DNA methylation
could not be established at the CpG islands where H3K4 is methylated. This could
explain why CpG islands in normal tissues are generally unmethylated.
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Figure 1.6: DNA methylation establishment through histone methylation during embryonic
development. During pre-implantation, most CpGs are unmethylated (light purple circles). However,
some regions are in the nucleosome that contains methylated lysine 4 at histone H3 (Me). During
implantation, de novo methyltransferase (DNMT3) facilitated by its binding partner, DNMT3l can only
bind to unmethylated lysine 4 resulting in methylated CpGs (dark purple circles). Meanwhile a DNMT3-
DNMT3l complex could not bind to methylated lysine 4, thus leaving these CpGs as unmethylated.
Diagram taken from Cedar and Bergman (2009)
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1.1.4. DNA methylation in normal development
DNA methylation plays major roles during human development,among which
genomic imprinting, X chromosome inactivation and repressing repetitive element
transcription (McCabe et al., 2009) which will be briefly discuss here.
1.1.4.1. Genomic Imprinting
Genomic imprinting refers to a mechanism of gene regulation that results in
parental-specific expression of these genes (Ferguson-Smith, 2011, Bartolomei, 2009).
In other words, the affected genes will only be expressed from one allele (either
maternal or paternal) while the other allele is silenced. Disruption of this process can
lead to male infertility (Poplinski et al., 2010), neurodevelopmental disorders such as
Prader-Willi and Angelman syndrome (Horsthemke and Wagstaff, 2008), growth
disorders such as Beckwith-Wiedermann and Silver-Russell syndrome (GicqueJ et al.,
2005, Reik et al., 1995) and also has been implicated in tumour development (Kaneda
and Feinberg, 2005).
Imprinted genes are usually located in a cluster that contains one non-coding
RNA (ncRNA) and also an imprinting control region (lCR) (O'Neill, 2005). ICRscontrol
the imprinting of genes in these clusters and these ICRs are usually methylated
(Lucifero et al., 2002). Of all ICRstested, all but one revealed a role for DNMT3A and
DNMT3L in establishing methylation at these ICRs (Hata et al., 2002, Kaneda et al.,
2004). Using crystallography, Jia et al. (2007) showed that the tetra mer complex of
DNMT3A and DNMT3L contains two active sites. These active sites were able to
methylate two CGdinucleotides at once with a preference towards CGpairs that were
eight to ten base pair apart. Since this feature is only observed in the maternally
methylated imprinted loci but not in the paternally methylated imprinted loci, it is
believed that both DNMT3A and DNMT3l are involved in establishing the imprinting at
the maternal allele. Another mechanism that has been suggested for maternally
methylated imprinted loci was by interaction between DNMT3l and the unmethylated
lysine 4 of histone H3 which leads to recruitment of DNMT3A2 (Ooi et al., 2007). On
the other hand, methylation of the paternally methylated Rasgrjl ICR involved
Dnmt3b. This is believed to be due to the abundance of repetitive sequence
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surrounding Rasgr/l (Kato et al., 2007). While the DNMT3 family has been recognized
to establish imprinting, DNMT1 has been established to function in maintaining the
imprinting (Li et al., 1993). However in preimplantation embryos, imprinting is believed
to be maintained by a combination of oocyte-specific Dnmtl (Onmtlo) and Onmtl due
to the low level of the latter during this period of time (Cirio et al., 2008).
1.1.4.2.X-chromosome Inactivation (XCi)
X-chromosome inactivation (XCi) represents a gene dosage compensation to
equilibrate sex-linked genes between males (XY)and females (XX).This inactivation will
render one female X allele silenced and inactive (Xi) while the other X allele remains
active (Xa).This process is regulated by Xist, which is transcribed from a specific site on
the X-chromosome called the X-inactivation center (XIC).Xist appear to be involved in
counting and selecting X chromosomes for inactivation (Lyon, 2002). This is especially
true in the cases of supernumerical X chromosomes (XXY, XXX) where there could
otherwise be two active X chromosomes. Usually for embryonic lineages, either the
maternal or paternal X chromosome will be inactivated, but for extra-embryonic
lineages, it is the paternal X chromosome that is preferentially inactivated (Figure 1.7)
(Lyon, 2002). This is also referred to as imprinted type X-inactivation. To inactivate an
X-chromosome, it was found that Xist is required in cis (Penny et al., 1996). In addition
to that another gene was found called Tsix that overlaps with Xist in the opposite
direction (Lee et al., 1999) and overexpression of Tsix was found to inactivate Xist
(Stavropoulos et al., 2001). Therefore, Tsix appears to regulate Xist and this is
particularly true for the imprinted type X-inactivation. In this particular type of
inactivation, Tsix is imprinted itself resulting in expression only of the maternal allele.
Therefore, Xist is only expressed from the paternal X-chromosome which leads to
inactivation of that chromosome (Sado et al., 2001). Once X-inactivation occurs, Xist on
the Xa chromosome is repressed by methylation in order to maintain the
chromosome's activity (Lyon, 1999)
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Figure 1.7: Diagram showing the X-inactivation process that occurs in the mouse embryo. Xp and Xm
represent X-chromosomes of paternal and maternai origin respectively. Thick line represents the Xist
RNA while short arrows represent active transcription. X inactivation center is represented by oval
shape. In the early stage, Xist RNA is only expressed from Xp and not Xm due to paternal imprint. This
imprint is retained in the extraembryonic lineages and with further counting mechanism and
developmental factor (dotted line), Xp is inactivated. In the embryonic lineages, this imprint Is lost and
Xist RNA is expressed in both Xp and Xm. This is followed by random inactivation where one allele is
inactivated (hatched line) and in the active allele, Xist is switched off (black oval). Diagram taken from
Lyon (2002)
DNA methylation with DNMT activity is believed to playa role in X-inactivation
since Dnmtl mutant mice could not maintain the repression on the Xi (Sado et al.,
2000). Using the methylated DNA immunoprecipitation (MeDIP) assay, it was found
that inactive X (Xi) display higher methylation at both promoter and the intergenic
regions (Sharp et al., 2011). Interestingly, these authors found that significant numbers
of CpG Islands (CGI)exhibited reduced methylation at the Xi and the majority of these
CGI positions correlated with those genes that escape XCI. This supports the
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involvement of DNA methylation in XCI.Furthermore, demethylating agents have been
shown to reactivate genes on the Xj(Mohandas et al., 1981) which further implies a
role played by DNA methylation in X-inactivation.
1.1.4.3. Retrotransposon silencing
DNA methylation in normal cells also represses transposable elements such as
retrotransposons. These retrotransposons originated from provirus insertion into the
human genome millions of years ago, and represents almost 40% of the human
genome(Goodier and Kazazian,2008).
Retrotransposons can be subcategorized into two groups; autonomous which
have the necessary apparatus for mobility, and non-autonomous which do not.
Autonomous retrotransposons consist of two groups; the long terminal repeat (LTR)
form and non-long terminal repeat (non-LTR) form. An example of an LTRis the human
endogenous retroviral (HERV), however they have lost their ability to move because
they no longer encode functional proteins (Goodier and Kazazian, 2008, Prak and
Kazazian, 2000). The only HERVfamily believed to be functional in human is HERV-K
since antibodies have detected them in germ cell tumour cell lines and testicular
cancer patients (Goedert et al., 1999). Nonetheless, to date, no mobilization of HERV
retrotransposons has been demonstrated. On the other hand, another autonomous
retrotransposon, LlNE-l (Ll), which belongs to the long interspersed nuclear element
(LINE)family, is believed to be the most active retrotransposon in the human genome.
It occupies almost 17% of the human genome. Full length L1 is 6 kilobases in length
and consists of a 5' untranslated region (UTR), two open reading frames (ORFl and
ORF2) and a 3'UTR that ends with a poly (A) signal and tail (Goodier and Kazazian,
2008) (Figure 1.8). ORF2 encodes a protein with endonuclease and reverse
transcriptase activities while ORFI is believed to be essential for retrotransposition
(Alisch et al., 2006). Although only a few thousand of these full length LIs' are left in
the genome, there are still a handful of them considered to be active (Sassamanet al.,
1997). Other well known transposons are non-autonomous retrotransposon such as
Alu in human and B1 in mice. Alu belongs to the short interspersed nuclear elements
(SINE)family and unlike L1, they do not have any ORFin their structure. Due to this, it
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is believed that they require help from other mobile element such as Ll for their
mobilization (Deininger and Batzer, 1999).
Although not yet proven, retrotransposition of L1 and Alu is believed to
involved mechanism called target-primed reverse transcription (TPRT).Through this
retrotransposition, these repeat elements could cause deletions, duplication or gene
sequence rearrangements. It has also been postulated that repeat element insertion
could have an impact on nearby gene expression (Cruickshanks and Tufarelli, 2009,
Weber et al., 2010a, Wolff et al., 2010). Therefore by repressing these repeated
sequences, DNA methylation helps to maintain the integrity of the human genome.
Indeed a knockout study in mouse has shown that Dnmt3a, Dnmt3b and Dnmt3/ are
required for SINEB1and LlNE1methylation (Kato et al., 2007).
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Figure 1.8: Diagram showing the domains of both autonomous and non-autonomous
retrotransposons. Autonomous retrotransposons can be categorized into long terminal repeat (LTR) and
non-long terminal repeat (Non-LTR). Both have the necessary accessory for mobilization but only LlNEl
known to be actively mobile. Meanwhile Non-autonomous retrotransposon such as Alu relied upon Ll
for their mobility. Abbreviations: Gag: group-specific antigen, Prt: potease, Pol: polymerase, Env:
envelope, RT: reverse trascriptase domain, INT: integrase domain, T5D: target site duplication, LTR: long
terminal repeat, EN: endonuclease domain, C: zinc knuckle domain, An: poly(A), AlB: A- and B- box Pol III
promoter. Diagram taken from Goodier and Kazazian (2008).
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1.1.5. DNA methylation in cancer development
1.1.5.1. Global hypomethylatlon
Genome-wide hypomethylation has been identified in many types of cancer.
Numerous studies have shown the presence of global hypomethylation not only in the
early stage of cancer but also have been linked to the progression of cancer (Jacksonet
al., 2004, Park et al., 2009b, Roman-Gomez et al., 2008, Yegnasubramanian et al.,
2008).
The mechanism behind global hypomethylation in cancer is not yet fully
understood. However, many possible factors have been postulated. A hypothesis that
genome hypo methylation in tumours may be due to the presence of precancerous cell
that have undergone senescence. Studies to support this theory have shown reduced
DNA methylation observed in senescent human fibroblast genome prompting a
possible link between senescence and DNA demethylation (Suzuki et al., 2002).
Fibroblast approaching senescence showed reduced activity of DNA
methyltransferases (DNMTs) (Vertino et al., 1994). Meanwhile fibroblast that escapes
senescence showed cessation of DNA demethylation but still retain low level of
genome methylation (Vertino et al., 1994). This process is believed to be mediated
either by active form of retinoblastoma gene (RB) or an increase in p21. Both of these
mediators of senescence have been found to interact with DNMT1. RB for instance
was found to bind directly to DNMTl and reduce DNMTl methyltransferase activity
(Pradhan and Kim, 2002). In addition to that, inactivation of pRb pathway In murine
prostate epithelial cells was found to lead to elevation of DNMTl expression level and
gene hypermethylation (McCabe et al., 200S) which suggest DNMTl regulation by RB.
Meanwhile, p21(WAF1}, a cell cycle regulator was found to disrupt the interaction
between DNMT1 and proliferating cell nuclear antigen (PCNA) needed during DNA
replication and repair (Chuang et al., 1997). This might suggest the regulation of
methylation by p21.
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Another factor that may contribute to genome hypomethylation is cell hypoxia.
In tumours, it has been shown that necrotic tissue occurs due to lack of blood and
oxygen supplies. Experiments performed in glioblastoma, colorectal and melanoma
cell lines that were cultured under hypoxic condition were found to show low level of
short interspersed nuclear elements (SINE) and S-methylcytosine, respectively,
indicating loss of methylation (Pal et al., 2009, Shahrzad et al., 2007). It was postulated
that hypoxia caused the reduction in S-adenosylmethionine from inactivation of
methionine adenosyltransferase (Shahrzad et al., 2007). Since S-adenosyltransferase
act as a methyl donor during cytosine methylation, its reduced level may affect
genome methylation.
Even though there is evidence towards genome hypomethylation it is not clear
how it contributes to hypomethylation. Among the postulated contrlbutlon of genomic
hypomethylation to tumour development is by causing overexpression of oncogenes
and expression of cancer testis antigen (CTA) that were usually repressed in normal
cells (De Smet and Loriot, 2010). This is based on studies that showed overexpression
of oncogenes associated with hypomethylation. Among those genes were MYC and
HRAS in gastric carcinoma (Fang et al., 1996), TCLl in Burkitt's lymphoma (Yuille et al.,
2001), and TKTLl in head and neck squamous cell carcinoma (HNSCq (Sun et al.,
2010). Meanwhile methylation studies performed in leukemia, melanoma and
colorectal cancer samples revealed activation of cancer testis antigen HAGE, MAGE-Al
and MAGE-A3 respectively (Roman-Gomez et al., 2007, Kim et al., 2006, Loriot et al.,
2006). This activation was found to be correlated with the hypomethylation of the
gene promoter region.
Beside activation of normally repressed genes, hypo methylation was also
thought to cause genomic instability. In an experiment, global hypomethylation was
observed in DNMTl hypomorphic mice which have only 10% of the wild type DNMTl
expression (Gaudet et al., 2003). Furthermore, these Dnmtl hypomorphic mice
developed aggressive T-cell lymphomas which feature high level of chromosome 15
trisomy. In subsequent study by the same group, insertion of Dnmtll hypomorphic
allele in mice carrying mutation of neurofibromatosis 1 and pS3 caused the
37
development of sarcomas at an earlier age as compared to the same group of mice
with normal methylation level (Eden et al., 2003). They also found that the
hypomethylated cells showed significant increase in loss of heterozygosity (LOH) rate
as compared to the methylated cells. Thus, they suggest that DNA hypomethylation
promotes tumour development through chromosomal instability.
DNA hypomethylation has also been suggested to cause activation of repeat
elements and leading to tumourigenesis. Hypomethylation is believed to enable
mobilization of the repeat elements and creates genome instability. Indeed, studies in
colorectal, lung cancer and HNSCC have associated hypomethylation of repeat
elements with genomic instability detected through the use of microsatellite markers
and microarray (Daskalos et al., 2009, Martinez et al., 2012, Ogino et al., 2008).
However, to .date no study has yet shown a direct link between activation of repeat
elements and genome instability. In fact, Howard et 01.(2008) in their experiment
found that the expression of the intracisternal A particle (lAP), an endogenous
retroviral-like element found in mice, was only elevated in the induced-tumour of the
Dnmtl hypomorphic mice but no significant increase was observed prior to tumour
development. Since Dnmtl hypomorphic mice have previously displayed genomic
instability(Eden et al., 2003), there is a question of whetheractivation of the repeat
elements are just a consequences of further demethylation events and therefore have
no effect on genomic instability. On the other hand, another avenue where activation
of repeat elements might contribute to tumourigenesis is by activating transcription of
adjacent genes. LlNE-l repeat elements for instance have a bidirectional promoter in
its sequence; a sense promoter that transcribe its two open reading frame and an
antisense promoter that can trancscribe adjacent genes (Speek, 2001). Indeed, many
studies in multiple type of cancer have shown the presence of genes that were
transcribed by L1 antisense promoter (Lt-ASP) (Lin et al., 2006, Roman-Gomez et al.,
2005, Weber et al., 20l0a, Wolff et al., 2010). In fact in one of these studies, truncated
isoform of MET proto-oncogenes transcribe by Lt-ASP in acute myeloid leukemia
patients has been associated with increased risk of progression into blast crisis
(Roman-Gomez et al., 2005).
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Despite all these studies, none have shown conclusive evidence that can
directly link global hypomethylation and tumourigenesis. Thus this area might be
worth investigating in the future.
1.1.5.2. Promoter hypermethylation
Another common feature of cancer is the hypermethylation at gene promoter
region. Although both genome-wide hypomethylation and promoter hypermethylation
often observed together in many cancers, studies suggest the two events may not be
linked (Ehrlich et al., 2002, Ehrlich et al., 2006, lee et al., 2009).
Unlike genome-wide hypomethylation, contribution of the promoter
hypermethylation to tumour development has been pin-pointed to its effect in causing
gene silencing. As mentioned before, this could be achieved by direct inhibition of
transcription factor binding or through mediation of methyl-binding protein (MBP).
However, the mechanism behind the selection of genes to be methylated is still
unclear. One hypothesis proposed that specific genes were preferentially inactivated in
order to provide selective clonal growth advantage. In one study, mice with
overexpressed Myc which developed immature T cell lymphoma, were crossbred with
mice deleted for tumour suppressor gene (either p53, Pten or E2f2) (Opavsky et al.,
2007). Strikingly, each genotype showed different CpG island methylation pattern and
using unsupervised hierarchical clustering, each genotype segregated perfectly. This
suggests that the loss of tumour suppressor function led to selective pressure on the
cells and caused specificity of CpG island methylation.
Another hypothesis suggests that promoter methylation might have developed
by targeting DNMTs to certain region in the genome and/or the regions possess a
feature that made them a better substrate for methylation. This is based on the finding
that PML-RAR,an oncogenic fusion protein is able to direct DNMTs to its target genes
(Di Croce et al., 2002). In addition, DNA binding studies have shown that Kaiso, a
methyl binding protein, required two adjacent methylated CpG for DNA binding. Any
nucleotide in between these two methylated CpGswas found to disrupt Kaiso binding
to the DNA (Prokhortchouk et al., 2001). Analysis of MeCP2 bound DNA fragment was
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found to have four or more A/T basesadjacent to the methylated CpGand this feature
was essential for MeCP2 binding to its target genes such as Bdnf and D/x6 (Klose et al.,
200S).
Promoter hypermethylation is thought to deliver the 'second-hit' as proposed by
Knudson in his theory of 'two-hit' model (Knudson, 2001). This model proposed that
loss of tumour suppressor genes function could only occur if both of its allele is
inactivated. Indeed, studies of familial cancer have shown that when one of the gene
allele is mutated, promoter hypermethylation in the wild type allele will lead to gene
inactivation (Kim et al., 2003, Ohtani-Fujita et al., 1997, Grady et al., 2000). In contrast,
BRCAl germ-line mutation observed in familial breast and ovarian cancer was rarely
found in the sporadic form of both cancers (Berchuck et al., 1998, Merajver et al.,
1995, Futreal et al., 1994). Instead in this form, loss of function of BRCAl has been
shown to be due to promoter hypermethylation in association with loss of
heterozygosity (LOH) in the other allele (Dobrovic and Simpfendorfer, 1997, Esteller et
al., 2000b). This suggests promoter hypermethylation is enough to cause loss of
tumour suppressor gene function. Indeed, subsequent methylation studies revealed
many tumour suppressor genes that are silenced only by promoter hypermethylation.
Cheung et 01.(2009) in their review of methylation studies have listed down 14 genes
commonly found to be hypermethylated in multiple type of cancer. Among them are
genes involved in cell cycle (CDKN2A/p16-INK4, CDKN2B/p15-INK4B), cell growth
(RARB), DNA repair (MGMT, MLH1), apoptosis (DAPK, TP73), metastasis (CDH1),
detoxification (GSTP1), hormone response (ESR1), Ras signaling (RASSF1) and Wnt
signalling (APC}. Clearly, silencing of these genes by methylation offers an advantage
for tumour growth and development.
The recent introduction of genome-wide methylation technology revealed new
information on promoter hypermethylation in cancer. From these genome-wide
studies, it was found that promoter methylation in cancer were not restricted to the
CpG islands but can also be found in regions adjacent to the CpG islands called CpG
shores (Irizarry et al., 2009, Saied et al., 2012, Shen et al., 2013). Furthermore,
methylation at the CpG shores has been found to be more correlated to gene
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expression as compared to methylation at the CpG islands (Irizarry et al., 2009). This
finding has shifted the paradigm on how methylation affects tumour development
since previous studies were focusing only on CpG islands methylation. In addition to
this, genome-wide methylation analysis also enable researcher to map tumour
methylomes and studies revealed that each tumour displayed a distinct and unique
methylation profile (Figueroa et al., 2010b, Houshdaran et al., 2010, Martinez et al.,
2009, Wu et al., 2010a). Furthermore, genome-wide analysis could also distinguished a
distinct phenotype in tumours which displayed hypermethylation of a subset of genes
(Arai et al., 2012, Noushmehr et al., 2010, Shinjo et al., 2012, Weisenberger et al.,
2006). This so-called CpG island methylator phenotype (CIMP) has also been found to
be associated with poor prognosis in renal clear cell carcinoma and lung cancer (Arai et
al., 2012, Shinjo et al., 2012, Takai and Jones, 2002)
Although a plethora of studies have linked promoter methylation to gene
silencing, promoter hypermethylation has also been associated to higher frequency of
mutation. Studies performed in colorectal cancer showed that MGMT
hypermethylation was linked to significantly higher frequency of transition mutation of
TP53 and KRAS as compared to unmethylated MGMT (Esteller et al., 2001, Esteller et
al., 2000c). The same finding was observed in low grade astrocytoma where majority
(92%) of low grade astrocytoma with MGMT hypermethylation showed significantly
higher G:Cto A:T transition mutation of TP53 as compared to those with unmethylated
MGMT (39%). This suggests that promoter methylation might also contribute to
tumourigenesis by causing genetic changes.
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1.2. Germ Cell Tumours (GCTs)
A germ cell tumour is a tumour believed to derive from germ cell progenitors.
Since most studies available were performed in adolescence and young adults with
testicular GCTs,all discussion here will be about these unless otherwise stated. To
have a better understanding of how a germ cell might transform into a tumour, it is
essential to know how germ cell develop and function in normal conditions.
1.2.1. Germ cell development
Primordial germ cells (PGCs)arise from a population of pluripotent cells in the
epiblast. In mice, they are visible at embryonic day 7.5 (E7.s) as a group of 20 cells at
the base of the allantois (Donovan, 1995). Their fate has been earlier determined
during gastrulation, around E6.S, via bone morphogenetic signalling (BMP) and other
undetermined signal from surrounding tissue (Saga, 200S, Saitou et al., 2002). These
epiblast cells are also regulated by B-Iymphocyte-induced maturation protein 1
(Blimpl or the human homolog PRDMl) which is essential in PGCspecification as it
repressed expression of somatic genes such as the Hox family genes (Ohinata et al.,
2005). Other than Blimpl, a recent study also identified another transcriptional
regulator, Prdm14 that displays a similar function in preserving PGCs as germ cell
(Yamaji et al., 200S). Knockdown of either gene showed loss of PGCspecific markers
and an increase in Hox gene's expression (Kurimoto et al., 200S, Ohinata et al., 2005).
After the specification stage, PGCsstart to initiate their migration from the
primitive streak into the endoderm around E7.s before entering the hindgut (ES.O-
E9.s). From there, they migrate into the mesoderm before continuing to the genital
ridge (E10.5-Ell.s) (Anderson et al., 2000, Molyneaux et al., 2001). At the moment,
the mechanisms involved in initiating PGC migration are still not well understood.
Using RNA interference, Tanaka and his group found that silencing of interferon-
induced transmembrane protein 1 (I!itml) in mouse embryos prevented PGCsfrom
migrating into the endoderm, suggesting that this gene is involved in regulating PGC
migration (Tanaka et al., 2005). However, a recent study in mice carrying a deletion of
this gene showed normal germ cell migration (Lange et al., 200S) which makes l!itml's
role in initiating PGCmigration questionable. Other genes that have been identified in
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the PGCmigration process are SOX17 (Hara et al., 2009), SDF-l and its receptor CXCR4
(Ara et al., 2003, Takeuchi et al., 2010) and c-kit and its ligandstee/{Gu et al., 2009,
Runyan et al., 2006}. Mutant Sox17 mice were found to have failure of hindgut
expansion which leads to immobilization of PGCsin the hindgut. The majority of these
PGCswere observed to move into the visceral endoderm layer and relocate outside of
embryonic gut, resulting in PGCsscattered in the extraembryonic yolk sac endoderm
{Hara et al., 2009}. While SOX17 is crucial in early PGC migration, SDF-l and its
receptor CXCR4 was found to be important in the late migration phase {Ara et al.,
2003, Takeuchi et al., 2010).SDF-l is a member of a family of chemoattractive
chemokines and is expressed around the genital ridges while CXCR4 is abundantly
expressed on PGCs.It is believed that PGCsmigration into the genital ridge depends
upon this interaction (Figure 1.9) since knockdown of either one of these genes in mice
will significantly reduces PGCnumbers in the gonad (Ara et al., 2003). In addition to
that, induced expression of Sdfl outside of the gonad region was found to attract PGCs
resulting in PGCsaccumulating at these ectopic sites (Takeuchi et al., 2010). On the
other hand, PGCscontinuously express c-kit and the somatic cells along the migration
route expressed steel which implies the importance of this Signalling throughout PGCs
migration (Richardson and Lehmann, 2010, Keshet et al., 1991). A hypomorphic
mutant of KitL (steel) in mice showed impairment in PGCsmigration with the majority
of them ended up in the hindgut region (Mahakali Zama et al., 2005) believed to be
due to impairment in PGCmotility (Gu et al., 2009). Once PGCsarrive at the genital
ridge, PGCsbecome known as gonocytes. Depending on the micro-environment, they
undergo different fate decisions. In the male micro-environment, they will enter
mitotic arrest and become pre-spermatogonia while in the female environment they
enter meiosis I arrest, during which they become oocytes.
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Figure 1.9: Mechanism behind PGCsmigration towards the genital ridge. Interaction between CXCR4
and SDF-1 will guide PGCs towards the genital ridges. Interaction between steel and c-kit helps PGCs
migration by regulating the PGCsmotility. Diagram taken from Richardson and Lehmann (2010)
1.2.1.1. Epigenetics in Germ Cell Development
Around the time of PGC specification, epigenetic marks related to
transcriptional repression, such as DNA methylation, dimethylation of lysine 9 of
histone H3 (H3K9me2) and trimethylation of lysine 27 of histone H3 (H3K27me3) were
observed and seem to be similar to those in somatic cells (Seki et al., 2005). During the
migration period, extensive epigenetic modification occurs. Starting at E7.5 and E8.0,
H3K9me2 and DNA methylation marks start to decrease while H3K27me3 mark is
upregulated beginning at E8.2s and reaching a significant level at E9.s (Seki et al.,
2007). Decrease in H3K9me2 has been proposed to be due to downregulation of a
methyltranferase called GLP that is required for H3K9 methylation (Tachibana et al.,
2005, Hackett et al., 2012). It is also believed that upregulation of H3K27me3 is to
compensate for the decrease in H3K9me2 and retaining the genome repressive state
(Sasaki and Matsui, 2008).
By comparing the DNA methylation profile of E7.s epiblast and E13.s PGCs,
Guibert and his group showed extensive demethylation occurred during this
timeframe. In support of previous studies, they found high methylation at intergenic
regions and gene bodies in E7.S epiblast (Borgel et al., 2010, Smallwood et al.,
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2011)but this was erased in El3.S PGes(Guibert et al., 2012). They identified 511 gene
promoters that were heavily methylated at E7.5 epiblast and the majority of these
promoters were demethylated in E13.S PGes. Interestingly, the affected genes were
not restricted to germ line specific genes but also included genes with somatic
function. Guibert and his group also showed that some genes start the demethylation
process at much earlier stage, at E9.5 and complete this by ElLS. This is in contrast to
previous studies of imprinted genes which showed demethylation between EIO.5 and
El2.S (Hajkova et al., 2002, li et al., 2004). They conclude that imprinted and non-
imprinted genes underwent demethylation at different stage of PGe development.
Interestingly, lAP and LTR-ERV1,repeat elements in mice were found to be able to
resist both waves of demethylation, thus supporting the importance of repressing
these elements. Despite this, Guibert and his group proposed that methylation erasure
in PGesis more complete as compared to those in pre-implantation embryos (Saitou et
al., 2012) and suggested that PGesare the main site of reprogramming (Guibert et al.,
2012).
1.2.2. GCTsclassifications
1.2.2.1. Histology
Germ cell tumours (GCTs)can be classified into two group, seminomatous and
non-seminomatous, based on their histology. Seminomatous GeTs consist of
undifferentiated cells that resemble germ cell progenitors. They are also known by a
number of terms depending on the tissue where they arise. In the testis,
seminomatous GeT are called seminomas while in the ovary, they are also known as
dysgerminomas. For those that arise at extragonadal sites, the term germinoma has
also been used. For the purpose of this discussion, the term seminoma will be used to
represent all seminomatous GeTs.
On the other hand, non-seminomatous GeTs consist of more differentiated
cells and their histology varies, resembling different stages and pattern of either
embryonic or extra-embryonic differentiation. From this histology, non-
germinomatous GeTs can be further categorized into embryonal carcinoma (EC),
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teratoma, yolk sac tumour (YST) and choriocarcinoma (CC). Most EC consist of
undifferentiated cells which are able to differentiate into many cell types thus
suggesting them to be the stem cells of GCTs(van de Geijn et al., 2009, Kristensen et
al., 2008). On the other hand, teratomas represent somatic differentiation while YSTs
and CCsdisplay extra-embryonic differentiation (van de Geijn et al., 2(09).
1.2.2.2. Multifactorial classification
Another type of GCT classification is based on a combination of parameters.
This includes cell of origin, histology, genomic imprinting status, age at diagnosis, and
chromosomal constitution (van de Geijn et al., 2009, Oosterhuis and looijenga, 2005).
This type of classification is believed to be much better in helping clinical diagnosis and
treatment choice and has been recognized by World Health Organization (WHO).
Following this classification, GCTscan be categorized into five entities.
Type I GCTsrepresent teratomas and YSTsthat occur in neonates and infants.
Type II represents the most common GCT,which occurs in young adults. Similar with
Type I, type II GCTcould occur in the gonad and extragonadal sites. Both types were
believed to arise from PGCsalthough in Type I the PGCsresponsible are still at earlier
stage than PGCsprecursor in Type II. Type III GCTis testicular GCTsthat are restricted
to men over SO years old. Rather than PGCs,precursor lesion for this group of GCTsis
believed to be spermatogonium or spermatocyte since they showed paternal
imprinting. Meanwhile, type IV GCTsoccur only in females over SO years old and are
believed to arise from oogonia or oocytes. The last group, called type V consists of
hydatiform moles that have developed from the fertilization of a non-nucleated egg,
these usually occur in the placenta or uterus.
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1.2.3. GCTsepidemiology
Germ Cell Tumours (GCTs) can arise in the gonads where germ cells are
normally found, but also can be found in extragonadal sites. These extragonadal sites
are usually along the body midline such as in the coccyx, thorax and the ventral midline
of the brain.
1.2.3.1. Adult GCTs
In a recent epidemiological study carried out using 8 regional registries In the
UK, the majority of GCTpatients were male with an overall adjusted incidence rate of
26.44 per-million person-year (Arora et al., 2012). The majority of GCTscases were
testicular GCTs(92.5%) followed by ovarian GCTs(3.9%) and extragonadal GCTs(3.2%).
The most common extragonadal GCTsIn the adult population are mediastinal
and retroperitonium (Schmoll, 2002). In general, non-seminomatous GCT is more
common than seminomatous GCT at extragonadallocations with non-seminomatous
usually present in younger patients (Schmoll, 2002)
Another extragonadal GCT, intracranial GCT,represents a smaller proportion of
adult GCTs in the West. However, the incidence in Japan and the Far East is five to
eightfold greater. Most intracranial GCTsconsist of germinoma and normally arise in
the suprasellar and pineal region of the brain although other parts of the brain can be
affected.
1.2.3.2. Paediatric GCTs
From the data available concerning the incidence amongst paediatric
population, a bimodal distribution of age was observed only in male patient diagnosed
with gonadal GCTs(Johnson et al., 2009, Murray and Nicholson, 2009). As illustrated in
Figure 1.10, the incidence of gonadal GCTsin this sub-population usually peaks before
3-years old and after puberty. Meanwhile for female gonadal GCTs,the incidence only
starts to increase from 6-years of age again peaking around puberty. Beside bimodal
distribution, testicular GCTsin paediatric patients also present with distinct histology
associated with these age groups. Testicular GCTs in infants and toddlers
predominantly consist of teratoma (mature and immature) or yolk sac tumour while
the adolescents showed similarity with the adult population which consist of
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seminoma, embryonal carcinoma or choriocarcinoma (Horton et al., 2007, Rosset al.,
2002, Schneider et al., 2004). On the other hand, ovarian GCTsconsist of teratoma
followed by seminoma, yolk sac tumour, embryonal carcinoma and mixed tumour
regardless of age (Horton et al., 2007).
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Figure 1.10: Graph showing the incidence rate of GCTs in Great Britain from 1962 to 1997. It clearly
showed that the incidence of gonadal GCT in male are at highest either during infancy or during teen
age while female GCTs usually arise during teen age years. On the other hands, intracranial GCTs
incidence is at the highest before or right after birth. Diagram was taken from Murray and Nicholson
(2009).
Extragonadal GCTs in children are commonly found in those aged less than 5
years old (Gobel et al., 2000, Veltman et al., 2003) although they can also arise in the
adolescent. The most common extragonadal GCT in the paediatric population is the
saccrococcygeal tumours (SeTs) (Horton et al., 2007). This could be categorized into
two types; the benign form which usually arises in the neonatal period or the
malignant form with intra-pelvic or intra-abdominal tumour involvement which usually
presents between birth and 4 years old (Horton et al., 2007). Beside SCTs,mediastinal
and retroperitoneum GCTsalso arise in the paediatric population although they are
quite rare representing only around 5% of all GCTs in this age group (Horton et al.,
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2007, Billmire et al., 2001). Despite this, 15% of these type of GCTcan be malignant
and have a poor outcome (Billmire et al., 2003, Billmire et al., 2001).
The incidence of intracranial GCTs in the paediatric population varies
geographically. In Western countries, they account for 0.4-3.4% of all paediatric brain
tumours but in Japan and Asian countries, this incidence could be as high as 11% of all
paediatric brain tumours (Echevarria et al., 2008). Males usually present with tumours
in the pineal region while in females, tumours at the suprasellar regions are most
common. Histologically, younger children usually present with non-seminomatous
histology while seminomatous histology is more common in older children (Echevarria
et al., 2008)
1.2.4. Risk factor to GCTs
Certain factors have been found to increase the chances of getting GeTs, in
particular testicular GeTs.These include family history (Forman et al., 1992, Hemminki
and Chen, 2006) and previous experience of GCTs(Wanderas et al., 1997). However,
efforts to identify genes responsible for familial TGCThave been quite a challenge due
to small sample sizes (Rapley et al., 2000, Lutke Holzik et al., 2004, Rapley et al., 2003).
A genotyping study has identified that individuals with gr/gr deletion at Y
chromosomes have an increased two-fold risk of TGeT and this increases to three-fold
if the individual has a family history of TGeT (Nathanson et al., 2005). This might be
linked to infertility as this gr/gr deletion removes AZFc regions on the Y chromosomes
which have been associated with reduced fertility{Ferlin et al., 200S).An environmental
cause has also been proposed to influence the chances of getting TGCT.This is based
on observation of Finnish immigrants in Sweden who have lower risk for TGCT, but
develop the same risk as Swedish population in their second generation (Hemminkl
and Ll, 2002).
Men with infertility problems have also been identified as at a higher risk for
TGCT(Doria-Rose et al., 2005, Baker et al., 2005). In addition to this, the risk of getting
TGCTis even higher in this population if they showed a presence of minutes particles
in the testis, also known as microlithiasis (de Gouveia Brazao et al., 2004). Beside this,
low sperm count has also been suggested as a risk factor for testicular cancer. This was
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based on association studies that showed Danish and Norwegian men have higher
incidence of testicular cancer and low sperm count as compared to Finnish and
Estonian men respectively (Jensenet al., 2000, Jorgensen et al., 2002). Other testicular
dysgenesis syndromes (TDS)such as cryptorchidism and undescended testis were also
recognized as TGCT risk factors (Looijenga et al., 2007). In fact, cryptorchidism is the
only congenital abnormalities found to be associated with paediatric GCTsin a recent
study conducted by Children's Oncology Group (Johnson et al., 2009). These
reproductive abnormalities are postulated to occur due to high estrogen exposure
during fetal life according to the estrogen hypothesis, and this definition has been
expanded to other endocrine disruptors that can cause similar disruption in hormonal
balance (Sharpe, 1993, Sharpe and Skakkebaek, 1993). Indeed, estrogen has been
shown to suppress androgen production and insulin-like factor 3 that leads to
cryptorchirdism and birth defects of the urethra (Sharpe, 2003). Other chemicals have
also been suggested to be able to alter hormonal function such as certain phthalates
and polychlorinated biphenyls (Fisher et al., 2003, Sharpe, 2003). However, until now
no direct cause has been established between hormonal imbalance and GCTs.
Males with Klinefelter syndrome, characterized by multiple X chromosomes, has
been associated with higher risk of extragonadal GCTs(Hasle et al., 1995, Aguirre et al.,
2006) with majority of them were germinoma (Kaido et al., 2003, Inai et al., 2005).
Meanwhile, individuals with skeletal defects, mental retardation and congenital heart
disease have also been identified to have higher risk for extragonadal GCT(Johnson et
al.,2009)
1.2.5. Origin of GCTs
1.2.5.1. Gonadal GCTs
Gonadal GCTsare believed to arise from carcinoma in situ (CIS),also known as
intratubular germ cell neoplasia, unclassified (ITGCNU).CISis a lesion characterized by
enlarged, atypical germ cells (Reuter, 200S), believed to develop from gonocytes/PGCs
that are arrested in their development.This is supported by the similarities in gene
expression profile between CISand gonocyte (Sonne et al., 2009) and the finding that
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genes involved in testicular development are differentially expressed in CIS (Hoei-
Hansen et al., 2004). This theory of CIS as the precursor lesion for gonadal GCTs is
based on the observation that patients with CIShave a tendency to develop invasive
GCTs (Skakkebaek, 1978). Furthermore using a mathematical modelling, it was
predicted that 50% of patient with unilateral GCTsand positive with CISwill develop
invasive GCTswithin 5 years (von der Maase et al., 1986). Indeed, CISare usually found
adjacent to the invasive GCTs (Jacobsen et al., 1981, Reuter, 2005). Recent
morphological analysis has further shown the presence of intratubular seminoma and
intratubular embryonal carcinoma adjacent to invasive GCTsand, this was suggested
to be the intermediate stage between CISand invasive GeTs (Oosterhuis et al., 2003).
This came as no surprise since CIS,seminoma and embryonal carcinoma do share some
similarities in terms of gene expression and chromosomal constitution (Almstrup et al.,
2004, Sperger et al., 2003, Summersgill et al., 2001, Looijenga et al., 2000). In fact, the
only thing that sets CISapart from the invasive GCTsis the absence in chromosomal
gain of 12p (Rosenberg et al., 2000). Even more striking is that this gain of 12p is first
detected at the preinvasive state (Ottesen et al., 2003). Therefore, it has been
suggested that gain of 12p is important for the development of invasive GCT
(Rosenberg et al., 2000, Summersgill et al., 2001). However, this model is only
applicable to gonadal GCTs in young adults as the paediatric population does not
shares similar aneuploidy, the full erasure of imprinting and 12p amplification seen in
adults (Bussey et al., 2001b, Schneider et al., 2001). Instead, partial erasure of
imprinting pattern in the paediatric GCTssuggests that they arise from early PGCs,
possibly before they enter the gonad and become gonocytes (van de Geijn et al., 2009,
Reuter,2005).
1.2.5.2. Extragonada/ Gas
Unlike gonadal GCTs,the origin of extragonadal GCTs is still contentious. The
current accepted theory is based on PGCsdisplacement during migration, however
another theory that involves stem cells has more recently been proposed.
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1.2.5.2.1. PGCmigration theory
The germ cell migration theory states that extragonadal tumours arise from
displaced PGCs during their migration towards the genital ridge. These PGCs are
usually displaced along the migration route which is along the body midline. Later, due
to local environmental cues, these displaced PGCs will undergo reactivation and
proliferate to form tumours(Teilum, 1958, Teilum, 1965, Takeuchi et al., 2009)
This theory is supported by the finding that extragonadal and gonadal GCTsin
young adults shares many similar characteristics suggesting they both arise from PGCs.
Both of them share 12p amplifications (Looijenga et al., 2003), similar expression
profiles (Palmer et al., 2008, Sperger et al., 2003) and epigenetic profiles (Netto et al.,
2008, Furukawa et al., 2009).
This is further supported by previously mentioned studies which showed PGCs
have a tendency to stay outside the gonad after deletion of SOX17, SOFt, CXCR4or
steel (Mahakali Zama et al., 2005, Ara et al., 2003, Hara et al., 2009, Takeuchi et al.,
2010). Furthermore, Bax mutation has been shown to favour the accumulation of PGCs
outside the gonad regions (Runyan et al., 2008). All of these imply many possibilities
that extragonadal tumour may arise from PGCsthat are displaced during migration.
1.2.5.2.2. Stem Cell theory
Unlike previous theories relating to PGCmigration, this theory proposed that
extragonadal GCTsarises from cells localized to the tissue where the tumour occurs.
However at the moment, studies that support this idea came from studies conducted
in neural progenitor (Tan and Scotting, 2012). Thus, further discussion will revolve
around neural progenitor cells and intracranial GCTs.Teratoma, a subtype of GCTs,is
able to give rise to all three germ layers and is thus regarded as pluripotent. Therefore,
it has become a standard in reprogramming studies that cells need to be able to form a
teratoma before they can be considered as pluripotent. Indeed it has been proven that
this can be achieved by just overexpressing four key genes in the somatic cells such as
fibroblast (Takahashi and Yamanaka, 2006). This study therefore suggests that not just
PGCs,but any cells could have the ability to give rise to teratoma. In addition to this, a
further study in mouse neural stem cells (mNSCs)showed that reactivation of only one
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out of these four key genes, Oct4, was enough to induced mNSCs to become
pluripotent and give rise to a teratoma (Kim et al., 2009). The reason behind this is the
expression of all pluripotency genes except Oct4 in the brain. A study in mice has
showed that Oct4 expression in the brain starts to decline after embryonic day 8.5
(E8.s) and becomes undetectable after Els.s and this decline was found to coincide
with methylation of the Oct4 promoter region (Lee et al., 2010). Interestingly, a recent
animal study showed that demethylation using s-azadeoxycytidine can reactivate Oct4
expression (Lim et al., 2011). If this finding can be applied to human cells, it would
mean that a disruption of methylationwould allow continuous expression of OCT4 in
neural stem cells and might allow them to be transformed into teratoma. Thus it has
been proven that NSCscould give rise to teratomas, but could NSCsforms the other
subtypes of GCTs?Given that GCTsoften have a mixed histology (Taccagni et al., 1989)
and several reports showed GCT recurrence as another subtype following resection
(Wong et al., 2010, Sugimoto et al., 2002) suggests that all GCTsshares common cell
lineage. Thus, the suggestion has been made that OCT4 activation could initiate
teratoma formation from NSCswhich after some time could convert into any subtype
of GCTs(Tan and Scotting, 2012).
Other evidence that links NSCsas the cell of origin for extragonadal GCTscome
from studies looking into the profile of imprinted genes such as SNRPN. Study in mice
showed that during gametogenesis, Snrpn is unmethylated and expressed at the
paternal allele while in the maternal allele it is silenced by methylation(Shemer et al.,
1997). Furthermore, lack of SNRPN methylation has not been associated with other
type of tumours like other imprinted genes have (Zhan et al., 1995, Kohda et al., 2001).
Thus, its restricted methylation pattern in GCTs and PGCs suggested that SNRPN
imprinting pattern could be used to determine the PGCdevelopmental stage at which
the tumour arises (Schneider et al., 2001). Indeed, studies have shown that both
gonadal and extragonadal GCTs exhibited PGC-like pattern of SNRPN methylation
(Bussey et al., 2001a, Schneider et al., 2001) which ledthe authors of both papers to
conclude that PGCscould be the cell of origin for extragonadal GCTs.However, recent
methylation analysis using restriction enzyme and bisulfite sequencing on human NSCs
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also showed hypomethylation of SNRPN that resembles PGCsand GCTs (lee et al.,
2011). This therefore also supports the possibility of NSCSas the cell of origin for
intracranial GCTs.
1.2.6. Aberrant DNA methylation as potential mechanism In paediatric GCT
development
Paediatric germ cell tumours (GCTs) like other childhood cancers, develop in
quite a short time, with most of them occuring within the first fiveyears after birth or
even while still in the womb. Thus, there is little time for cells in the paediatric
population to accumulate a series of mutations. This was evident from a recent study
that screened 70 paediatric GCTsamples for BRAF and KRAS mutation (Masque-Soler
et al., 2012). In this study, BRAF V600E point mutation and KRAS mutation at codon 12
and 13, both previously shown to be presence in adult GCTs(Honecker et al., 2009),
were screened using Sanger sequencing and pyrosequencing. Comparing their data to
previous study performed in adult GCTs(Honecker et al., 2009), this group found no
evidence of mutation in all paediatric samples analysed. This finding was not restricted
to paediatric GCTs, as genome wide screening studies performed in other paediatric
cancers such as retinoblastoma (Zhang et al., 2012) and glioblastoma
(Schwartzentruber et al., 2012) also revealed less frequent mutations as compared to
the same tumour type in the adult population. In addition to that, paediatric GCTssuch
as teratoma subtypes have been shown to have little or no cytogenetic damage
(Oosterhuis and looijenga, 2005, Mostert et al., 2000, Rickert, 1999). This suggests
that in this class of GCT,mutations and DNA damage may not be the main culprit in
causing dysregulation of gene expression. Thus, other mechanisms such as DNA
methylation could be responsible for such rapid development of GCTsin the paediatric
population.
As mentioned before, DNA methylation plays a major part during PGC
development. Therefore, any disruption to this regulation would result in abnormal
PGCsdevelopment that could lead to tumour formation. Thus, methylation studies in
these populations are warranted to further improve our understanding of these
tumours.
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1.2.7. Previous studies in GCTs
1.2.7.1. DNAmethylation study
Among the first evidence of differences in methylation between seminomatous
and non-seminomatous GCTcame from a study that looked into the methylation of
the 5' region of two X-chromosome genes, hypoxanthine phosphoribosyltransferase
(HPRn and phosphoglycerate kinase (PGK) (Peltomaki, 1991). Using methylation
sensitive restriction enzyme digestion, they found that teratocarcinoma samples
displayed hypermethylation in both genes. In contrast, seminoma samples featured a
hypomethylated pattern resembling active X-chromosome genes. Similar findings were
also found when they expanded their analysis to other chromosomal regions leading
them to conclude that teratocarcinomas in general display hypermethylation
characteristics while seminomas are usually hypomethylated.
In another study using restriction landmark genomic screening (RLGS) to
measure the 5-methylcytosine (5-mC) level across the genome, it was also found that
non-seminomas possessed much higher 5-me levels (an average of 1.11%) as
compared to the seminomas with an average level of 0.08% 5-me (Smiraglia et al.,
2002). The same finding was observed when using immunohistochemical staining of 5-
me as a measurement of the methylation level in GeT samples (Wermann et al., 2010).
Despite having higher methylation than seminoma, both seminomas and non-
seminoma were found to show significant hypomethylation of lINE-1 repeat elements
when compared to other tumours of somatic tissue origin (Ushida et al., 2011). Since
the lINE-1 methylation level has been shown to be a good surrogate for measuring
global methylation level (Estecio et al., 2007), this suggests that GeTs in general are
hypomethylated across the intergenic regions of the genome. Based on these studies,
it can be concluded that most GCTsusually display global hypomethylation of lINE-1
repeat elements.
Besides global hypomethylation, all cancers analysed so far feature
hypermethylation at gene promoter regions, and GeTs are no exception. Adopting a
candidate gene approaches, among the genes found to be hypermethylated in
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testicular GCTsare MLHl and p16'NK4 (using a real-time PCRand methylation sensitive
restriction enzymes respectively) (Chaubert et al., 1997, Olasz et al., 2005). In their
study, Olasz et al. (2005) found that 21.6% of testicular GCTsshowed methylation of
hMLH1 while Chaubert and his group showed methylation of p161NK4 in half of their
testicular GCTsamples. Unfortunately, these studies did not provide any methylation
data for the different types of GCTs samples analysed. However, looking at other
methylation studies performed in testicular GCTs (listed in Table I. I) it is clear that
non-seminomatous GCTsare characterized by a higher number of hypermethylated
promoters as compared to seminomatous GCTs.To date, only two genes, SORBSl and
GSTP1, have been shown to be hypermethylated in seminomas (Koul et al., 2002, Lind
et al., 2006). Even then, both genes are only methylated in 5% (1/20 samples) and 3%
(1/29 samples) of the seminoma samples respectively. Clearly, more data is needed to
confirm these findings.
One study comparing seminoma, teratoma and YST, showed that the latter
were found to have a significantly higher number of methylated tumour suppressor
genes (TSGs) as compared to the former two (Furukawa et al., 2009). In fact, YST
comprise the majority of non-seminomatous GCTsthat have methylated genes in most
of the methylation studies performed in testicular GCTs.Furthermore, at the moment,
five genes (APC, RASSF1A, HOXA9, SCGB3Al and HIC1) have been shown to be
hypermethylated in 100% of the YSTsamples analysed (Koul et al., 2002, lind et al.,
2006). Interestingly, YSTs have also been shown to have a higher number of
methylated tumour suppressor genes as compared to other childhood solid tumours
such as neuroblastoma, hepatoblastoma and Wilm's tumour (Furukawa et al., 2009).
Other genes that were also found to be methylated in non-seminomatous
testicular GCTsare XPA1, EMX2, MSXl (Lind et al., 2006) and NME2(Koul et al., 2002).
However, the number of non-seminomatous GCTsamples that showed methylation of
these genes was too small.
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Genes Percentage of samples exhibiting References
methylation (%)
Seminoma Non-seminoma
APC 0-11.6 24-85 (Honorio et al., 2003, Koul et al., 2002,
Koul et al., 2004, Okpanyi et al., 2011,
Brait et al., 2012)
RASSFIA 0-78 21-84 (Furukawa et al., 2009, Lind et al., 2006,
Tian et al., 2011)
HOXA9 0-11 26-88 (Furukawa et al., 2009, lind et al., 2006)
PRS521 86 87 (Manton et al., 2005, Kempkensteffen et
al.,2006)
RUNX3 0-11 3-80 (Furukawa et al., 2009, lind et al., 2006,
Kato et al., 2003)
MCAM 32.6 71.4 (Brait et al., 2012)
MLH1 27.9 71.4 (Brait et al., 2012)
MGMT 0-24 20-69 (Honorio et al., 2003, Koul et al., 2002,
Koul et al., 2004, Smith-Sorensen et al.,
2002, Brait et al., 2012)
fR-6 27.9 64.3 (Brait et al., 2012)
5100 0 57.1 (Brait et al., 2012)
SCGB3A1. 0-11 52-54 (Furukawa et al., 2009, lind et al., 2006)
VGF 16.3 SO (Brait et al., 2012)
DCR2 11 44 (Furukawa et al., 2009)
HIC1. 0 41 (Koul et al., 2002, Koul et al., 2004)
te« 18.6 35.7 (Brait et al., 2012)
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FKBP4 2.3 35.7 (Brait et al., 2012)
FHIT 0 6-29 (Honorio et al., 2003, Koul et al., 2002,
Koulet al., 2004)
AIMl 0 21.4 (Brait et al., 2012)
RAR-82 2.3 21.4 (Brait et al., 2012)
RASSF2A 0 20 (Furukawa et al., 2009)
BRCAl 3 18 (Koulet al., 2002, Koulet al., 2004)
CCNAl 4.6 14.3 (Brait et al., 2012)
PGP9 9.3 14.3 (Brait et al., 2012)
HOXB5 0 13 (Lindet al., 2006)
COH13 0-6 9-12 (Honorio et al., 2003, Lindet al., 2006)
COHl 0 4-11 (Honorio et al., 2003, Koul et al., 2002,
Koulet al., 2004)
RARB 0 5-23 (Honorio et al., 2003, Koul et al., 2002,
Koulet al., 2004)
FANCF 0 6 (Koulet al., 2002, Koulet al., 2004)
TIMP3 0 3 (Koulet al., 2002)
Table 1.1: List of genes previously found to be methylated and their percentage of methylation In
semlnomatous and non-semlnomatous TGCT.Genes in bold were those found to be methylated In
100%ofYST.
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1.2.7.2. Gene expression studies
Based on the previous findings of amplification and overrepresentation of
chromosome 12 and 17 in adult TGCTs (Kraggerud et al., 2002, Roelofs et al., 2000,
Summersgill et al., 2001), two gene expression microarrays were performed to identify
genes overexpressed in these two chromosome arms (Rodriguez et al., 2003, Skotheim
et al., 2002). Rodriguez et al. conducted arrays using a chromosome 12 specific array in
18 adult TGCTsamples (eight seminomas samples, three ECsamples, four ECcell lines,
two teratoma cell lines and one YSTcell lines). They reported that many genes showed
a correlation between their expression and amplification. Among the genes found to
be overexpressed in most TGCTswere MRPS35, LDHB, CMAS, EKI1, LRMP, KRAS2,
ITPR2, TM7SF3, SURB7, CCND2, MLF2, PTMS, GLU3, HPHl AND LRP6(Rodriguez et al.,
2003). However, they mentioned BCATl as the only gene that was highly expressed
specifically in the non-seminomas. Using a similar approach Skotheim et al. used a
microarray mainly specific to chromosome 17 (Skotheim et al., 2002}.Comparing to
normal testis, they found that all eight seminomas and six non-seminomas in their
analysis showed higher expression of GRB7, JUP, LLGL2 and PDE6G(Skotheim et al.,
2002). They also mentioned that GRB7 was significantly more expressed in the non-
seminoma while expression of JUP was higher in the seminoma samples compared to
normal testis. Looking at locations other than chromosome 17, they found CCND2,
POVl and MYCLl were among the genes overexpressed in all TGCT samples as
compared to normal testis; with the latter two showing significantly higher expression
in the seminoma samples (Skotheim et al., 2002).
Meanwhile, 23 overexpressed genes were identified when CISwere compared
with normal testicular parenchyma (Hoei-Hansen et al., 2004). Among those genes
were CCND2, LDHB and XIST,whichhad been previously shown to be overexpressed in
CISor seminoma (Houldsworth et al., 1997, Kawakami et al., 2003b, Looijenga et al.,
1997, von Eyben et al., 2000). This study also identified the'overexpressed in CIS'
(OICl) gene as a novel gene that was highly expressed in CIS.Other genes found to be
expressed only in the CISwere CALD1, C7, CYBRDl and DCN.
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On the other hand, gene expression analysis performed in 26 adult GCT
samples and cell lines and embryonic stem (E5) cells revealed the similarity between
ECand E5 cells (Sperger et al., 2003). This group found that ECand EScells share a
much higher number of overexpressed genes than EC or ES cells share with
seminomas. They also found that almost half of the overexpressed genes shared by EC,
ES and seminomas were identified only as accession numbers, ESTor hypothetical
protein which suggests there were many unexplored genes in this group of cells.
Meanwhile, between ECand EScells but not in seminoma, DNMT38, FOXD3 and SOX2
were highly overexpressed. Interestingly, when they compared ECand EScells, they
found a significantly higher number of genes from chromosome 12 were
overrepresented in ECswhich was in line with chromosome 12 amplification in TGCT
(Roelofs et al., 2000, Summersgill et al., 2001).
The only gene expression study that used CISas a control was conducted by
Almstrup (Almstrup et al., 2005). They only reported a small number of genes that
showed differential expression between seminoma and non-seminoma which might be
due to the experimental design that only included one sample for each tumour type.
They did find some genes overlapped with the study done by Sperger (Sperger et al.,
2003) which included DNMT38 in non-seminoma and KITin seminoma samples.
As mentioned before, the presence of two or more histological components in
GCTsis not unusual. In a bid to identify genes that can predict the major histological
components of mixed non-seminomatous GCTs,Korkola et al. performed Affymetrix
gene expression arrays on 84 non-seminomatous GCT samples, with 42 samples of
mixed histology (Korkola et al., 2005). Using predictive analysis of microarray (PAM) on
all pure GCTsamples, this group found 146 transcripts unique for each histology. This
finding was found to be valid when they did RT-PCRof the genes in their pure and
mixed GCTsamples. Unfortunately, they only did validation on two genes unique for
each histology. Furthermore, only two mixed samples (choriocarcinoma with EC
component) were used with one showing expression of CSTl that was found unique to
YST. This suggests the presence of YST component in the mixed choriocarcinoma
samples that was not detected before. While this might imply the gene specificity in
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discriminating VSTcomponent from the mixed GCTsamples, more samples might be
needed to make this finding more credible. In addition, more validation needs to be
done on all of the genes to determine its reliability as a marker for each GCTsubtype.
All genes found to be overexpressed in previously mentioned studies are
summarized in Table 1.2.
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Phenotype Highly expressed genes References
CIS XIST, SFRP1, IGFBP6, TXNIP, OICl, (Hoei-Hansen et al., 2004)
CALOl, C074, Cl, CXCLl6, CYBR01,
IFITM1, CCNOl, SALL1, TRA1,
COLlAl, HDAC3, HLA-DRA, OPAl,
BPAG1,DCN,LDHB
Seminoma POUSF1, KIT, TFCPlLl, UTP14C, (Sperger et al., 2003,
HLXB9,LBP9, TCLlA, FRCPl, MMP9, Almstrup et al., 2005,
JUP, XIST, CD74, CXCLl6, IFITM1, Skotheim et al., 2002,
CCNDl, SALL1, TRA1, HDAC3, HLA- Hoei-Hansen et al., 2004)
ORA, BPAG1,LOHB
EC DNMT3B, FOXD3, SOX2, KRT19, (Almstrup et at, 2005,
ONMT3L, AGRl, FGB, STELLA, Sperger et al., 2003, Hoei-
CDXl, TDGF1, EBAF, CBS, GPC4, Hansen et al., 2004,
TERF1, GABARAPLl, IMP1, Skotheim et al., 2002,
SEMA6A, GGTLA1, GABRB3, GAL, Korkola et al., 2(05)
AK3, NALPl, SCNN1A, CXCL16,
IFITM1, CCNDl, SALL1,TRA1,OPAl,
LDHB, GRB7, NANOG, MICB,
POUSF1, UPP1, DPPA4, NALP7,
SEPT6
Teratoma SFRP1, IGFBP6, TXNIP,SALLl, TRA1, (Hoei-Hansen et al., 2004,
COL1Al, HDAC3, HLA-DRA, OPAl, Korkola et al., 2(05)
MFAP4, EMP1, MAIL, TM4SF3,
EMPl
VST
Choriocarcinoma CGB, CGA, PLAC6, HSD3Bl, LEP, (Korkola et al., 2(05)
TFPl
csn. APOA2, BMPl, FOXAl, VTN, (Korkola et al., 2(05)
CS,EOMES,CYPl6Al, CCKBR
Table 1.2: Genes previously found to be overexpressed In CISand each type of TGCT.All genes that
were found to be uniquely expressed In each TGCTsubtype are highlighted In bold.
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Expression analysis of GCTsin paediatric populations is still scarce. Among the
earliest studies using Northern hybridization and immunohistochemistry, it was found
that paediatric YSTsand their cell lines showed expression of GATA-4(Siltanen et al.,
1999). This gene was previously shown to be a marker for yolk sac endoderm in mouse
(Arceci et al., 1993). However, since immature teratoma was also found to express
GATA-4, this marker should not be regarded as specific to YSTs. This was further
supported by a recent study using immunohistochemistry (Salonen et al., 2010). They
found that GATA-4 was also expressed in gonocytes until 17th gestational week, after
which it became undetectable. They also found that variable expression of GATA-4
could be observed in CIS, although this could be due to contamination as the CIS
samples were heterogenous and mixed with either seminoma or non-seminoma
component. By testing the GATA-4 antibody in their adult GCTssamples; which include
seminoma, embryonal carcinoma, YST, choriocarcinoma and immature teratoma,
Salonen et al. (2010) also found that all samples except embryonal carcinoma and
choriocarcinoma showed expression of GATA-4.
One limitation of GCTsstudies in paediatric populations is the small number of
samples available especially those taken from extragonadal sites. This was agreed
upon by Palmer and his group when they analysed 27 samples of paediatric GCTs,
where only five were from extragonadal samples (Palmer et al., 2008). Out of the 27
samples, nine were seminomas while the rest were YSTs.Only ten samples were from
patients less than 5 years old and (all of which were YSTs)while 17 samples (including
all seminoma samples) were from patients more than 5 years of age. Interestingly,
when they compared their YST testis samples to adult YST testis samples from a
previous study (Korkola et al., 2006), they observed a separation between these two
cohorts from hierarchical clustering analysis. From this observation, they concluded
that such a difference was not due to the site of the tumour. Although not mentioned,
it is possible that this observation could have been due to a batch effect that can arise
from comparing data between independent experiments. In this case, different
techniques were used for sample preparation and different array panels were used by
each group (one used U133A panel while the other used U133 A+B
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panel).Unfortunately, due to unavailability of seminoma testis samples, they could not
make similar comparisonto their paediatric seminoma testis samples. Seminomas and
YSTswere also found to have different chromosomal enrichment. Transcripts from
ISq, 12p, 8q and 1p were highly expressed in seminomas while YSTsshowed higher
expression at llq, IIp, 3p, Sq, lOp and 13q. Interestingly, they also found two
separate enrichments when they compared YSTsamples according to age.
Samples from patient age between 5 to 16 years old have higher transcript
expression at chromosome 19, Xp, Xq, 2q, 7q and 22q while samples from patient less
than 5 years old showed enrichment at 12q, 2p and 3p. looking into differentially
expressed genes, they found seminomas to display higher expression of pluripotency
genes such as NANOG, POU5Fl (OCT4) and UTF. Other genes that were highly
expressed in seminoma were TFAP2C, ASHIL and PDPN. On the other hand, YSTs
exhibited higher expression of differentiation associated genes such as KRT19 and
KRT8. Beside these two genes, AFP, APOA1, APOA2, CCKBRand PDZKl were also found
to be highly expressed by YSTs.
In light with the findings that suggest the importance of TGF-~ and BMP
signalling in germ cell development and PGCsspecification respectively (Itman et al.,
2006, Saitou et al., 2002, Surani et al., 2004), Fustino et of. evaluated these pathways
in eleven paediatric samples (seven YSTsand four seminomas) using a custom tissue
microarray and immunohistochemistry (Fustino et al., 2011). They only observed a
significant difference in BMP Signalling with YSTs showed higher activity than
seminomas. Using quantitative RT-peRof genes involved in TGF-~/BMP signalling, they
found that 29 genes were highly expressed in YSTsbut only S were highly expressed in
seminomas (Table 1.3). Interestingly, among the genes highly expressed in YSTswere
NOG and F5T, which are known to be negative regulators of the pathways (Bartholin et
al.,2002).
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TGF':P/BMP slgnalllng pathway genes fQ~.md,blg,hly~xpre$sed ..In YSTand
semlnoma:
HiJJher,expression in VST Higher expression .ln seminoma
NODAL,AMH, TGFB2, LEFTY1,BMP7, GOFS, PLAU,BMPR1B, ACVR1, STAT1
BMP4, GOF3, GOF6, BMPS, BMP2,
C0L3A1, COLlAl, LTBPl, BMP1, NOG,
FSl; CER1, 101, 102, JUNB,I~FBP3,
T~C2201, JUN, ,GSC,EVil, TGFB1/1,
AMHR2, BMPER, ENG
Table 1.3: List ofTGF-B/BMP signalling pathways genes found to be highly expressed in YSTand
seminomas from study conducted by Fustino et al (2011)
1.2.7.3. Limitations 0/previous studies
From all previous studies involving GeTs, it is clear that most focus has been on
adolescence and young adult populations. In addition, the majority of these studies
revolved around testicular GeTs. Thus, there is still lack of study involving paediatric
populations and also insufficient knowledge of extragonadal GeTs.
It is also notable that the majority of the studies looking at promoter
methylation used a technique called methylation specific peR (MSP). This technique
involves the use of bisulfite-treated DNA that will convert unmethylated cytosine into
thymine but leaves methylated cytosine unaffected. By using a specific primer pair for
each methylated and unmethylated CpGsite, the level of promoter methylation can be
determined by the intensity of the amplified peR products. Since it is quite laborious to
design primers for all the genes, most studies have pre-selected their genes of interest.
These genes of interest are usually those known to be a tumour suppressor or gene
previously shown to be methylated in other types of cancer. Therefore, previous
analysis on promoter methylation was restricted to a few genes and did not represent
the global genome-wide characteristics of GeTs. In addition, only a few of these
studies were analysed for both their methylation and their expression using germ cell
tumour cell lines (Koul et al., 2002, Koul et al., 2004, Lind et al., 2006). These studies
also looked at reactivation of silenced genes using the demethylating agent, 5-
azadeoxycytidine (Koul et al., 2002, Koul et al., 2004). Although it proved that these
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genes were repressed by methylation, the notion that CpG islands methylation at the
gene promoter region was responsible for such repression needs to be treated with
caution. This is because in recent genome-wide scale methylation analysis in colorectal
cancer, it was shown that CpGshores (a region 2kb away from the CpGislands) instead
of CpG islands were the most differentially methylated regions (Irizarry et al., 2009).
Furthermore, they also suggest that methylation at CpG shores were the most
correlated with the gene expression. Since no genome-wide methylation study has
been conducted in GCTs,it is still unknown whether the methylation at CpG islands or
shores will have any effect on gene regulation in GCTs.
Similar to the methylation studies, gene expression analysis conducted in GCTs
was mainly using samples taken from young adults testicular GCTs.Only a handful of
studies were conducted in the paediatric population to date (Palmer et al., 2008,
Fustino et al., 2011). Despite revealing quite a number of uniquely expressed genes in
most of the GCTssubtype, none of these studies have any methylation data linked to
it. Therefore, there is still a knowledge gap in determining the extent of DNA
methylation in regulating the expression of these genes.
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1.3. Aims & Objectives
1) To investigate the methylation profile of paediatric GCTs (gonadal and
extragonadal) using global approaches. A global methylation profile performed
by measuring methylation of L1NE-l (Li) repeat elements using the
combination of bisulfite and restriction enzyme analysis (COBRA)technique will
be discussed. On the other hand, Golden Gate methylation arrays will be used
to assessthe methylation status of gene promoter regions.
2) To gain a more genome-wide methylation profile and a wider coverage of
genes, InfiniumHumanMethylation 450K array will be utilized on representative
GCTcell lines for all histological cell type.
3) Genes repressed by methylation in the paediatric samples and the GCT cell
lines will be identified by correlating methylation array data with their
corresponding gene expression array data.
4) To identify factor(s) behind the methylation profile of paediatric samples and
GCT cell lines by measuring expression levels of DNMT38, EZH2 and SUZ12
using real-time quantitative PCR.
5) To investigate the function of methylation in GCT by knocking down the
contributing factor(s) and observing the effect on GCTcell line behaviour.
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2. MATERIALS&METHODS
2.1. Materials
2.1.1. 2.1.1: DNAsamples & Cell lines
2.1.1.1. Paediatric germ cell tumour cohort
The cohort of tumour samples used in this study consisted of seminomas, yolk
sac tumours (YSTs)and controls. All tumour samples were obtained from the Children
Cancer Leukemia's Group (CClG) in the form of genomic DNA and RNA. All samples
obtained from CCLGwere from both gonadal and extragonadal site. In addition, twelve
paediatric control samples were also acquired from the same group. However, no prior
history was obtained for these samples. The other 3 paediatric controls (infant's blood
controls) were kindly given by Dr Beth Coyle (University of Nottingham).
2.1.1.2.: Human Neural Stem Cells (NSCs)
The human NSCswere obtained from Milipore under the name of
ReNcell VM. These NSCshad been immortalized by retroviral transduction with the v-
myc oncogene. They were derived from the ventral mesencephalon region of a 10-
week old human fetal brain tissue. Cells were grown on Laminin (Sigma) as adherent
cells in 'NB medium' (DMEM/F12 (1:1) (lX)(lnvitrogen) and Neurobasal Medium (1X)
(Invitrogen)). Medium was supplemented with 20ng/ml FGF(Invitrogen), EGF(Sigma)
5X N2 (Invitrogen) and lOX B27 (Invitrogen) supplements. 0.5%
Penicillin/Streptomycinwas also added to these medium.
2.1.1.3. : Germ Cell Tumour (GCTs)Cell Lines
Four GCTscell lines were used in this study. They are NT201 (teratocarcinoma),
GCT27 (embryonal carcinoma), TCAM2 (seminoma) and GCT44 (yolk sac tumour) cell
lines. All except the teratocarcinoma were kindly given by Dr Janet Shipley (Institute of
Cancer Research UK), while the teratocarcinoma cell line was obtained from Dr Nicola
Royle (University of Leicester).
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All except the seminoma cell lines were grown in Oulbecco's Modified Eagle
Medium (OMEM) (Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma)
and 1% penicillin/streptomycin (Sigma).The seminoma cell line was grown in RPM1-
1640 medium (Sigma) supplemented with 10% FBS and 1% penicillin/streptomycin
2.2. : Standard Reagents
2.2.1. : Agarose Gel
2.2.1.1. : Preparation of O.SMEDTAsolution
93.05 grams of EOTA(Sigma) was dissolved in 400ml sterile deionized water
using a magnetic stirrer. Sodium hydroxide (Sigma) was added carefully until the pH
reached 8.0. Additional deionized water was added to the solution to make up to
SOOm!.
2.2.1.2.: Preparation of sox TAEbuffer
242 grams of Tris base (Invitrogen) was dissolved in 750ml sterile deionized
water. To this solution, S7.1ml glacial acetic acid (Sigma) and 100 ml of EOTA(pH 8.0)
were added. Additional deionized water was added to the solution to make up to 1
litre.
2.2.1.3.: Preparation of working 1J( TAEbuffer
20ml of SOXTAE buffer was added to a 1 litre bottle. Sterile deionized water
was then added to make up to 1litre.
2.2.1.4. : Preparation of agarose gel
For 1.0% agarose gel, 0.5 grams of Tris base (Invitrogen) was added to SOml1X
TAE buffer. The solution was then heated in a microwave for 5 minutes at high
temperature. Once the solution cooled enough to be held, S~I of 10mg/Sml Ethidium
bromide (Sigma) was added to the solution. The solution was then poured into a gel
rack with a comb and was left to solidify at room temperature. Once solidify, the gel
was then submerged into a gel tank containing IX TAEbuffer.
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2.2.2. : Chemicals
2.2.2.1. : Decitabine (S-azadeoxycytidine, S-azadC)
5 mg Decitabine (Sigma) was diluted with 438 III of PBSto make up 50 mM
stock solution. Working solution of 5 mM was made by mixing 100 III of 50 mM stock
solution into 900 III of medium (DMEM or RPMI-1640).
2.2.2.2.:Cisplatin
Cisplatin solution (Accord) was received at a concentration of 3.3 mM. For
working solution of 0.33 mM, 150 III of 3.3 mM Cisplatin were diluted with 1,350 III of
0.9% NaCI.
2.3. :Standard Methods
2.3.1. : DNA Extraction
300 III of lysis solution (Tris 1M at ph 8.5, EDTA0.5M, NaCI 1M, SDS10% and
water) and ProteinaseK 101lg/1l1were added to each DNA pellet and incubated at 37°C
over 1 hour or until all tissue were dissolved. Samples were then subjected to
centrifugation at 11,714 X G. The supernatants were transferred into l.5ml tube. 300
III isopropanol was then added to each sample to precipitate DNA. Visible DNA
precipitates were then transferred into new tubes and washed with 70% ethanol.
Samples were then air-dry before water was added to resuspend the DNA.
2.3.2. : BisulfiteConversion
Bisulfite treatment was performed according to the protocol supplied by EZ
DNA Methylation Kit (Zymo Research). Briefly, each sample consisting of SOOngof DNA
was mixed with M-Dilution Buffer and water was then added to a total volume of 50
Ill. Samples were then incubated at 3rc for 15 minutes. CTConversion Reagent was
then added to each sample and the samples were incubated overnight in the dark at
50°e. The next day, samples were incubated on ice for 10 minute. Samples were then
loaded into the designated column that had been already filled with a binding buffer
and were centrifuged at 13,000 X G for 30 seconds. Samples were then washed with
the wash buffer supplied before subjected to centrifugation at 13,000 X G for 30
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seconds. Then, desulphonation buffer was added to each samples and were left to
stand at room temperature for 20 minutes, after which samples were again
centrifuged at 13,000 XG for 30 seconds. Samples were then washed twice; each wash
was followed by 30 seconds centrifugation at 13,000 X G. DNA was then eluted by
centrifugation at 13,000 XG in a microfuge tube by adding the elution buffer.
2.3.3. : RNAExtraction
300 III of TRI Reagent (Sigma) was added to each sample, mixed and were left
standing for 5 minutes at room temperature. Each sample was then added to 100 III
chloroform and again mixed and left to stand for 5 minutes at room temperature. The
samples were then centrifuged at 13,000 X G at 4°C for 15 minutes. The supernatants
were then mixed with 250111isopropanol and were left at room temperature for 5
minutes. The mixtures were then centrifuged at 13,000 X G at 4°C for 10 minutes. The
pellet was then washed with 20011175% ethanol and was centrifuged at 13,000 X G at
4°C for 5 minute. The samples were then left for air-dry for 5 minutes. 20 111of water
were added to resuspend the pellet. 1X buffer and 2 III of DNAse (Invitrogen) were
added to each sample. Samples were then incubated at room temperature for 30
minutes. After this incubation, 25mM EDTA were added to each samples and
incubated at 65°C for 10 minutes. 1111of each samples were then taken for RNA
quantification. RNA samples were then used straight away for cDNA synthesis or
frozen down at -80°C.
2.3.4. : eDNA synthesis
0.25 11Mof random primer mix (Promega) was added to at least 2 I1gof RNA.To
each sample O.lI1M DNTP(Bioline) and water was added to make a total volume of 13
Ill. Samples were then heated at 65°e for 5 minutes before putting them on ice for 1
minute. Then, 5X buffer, O.lM on and 100U/IlI of reverse transcriptase (all Invitrogen)
were added except for samples used as a negative reverse transcriptase control. All
samples were then subjected to 1 cycle on a thermal cycler (25°e for 5 minutes, 50 0e
for 45 minutes and 75°Cfor 15 minutes).
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2.3.5. : Polymerase Chain Reaction (PCR)
20 III peR reaction was carried out by mixing 100 ng genomic DNA with 1X
Buffer (Invitrogen), 2.5 mM Mgeh (Invitrogen), 0.8 mM dNTP (Bioline), O.lIlM forward
and reverse primer and 0.05 U!1l1 Platinum Taq (Invitrogen). Samples were then
subjected to peR with a cycling condition as follows: 94°e for 5 minutes then 40 cycles
of 94°C for 1 minute, s8°e for 1 minute and 7re for 1 minute with a final extension for
5 minutes at rrc.
2.3.6. : Reverse-Transcriptase PCR
25 III peR reaction was carried out by mixing approximately 100 ng cDNA
samples with lX Buffer (NEB), 0.5 mM dNTP (Bioline), 0.5 IlM reverse and forward
primer (refer table 2.1) and 0.05 U!1l1 Taq Polymerase (NEB). Samples were then
subjected to 40 cycles of peR (9s0e for 1 minute, S8°e-GOoefor 1 minute and 7re for 1
minute). The peR products were then run on 1.0 - 2% agarose gel depending on the
expected product size.
2.3.7. : Real-Time PCR
Mastermix for each primer pair (refer table 2.1) were prepared by mixing 2X
SYBRGreen Mastermix (Applied Biosystem), 100 nM of forward and reverse primer, 30
nM of 1:500 reference dye (Applied Biosystem) and water up to 25 ml/well. 25 ml of
those matermix were then transferred into each designated well of 9G-well plate
before adding 50 ng cDNA into each well.
Samples were then subjected to peR using Stratagene MxPro 300SP machine.
The peR cycling condition are as follows: 9Soefor 10 minutes followed by 40 cycles of
95°e for 30 seconds, Gooefor 40 seconds and 7re for 40 seconds. All data were then
analyzed using MxPro software.
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2.3.8. : DNMT3B Knockdown using microRNA29b
3-4 X 107 YSTscell lines were trypsinized into a single cells using 0.05% (IX)
Trypsin-EOTA (Gibco) for 5 minute. Trypsin-EOTA was then neutralized by adding
OMfM medium at three times the volume of Trypsin-EOTA. Cells were then
centrifuged at 106 X G for 5 minutes. Cell pellets were then resuspended using 500 ~I
OMfM medium before being transferred into a 4mm/22mm electroporation cuvette
(Yorkshire Bio Science). MicroRNA-29b plasmid (Open Biosystem) was then added to
the medium at a concentration of 7 ~g and was left at room temperature for 5 minute.
The cuvette was then transferred into an electroporator and one pulse of electrical
current was given at 2S0V for 10 miliseconds. Cells were then transferred into a new
medium and were incubated for 48 hours. After that, cells were either pelleted down
by centrifugation at 106 X G for 5 minutes and stored in the minus 80 freezer or
trypsinized using Trypsin-fOTA to be used for other experiments.
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2.3.9. : DNA methylation inhibition using S-deoxyazacytidine (S-AzadC)
All four cell lines were grown in T1S flask until they were 70% confluent. Each
cell line was then treated with a range of S-AzadC (Sigma) concentrations (0.01 IlM
until 50 IlM) for 24 hours. After 24 hours, medium were changed with a fresh medium
without S-AzadC added into them. Once the cell reached confluence, they were
trypsinized and stored for further analysis.
2.3.10. : DNA Sequencing
2.3.10.1. : Sequencing Set-up
200 ng DNA was added to a 0.5 III peR tube and dried down at 80·C (if
necessary). To this tube, 10 pmol of primer, 2 III of 1:4 Big Dye (Applied Biosystem) and
water were added to make up to Sill.
In relation to CG-rich product, this protocol was modified to include 1M betaine
(Sigma) and 2.5% DMSO in 10 III reaction.
Sequencing was performed using G-Storm thermocycler with cycling condition
as follows: 9SDCfor S minutes followed by 99 cycles of 9S·Cfor 30 seconds, SO·Cfor 20
seconds and GO°Cfor 4 minutes.
2.3.10.2. : Sequencing Clean-up
Sequencing reactions were transferred into a 0.5 ml eppendorf tube. 95 III of
water was added to make up to 100 Ill. 10 III 3M Na acetate pH 5.2, lill glycogen and
200 1l1100%ethanol were added to the mixture and incubated at -20·C for 15 minutes.
Samples were then centrifuged at 13,000 X G for 15 minutes. The DNA pellets were
then washed with 100 III of 75% ethanol and were centrifuged at 13,000 X G for 5
minutes. Samples were air-dried for a few minutes before being sent to Source
Biosciences, Nottingham for sequencing analysis. Data obtained from that sequencing
were analysed using FinchTVversion 1.4.
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2.4. : LlNE-l Assay
A 60 1..1IPCRreaction was carried out according to (Yang et al., 2004), with a
slight modification. Briefly, 30ng of bisulfitetreated DNA were mixed with a final
concentration of 1X Buffer (Invitrogen), 0.8 mM dNTP (Bioline), 1.5mM MgCI2
(Invitrogen), 0.06M Tris-HCI, 0.1 IlM of forward and reverse primer (refer Table 2.1)
and 0.05U/IlI of Platinum Taq (Invitrogen). PCRcycling conditions were 94°C for 1
minute, 55°C for 1 minute and 72°C fer 40s for 45 cycles. The final PCRproducts were
digested with Hinf1 (New England Biolabs) restriction enzymes for 1 hour and were
separated by electrophoresis en 1.4% agarose gel. Some of the digested products (20
Ill) were sent for analysis using Genescan quantification. Data obtained from Genescan
were then analyzed using PeakScannersoftware version 1.0.
2.5. : Amelogenin XYidentification assay
This assay was performed according to the protocol supplied by Promega. 10
ng DNA was mixed with lOX STR Buffer, lOX primer pair (buffer and primer were
supplied in GenePrint Fluorescence Sex Identification system kit, Promega) and 5 UIIlI
KapaTaq (GRI) in 25 III PCRreaction. Samples were then subjected to 2-step PCR.The
first step involves 10 cycles of PCR(94°C for 1 minute, 64°C for 1 minute and 70°Cfor 1
minute and 30 seconds) and the second step involves 19 cycles of peR (90°C fer 1
minute, 64°C for 1 minute and 70°C for 1 minute and 30 seconds).. 15 III of PCR
products were run on 1.5% agarose gel. The remaining 10 III PCRproducts were sent
for Genescan quantification. Data obtained from Genescan were then analysed using
PeakScannersoftware version 1.0.
2.6. : Methylation Arrays
2.6.1. : lIIumina GoldenGate methylation array
2.6.1.1.:Methylation microarray analysis and quality control
Methylation array analysis was co.nducted at the Wellcome Trust Centre for
Human Genetics, University of Oxford, using the IIlumina GoldenGate Cancer Panel I
assay.This was done according to the maufacturer's instruction.
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All quality controls were carried out using Beadstudio version 3.2 methylation
module (ilium ina} and beadarray, a program in Bioconductor R package (Dunning et
aI., 2007) which identifies outliers in the array. In addition to this, confounding spatial
artefacts were also identified using the Beadarray Subversion of Highlight (BASH)
(Cairns et aI., 200S). All these outliers and confounding artefacts were excluded from
subsequent analysis.
After background signal normalisation, p-values for each probe were reported
and these values are in a range of 0 to 1, in which 0 means unmethylated while 1
represent a fully methylated probe.
2.6.1.2.: Cluster analysis and identification of differentially methylated loci
Using pvc/ust, another program from the R package, bootstrapped hierarchical
clustering were performed (Suzuki and Shimodaira, 2006). Subgroups with a p-value of
S 0.05 were considered significant. The clustering pattern was then assessed using
principal component analysis and k-mean analysis. For the later, a predetermined
optimal number of cluster for analysis were determined using Scree plot.
To determine differentially methylated loci, a Mann-Whitney U-test was
performed. loci with p-value S 0.05 after Benjamini-Hochberg false discovery rate
correction were considered to be differentially methylated. An additional filter was
also used for this purpose by using the average change in p-value between subgroups
of more than 0.2. This value was then increased to more than 0.34 when comparing
between tumour subtypes.
2.6.2. : Infinium Methyiation4S0K arrays
Infinium methyiation4S0 arrays were carried out at Queen's Mary University of
London according to the manufacturers protocol. Basically, genomic DNA was first
subjected to bisulfite modification before being denatured into single-strand DNA and
neutralized. These denatured samples were then isothermally amplified overnight at
3rc before being subjected to fragmentation using a controlled enzymatic process.
The fragmented DNA was collected via isopropanol precipitation and subsequently
resuspended in the hybridization buffer. These DNA samples were then subjected to
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hybridization by applying them to the Ilium ina BeadChips. All unhybridized and non-
specifically hybridized DNA was then washed away. Hybridized DNA were then
underwent the extension process. Beadchips were then scanned where the
fluorescence emitted from the single base extension products were recorded. This
data were then extracted using Genome Studio Methylation Module software where
the fluorescence intensity values were measured and represented as ~-values ranging
from 0 (not methylated) to 1 (fully methylated). Data normalization was then
performed by this software using the internal control present in the beadchip.
2.7. A/fymetrix gene expression array
2.7.1. RNA extraction
All four GCTcell lines were trypsinized and the number of cells was counted
using a haemocytometer. 2 X 106 cells from each cell lines were pelleted by
centrifugation at 300 X G for 5 minutes. RNA extraction was performed using the
RNeasy extraction kit (Qiagen) according to the manufacturer protocol. Briefly, cells
were lysed with lysis buffer (Qiagen) with added (3-mercaptoethanol (Sigma). Cells
were homogenized by passing the cell lysate into a shredder column (Qiagen) and
centrifuged at 13,000 X G for 2 minutes. Ethanol was added to the homogenized cells
lysate to promote RNA binding to the column supplied. Using the wash buffer supplied,
columns were washed before RNAwas eluted with RNAse-free water.
2.7.2. RNA Quality Measurement
It is a requirement for RNA to be of high quality in order to perform Affymetrix
Gene expression arrays successfully. Therefore, to determine the quality of GCTRNA
samples, we analyzed the RNA using a Bioanalyzer 2100 (Agilent) as suggested by the
manufacturer.
Briefly, machine's electrodes were decontaminated with RNAseZap (Ambion
Technology) to avoid sample decomposition. A gel-dye mix was made by mixing RNA
6000 Nano dye supplied by manufacturer with a filtered gel prepared earlier by the
technician and was centrifuged at 13,000 XG for 10 minutes. Once chips were set up in
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the priming station, gel-dye mix was put into the designated chip wells. RNA 600 Nano
markers were then placed into wells designated for ladder and the samples. ladders
were supplied by the manufacturer and RNA samples were then placed into their
designated wells. Chips were then placed into the Bionalayzer 2100 for analysis.
A successful sample run should feature one mRNA peak and two ribosomal peaks
(Figure 2.1). Measurement was calculated using 2100 expert software version B.02.07
and displayed as RNAconcentration, the ribosomal ratio and the RNA integrity number
(RIN). For the purpose of selecting samples for Affymetrix Gene Expression array,
samples with RIN> 9.0 were selected as this implies a high quality RNAsamples.
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Figure 2.1: Representative result for RNA quality measurement in one of GCTsamples which showed a
high concentration of high quality RNA determined by the high RIN number.
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2.7.3. Affymetrix Array
Arrays were performed at the Nottingham Arabidopsis Stock Centre, University
of Nottingham Sutton Bonington Campus using GeneChip Human Genome U133 Plus
2.0 arrays.
All data were then analysed using GeneSpring GX (Agilent Technologies).
Comparison between cell lines was made and significant differences of expression
between cell lines were determined using a default setting of fold change> 2.0.
2.B. : Pyrosequencing
50111PCRreactions were set-up for each sample individually (as each tumor
concentration varies) with a final concentration of lX buffer (2mM MgCI), forward and
reverse primer (SOOnmeach), 0.8mM dNTP, Dream Taq (Fermentas) 0.05 U/1l1 and
around lOO-120ng DNA. Samples were then subjected to 45 cycles of PCR.The PCR
cycling conditions were 94°C for 10 minutes, followed by 45 cycles of 94°C for 60
seconds, 55°C for 60 seconds, and 7rc for 40 seconds with a final 5 minutes
extension at 7rc.
10 III of PCRproducts were then run on 2% agarose gel to check for product
amplification and its quality. The remaining 40 III PCRproducts were purified using PCR
purification kits (Qiagen) and were sent to Queen Mary's University of london for
pyrosequencing analysis.
2.9. : Clonogenic Survival Assay
2.9.1. : Cell's preparation
Media were prepared in advance by adding 60 ml DMEM or RPMI-1640 into a
T7S flask. This amount of medium was needed to plate 3 X 6-well plates in which 3 ml
medium is needed for each well. These T75 flasks containing the medium were then
pre-heated to 3rC in the incubator.
A confluent T75 flask containing around 3-4 Xi06 cells was trypsinized using
Trypsin-EDTA (TED)and incubated for 5 minutes in the incubator. Once cells had been
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trypsinized into a single cell suspension, medium (OMEM or RPMI-IG40) containing
fetal bovine serum (FBS)was added in an amount of three times of that to the volume
of TED to neutralize the TED. Cell suspension was then centrifuged at lOG X G for 5
minutes. After removing the supernatant, cell pellets were then resuspended
thoroughly with 3 ml medium to make sure all the cells remained as single cells. Cells
were then passed through a 40 ~M cell strainer (MWG) into 50 ml Falcon tube.
2.9.2. : Cell counting
10 ~I of single cells were taken out from the SOml Falcon tube and mix with
10~1of Tryphan blue and the average number of cells was then determined using a
haemocytometer (A X 104 cells/ml). To determine the amount of volume needed to
plate 100 cells/ well, calculation was done using the formula below:
(A X 104 cells/ml) X VI = (100 cells/ 3ml) X GOml
VI = 33.3 cells/nil X 60ml
= (0.1998/ A) ml
= {199.8/ A) ~I
The calculated amount was taken out from the single cell suspension in the 50 ml
Falcon tube and transferred into a T75 flask containing GOml medium prepared earlier.
This cell suspension media was mixed thoroughly by pipetting a few times before
transferring 3 ml into each well of a 6-well plate. Plates were then incubates at 3rC in
the incubator with 5%CO2 for 1-2 hours to allow cells to attach on the plate.
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2.9.3. : Cisplatin treatment
Once cells had adhered following plating, Cisplatin (Accord) was added at a
range of 2.5 IlM to 12.5 IlM into each designated well. Cells were exposed to this
treatment for 2 hours after which time medium was changed. Cells were then
incubated for 7-10 days (depending on the cells' doubling time).
2.9.4. : Cell fixation and staining
Medium was removed from cells and these were then fixed with Iml/well 4%
paraformalaldehyde (PFA,Sigma) for 20 minutes at room temperature. PFAwas then
removed and cells were stained with 0.5 ml/well of 0.1% crystal violet (Sigma) for 5
minutes. Wells were then washed with distilled water and left to dry at room
temperature.
2.9.5. : Migration Assay
1.5 - 2 X 103 cells were plated on each well of a 6 well-plate and were left in
the incubator at 3rC with 5% C02. Once the cells reach 70-80% confluence, a scratch
was made in straight line using a 10111 tip. Medium was then removed and cells washed
with PBSfor 5 minutes. After removing the PBS,fresh medium was added to each well.
Cell migration was then observed under the microscope and pictures taken everyday
for 5 days or until the scratch had closed. The distance between the sides of the gap
created from the scratch was measured using ImageJsoftware.
2.10. : Statistical Analysis
All statistical tests were conducted using GraphPad Prism version 4.0 software.
Since tumour samples are from different patients, we assumed all data were
not normally distributed. Therefore, non-parametric Mann-Whitney test were used to
analyse the significance of the tumour data. The same applies when comparing
between GCTcell Jines.
For experiments investigating the difference before and after treatment of
each cell line, we used a parametric paired t-test to analyse the significance of the
findings.
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3. METHYLATION PROFILE OF PAEDIATRIC GERM CELL
TUMOUR SAMPLES
3.1. Introduction
There have been many methylation studies carried out in adult germ cell
tumours (GCTs), but these studies were only conducted in testicular GCTsand based
on a small number of candidate genes. The methylation profile of GCTs in the
paediatric population and also GCTsthat are formed outside of the gonads has not
been fully explored. Thus, our study set out to investigate the methylation profile in
these populations. To do this, two methods were employed, a LlNE-1 assay and the
lIIumina GoldenGate methylation array.
Both of these methods use bisulfite treated DNA as the basis to differentiate
between methylated and unmethylated DNA. This technique pioneered by (Frommer
et al., 1992), is based on the principle that uracil is a thymine analog. During bisulfite
treatment (Figure 3.1), addition of bisulfate will caused sulphonation of cytosine
residue into cytosine-6-sulphonate. This process is reversible and the reaction
equilibrium shifts towards formation of cytosine-6-sulphonate in acidic solution.
Cytosine-6-sulphonate will then be converted into uracil-6-sulphonate by Irreversible
process of hydrolytic deamination. In an alkali condition, rapid desulphonation process
will then result in the conversion of uracil-6-sulphonate into uracil.
LlNE-1 elements are repeat elements abundantly found in the human genome.
The measurement of LlNE-1 repeat elements has been found to be applicable as a
surrogate in determining genome-wide methylation (Estecio et al., 2007). Thus, this
method has been widely used for such purposes. Here, we used an established lINE-1
assay (Yang et al., 2004)that employed a combination of bisulfite treatment and
restriction analysis. By converting unmethylated cytosine to thymine, the recognition
sites for the restriction enzymes, in our case Hinf1, are lost (Figure 3.2). Therefore, only
methylated cytosines are digested, providing a simple and quick way to determine the
methylation state of a sample.
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Figure 3.1: Steps involved in cytosine conversion to uracil. In step 1, sulphonation of the cytosine (C)
residue by addition of bisulfite causes it to be converted to cytosine-6-sulphonate (C-S03l This process
is reversible with the equilibrium shifted towards (C-S03') in acidic solution. Step 2 is the irreversible
hydrolytic deamination of (C-S03') to uracil-6-sulphonate (U-S03l This molecule is stable in neutral
solution but desulphonation process (Step 3) occurs rapidly in alkali condition resulting in the formation
of uracil (U). Diagram was taken from Hayatsu (2008).
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Figure 3.2: Steps in LlNE-1 assay. In LlNE-1 Assay, only unmethylated cytosine will be converted to
thymine by bisulfite modification. This caused loss of Hinfl recognition site (GANT/C, represented by the
red triangle) and this site remains undigested.
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The JIIumina GoldenGate methylation array offers a genome-wide methylation
perspective covering 1505 epG sites that corresponds to 807 genes. Unlike previous
methods that used restriction enzymes, Golden Gate arrays use two allele specific
primers that can distinguish between the methylated and unmethylated sites and one
primer containing the lIIumina address code. All three primers will then hybridize to
the DNA sample. The allele-specific primer that is complementary to the interrogating
site will then undergo extension and ligate to the primer containing the Ilium ina
address code. This full length product will then served as a template for subsequent
peR process. In this peR, universal primer (Pl, P2 and P3) is used. Pl and P2 are
labeled with either red or green fluorescence that specifically recognized methylated
or unmethylated allele, respectively. After downstream processing, single stranded,
dye-labelled DNA will be subjected to hybridization to their complement bead type
according to the JIIumina address code. Successful hybridization to the Beadehip will
produce the signal readout which will then be further analysed using computer
software.
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Figure 3.3: JIIumina GoldenGate assay process, 1) DNA was activated to enable it to bind to the
paramagnetic particle. 2) Three oligonucleotide primers (AS01, AS02 and LSO)were added to the DNA.
ASOl and AS02 are specific primer that binds to either methylated or unmethylated allele while LSOis a
universal primer that contains IIlumina address code sequence attached to it.3) Primers that
complement the interrogating site will then extend and ligate to the LSO primer. This product will then
serve as a template for subsequent peR. 4) In the subsequent peR, three universal primers, Pl, P2 and
P3 will be used. Pl and P2 are f1uorescently labeled and each of them is specific to either methylated or
unmethylated allele (only Pl is shown in the figure) and they will then extend and ligate to P3. 5) After
further downstream processing, single-stranded, dye-labelled DNA will then be subjected to
hybridization to their complement bead type according to the Iliumina address code. 6) Successful
hybridization to the Beadehip will result in signal readout. Images taken from lliumina Inc. website
(www.illumina.com)
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3.2. Results
3.2.1. Investigating global methylation levels of paediatric germ cell tumours
It is generally believed that all cancers haveglobal genomic hypomethylation.
Currently, few studies have been conducted in paediatric GCTsaddressing this matter.
The most recent study of a 'so-called' paediatric population was done in testicular
GCTssamples with mean age of 35 years old (Ushida et al., 2011). Therefore, we would
like to know whether global hypomethylation is also a feature of all types of GCTsin a
younger population. In order to do so, we performed a lINE-l assay on the 32 GCTs
samples in our tumour bank.These samples were kindly given to us by our collaborator
in Cambridge and originate from the UK Children Cancer and Leukemic Group (CCLG)
bank. Out of these 32 samples, 12 were seminomas, 20 YSTsand 18 controls (Table
3.1). These samples were taken from patients of different ages with an average age of
eight years old (average of five, thirteen and seven years old for YSTs,seminomas and
controls respectively). To address the global methylation features of extragonadal
GCTs,samples taken from the brain, sacrococcygeal (SCT),liver and abdomen are also
included in our samples.
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Table 3.1: List of paediatric germ cell tumour samplesand controls used in LlNE-1Assay.
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Samples were subjected to bisulfite modification and 40 cycles of PCRusing
LlNE-1 specific primers. Each of the PCRproducts was divided into two, and one of
them was digested with Hinf1 for 1 hour. Both digested and undigested samples were
run on an agarose gel. We observed that most of the tumour samples showed a low
signal for the digested product compared to the controls (Figure 3.4). This indicates
that most of the tumour samples have low methylation of LlNE-1 repeat elements.
Sem VST Control Ovary
ud d ud d ud d
} unmethylated
} methylated
Figure 3.4: Representative gel picture of LlNE-l assay on paediatric GCT samples. It clearly showed
here that there are less amplification of the digested product in both YST and seminoma. ud is for
undigested and d is for digested
However, we found that this method did not give reliable quantitative data. To
improve this method and make it more quantitative, we designed a FAM-Iabelled
forward primer for the peR. The digested peR products were then analysed using
Genescan, where the fluorescence intensity from both digested and undigested
products were measured. Using Peak Scanner software, the digested and undigested
peR products were detected according to their sizes (Figure 3.5). The methylation level
of each samples were then calculated by using the equation below:
Area in point for the digested peak (methylated)
UNE-l methylation level =
Area in point for the digested peak (methylated) +
area in point for the undigested peak (unmethylated)
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Control
Tumour
-
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peak
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peak
Figure 3.5: L1NE-1 assay analysis using Genescan. Representative diagram of Genescan using Peak
Scanner software showing the methylated and unmethylated peak of digested LlNE-l assay peR
products.
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Using the above formula to calculate the methylation level of each sample, it
was evident that the majority of both seminoma and YST sampleshave lower
methylation levels than the controls (Figure 3.G). Due to the limited amount of DNA
available we were unable to complete replicates on all of the samples.
In order to determine the significance of hypomethylation seen, we grouped
these samples according to their tumour type. As expected, we found that both
seminomas and YSTsshowed significant hypomethylation of LlNE-1 repeat elements
(p<O.0001)with an average methylation of 32% and 42% respectively, when compared
to the control group with G8%methylation (Figure 3.7 A).
We then compared these tumour samples to their matched tissue. We found
that both seminoma and YSTs were hypomethylated when compared to control
samples (Figure 3.7 B & C). However, this hypomethylation was only significant in
ovarian tissue (Figure 3.7 B). We believe this is due to the small number of testis
controls and in addition that one of these controls exhibited an unusually low
methylation value (labelled as X in Figure 3.G). However, given that no prior history
was available for this volunteer's sample, we could not rule out whether other health
factorscould have influenced this observation.
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Figure 3.7: L1NE-1methylation level in A) each tumour group, B) matched tissues in seminomas, C)
matched tissues in YST. Both seminoma and YSTsamples displayed significant hypomethylation of L1NE-
1 repeat elements compared to the controls. However in both tumour types, only ovarian samples
showed significant hypomethylation of L1NE-1repeat elements compared to its matched tissue controls.
* denotes p-value <0.01 while ** denotes p-value <O.OOlusing Mann-Whitney Hest.
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3.2.2. : Methylation level at the gene regulatory region
3.2.2.1. : Data Analysis
We next investigated the methylation profile at gene regulatory regions using
the IIlumina Golden Gate methylation array panel. This Golden Gate Cancer Panel I
consists of 1536 CpGsites with 1505 of them (98%) corresponding to 807 genes while
the remaining 31 sites were designed to act as internal bead controls. The majority of
these genes (576 genes) contain two or more CpG sites to be analysed in the panel.
Based on previous studies (Eckhardt et al., 2006, Rakyan et al., 2004), this panel
assumed that the neighbouring CpG sites to the CpG site of interest has similar
methylation levels.For the purpose of analysing the methylation levels in paediatric
GCTs,a total of 15 tumour samples (seven germinomas and eight YSTs)and 5 controls
(buccal cells from two adults and peripheral blood from three infants) were initially
analysed.
As mentioned above, IIlumina GoldenGate arrays use two sets of labelled
primers that are specific to amplify either methylated or unmethylated CpGsites and
will fluoresce once they bind to their target sequences. The intensity of the
fluorescence is then captured and compiled in an intensity data file. This data file was
then exported into BeadStudio v3.2 methylation module?' (Il1umina, San Diego, USA)
and along with beadarray program available in the Bloconductor", probe quality
assessment was performed. Using both programs, tumour samples were excluded if
more than 1% of 1505 target probes showed a detection probe p-value > 0.05. In
addition to these programs, an additional program called Beadarray Subversion of
Hashlights (BASH)was also used to identify the presence of any spatial effect that may
undermine further analysis.
After quality control assessment, bead summary signal taken from the green
and red fluorescence channels were analysed with the beadarray program. After
background normalisation, the corrected methylation scores or ~-values were
calculated which produced a value between zero and one; zero represent
unmethylated CpGsite while one represent fully methylated CpGsite.
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Once the J3-valuewas corrected, 84 probes that represent 39 X-chromosome
genes were excluded due to discrepancies between male and female methylation
levels at the X-chromosome. This left 1421 sites representing 708 genes for further
analysis.
To determine any association between tumour types in terms of their
methylation, all the data were analysed using bootstrap hierarchical clustering (Fig 3.8
B). This was performed using R package pvclust (Suzuki and Shimodaira, 2006). The
generated clustering heatmap consist of rows and columns, representing the genes
and the samples respectively where green represents unmethylated site while red
represents methylated site. From the heatmap (Fig 3.8 A), we observed that there are
areas which are more methylated in YSTs as compared to the seminomas and the
control samples.
Further analysis from the clustering revealed that the seminoma samples were
clustered together with the controls while YSTsamples formed an independent cluster
on their own (Figure 3.8B).
. We next used principal component analysis (peA) to find out whether we can
separate our samples into smaller variable components. First, a scree plot was
measured to determine the minimum amount of variables that are considered
meaningful for peA. It was found that three variables were enough for PCA in our
paediatric samples. From the peA, we found that the clustering between seminoma
and the controls were still retained. Interestingly, there seem to be two separate
groups in the YSTsamples (Figure 3.9A).
In order to determine if we can further separate seminoma and the controls
into separate entity, another type of cluster analysis, k-mean analysis was used. From
this analysis we failed to separate seminomas and controls, which strongly suggest the
similarities shared between these two sets of samples in terms of their methylation.
Interestingly, we managed to further separate YSTsinto two groups (Figure 3.9B). This
suggests the presence of two YST subtypes that can be differentiated by their
methylation levels.
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Figure 3.8: Heatmap and bootstrapped hierarchical clustering analysis. A) Heatmap produced from
Infinium analysis showing differentially methylated area in YST when compared with seminomas, B)
bootstrap hierarchical clustering showing seminomas clustering together with the controls.
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Figure 3.9: Further clustering analysis using principal component analysis and k-mean analysis still
showed seminomas clustered with the controls. A) Principal component analysis showing VST (blue
circles) forming an independent cluster while seminomas (red circles) are clustering together with the
controls (green circles), B) k-mean analysis showing VSTcan be further clustered into two methylation
group.
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3.2.2.2. : Identification 0/ differentially methylated genes
In order to help identify genes that are differentially methylated between
seminoma and YSTs,an additional independent cohort of samples were analysed. This
independent cohort consisted of nine seminomas and eleven VSTsamples.
Previous methylation studies in other types of cancer that adopted a similar
array approach, defined a difference in methylation as a site having a delta beta-value
that ranges from 0.75 to 0.29 (Martin-Subero et al., 2009, Richter et al., 2009, Ang et
al., 2010). This range is quite large, so to determine which cut-off point to use for our
samples, we compared the reproducibility of our tumour cohorts at cut-off point of
more than 0.2 and 0.3. As summarized in the Table 3.2, genes with a delta beta-value
more than 0.3 in the first cohort of the paediatric YST samples were highly
reproducible in the second cohort compared to those with delta beta-values between
0.2 and 0.29. Similar result was observed in the paediatric seminoma samples, and in
genes with a delta beta-value less than -0.3. Figure 3.10A represent this observation
which showed OGG1, DDR1, LEFTY2,and WRN were among those hypomethylated in
the first cohort with delta beta-values between -0.2 and -0.3, but showed no
hypomethylation in the second cohort. Thus, we selected a delta beta-value of more
than 0.3 or less than -0.3 as our cut off point to identify differentially methylated
genes.
Percentage of genes Inthe first cohort that are reproducible Inthe second cohort
according to the delta beta-values
Delta beta-value More than 0.3 Between 0.2 and Lessthan -0.3 Between -0.2 and
0.29 -0.29
VST 84% 34% 44% 36%
Seminoma 25% 7% 75% 33%
Table 3.2: Majority of genes with delta beta-value more than 0.3 or less than -0.3 are reproducible.
Table shows the percentage of genes in the first cohort that pass the same delta beta-value thresholdin
the second cohort.This shows that genes with delta beta-values of more than 0.3 or less than -0.3 are
highly reproducible which leads us to use this value to define differentially methylated genes.
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In order to identify genes that were hyper or hypomethylated, we sorted the
raw data in an Excel file and ranked them from the highest to the lowest delta beta-
value. Only delta beta-values of more than 0.3 or less than -0.3, were considered to
show significant difference in methylation. In the first cohort there was little
hypomethylation seen in both tumour types (3/708 in seminomas and 17/708 in YSTs).
Out of these, three genes were hypomethylated in seminomas while only seven of
those in YSTswere hypomethylated in the second cohort (Figure 3.10B and C).
By comparing the methylation value of each tumour type to the controls, we
found that there were 85 genes hypermethylated in YSTs.Using the same approach,
we found 104 hypermethylated genes in the second cohort of paediatric GCTsamples.
Out of these 104 genes, 71 of them are among the 85 genes found to be methylated in
the first cohort (Figures 3.11). The top 25 genes reproducibly hypermethylated in the
YST samples are shown in Figure 3.11B. Only one gene (CD85) was found to be
reproducibily hypermethylated in seminomas.
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Figure 3.10:Relatlvely small amount of genes are reproducibly hypomethylated (with delta beta-value
less than -0.3) in both tumour types. Graph showing comparison of differentialy methylated genes
between the two cohorts of tumours A) hypomethylated in YSTsand B) hypomethylated in seminomas
C) hypomethylated in both YSTs and seminomas. Figure 3.l0A represent observation that genes with
delta beta-value of more than 0.3 or less than -0.3 are reproducible. For example OGGl, DDRI, LEFTY2,
and WRN that displayed delta beta-values between -0.2 and -0.29 in the first cohort (dark purple)
showed no hypomethylation in the second cohort (pale purple).This figuresalso showed that there was
little hypomethylation observed in both tumour type. Blue bars represent seminomas while purple bars
represent YSTs. Black line represents the cut-off point of 0.3. Darker colour bars represent the first
cohort while pale colour bars represent the second cohort of tumours
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Figure 3.11Majority of genes hypermethylated in YSTs in the first cohort were also found to
behypermethylated in the second cohort. A) Venn diagram summarizing the number of genes
hypermethylated in YSTs in the first (blue) and second (yellow) cohort showing an overlapped of 71
similar genes. B) Top 25 hypermethylated genes in YSTsin the first cohort (dark purple) and reproducibly
hypermethylated in the second cohort (pale purple). Out of those 25 genes, only one gene, WNT2, did
not maintain delta belta-value more than 3.0 in the second cohort. Blue bars represent seminomas.
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We then questioned whether the observed hypermethylation is due to
inclusion of a few samples in which those genes are highly methylated that skewed the
data. To answer this, we looked at methylation level for the 85 genes initially identified
in each tumour samples. We found that 27 of these genes were hypermethylated in
more than 85% of YSTsamples from both cohorts (Figure 3.12).
Next, we looked for any similarity between genes that were hypermethylated
in our samples and the adult GCTspopulation. Previous studies in adult testicular GCTs
have identified nine genes that are frequently methylated in non-seminomatous GCTs
(Manton et al., 2005, Koul et al., 2002, Koul et al., 2004, Smith-Sorensen et al., 2002,
Honoria et al., 2003, Lind et al., 2006, lind et al., 2007). By comparison to this data, we
found five of them (RASSF1A, HOXA9, SeGB3Al, Hlel, APe) are also significantly more
methylated in our YSTsamples compared to the seminomas.
Three previous studies also found these five genes to be hypermethylated in
100% of YSTsanalysed (Honoria et al., 2003, Koul et al., 2004, Lind et al., 2006). In
these studies a total of five, five and six YST samples were among other non-
seminomatous GCTssamples analysed respectively. However, we found only APe fits
this feature in our samples. One possible reason behind this is the presence of one YST
sample that has a lower methylation level when compared to the rest of YSTsamples.
This sample did not show significant hypermethylation in more than 70% of the genes
that were hypermethylated in the other YSTsamples. If we removed this sample from
our analysis, we found an additional two genes, HOXA9 and PYCARD, to be
hypermethylated in 100% of YSTsamples (Figure 3.13).
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Figure 3.12: AII27 genes that are hypermethylated in more than 85% of Y5T samples. Darker grey bars
represent YSTsamples while lighter grey bars represent seminoma samples
-_
t-
r-
-
- -
'- -
r-
'--,
--
-I
-
Gene of Interest
Figure 3.13: Additional 2 genes (HOXA9 and PYCARD) found to be hypermethylated in 100% of VST
samples after removing one VSTsample that lacked a methylator phenotype. It also showed 21 out of
30 genes that are methylated in more than 80% of YSTsamples, Darker grey bars represent YSTsamples
while lighter grey bars represent seminoma samples.
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3.2.3. : Validation using pyrosequencing
In order to verify that the methylation level seen in the array reflected the real
situation, and not due to bias from the method used in the array, we used
pyrosequencing to validate one of our hypermethylated genes from the array. For this
purpose, we choose PYCARD as our gene of choice. This is because it is one of the
genes that were significantly hypermethylated in all YSTsand it has been shown to be
differentially expressed in seminomas (will be discussed below). Despite this, PYCARD
only showed a moderate methylation level between YSTsand seminomas. Thus, we
believed validation performed on this gene represented a stringent validation of the
array. In addition to that, pyrosequencing also provides us with the information on the
methylation level at the neighbouring CpG site, thus giving us a clearer methylation
profile across the CpG islands. Furthermore since the GoldenGate probe was designed
with an assumption that CpGsneighbouring the methylated CpGsare also methylated,
pyrosequencing also serves as a test of this assumption.
This pyrosequencing of the PYCARD promoter region started at -234bp
upstream of the transcription start site. It amplified a lOObp region that covered six
CpGs, one of which was included in the methylation array (Figure 3.14). Due to the
limited amount of genomic DNA available, only 5 samples were used (two YSTsand
three seminomas) and they were only carried out in duplicate.
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PYCARD/NM_145182.1
-31214802
GTAGAGTCAGGoUTCMACAMGMCTGTATOGCITCMGTTCATGGTCTTTMTCTCCT~GTCTCTCnTCTTTTTTCTTTTTITTA
ATCAGTGITGGGATCMAITCTOGCTCCCCTAGGMGCATCTGGCMGGTTTCGGGAGCCATCGGGTTOGCCATGITATGCTGGMTAnTA
TMGCACCGGAGGGTTATCCCCATGTCGTAGAMATGMACTGMGCT~nT~JJJIGIA~
CCAGTATGTGGAATTGAGGGAGCTTCACGCUCTAGCTGTCA'lGAJJCCMGAm;TACSiACANTGGGAGAGGAJCCJMGGUCGGGG
AAccocr.r .... GGTTTrr.r<4UCTAGAAAlCCGAGGTTCTMGCCTAGGIGCICCAATMACCCAGIGI\GI\GCCAGCCCAGGTTTCCGGTj;
TGTACCCGCTGGIGCMGCCCAGt\GACMGCA.GGCGCCACCCATGAGCCCCTCTGCGGCCCCCTCCCGG~~CAG.C
TGGAGGGCGCGATCCTGGCGICCCCCGACGGCCTl---GGCCCCMTCCAGAGGCCTGGCiJ'GGGAGGGGACCMGGGTGTAGTMGGAA
GCGCCTTTTGCmGAGGGCMCGGACCGGGGCGGGGAGTCGGGAGACCAGAGTGGGAGGAAGGCGGGGAGTCCAGGTTCCGCCCCG
GAGCCGACTTCCTCC1GGTCGGCGGCTGCAGCGGGGTGAGCGGCGGCAGCGGCCGGGGATCCTGGAGCCATGGGGCGCG -31214001
Forward Primer
TJITTTGTTnTTTGTATMTTTAII II I IIIIAGTATGTGGAATTGAGGGAGTTTTACGTTTTTAGTTGTTATGATTTTMGATTTTACGATATGT
Sequencing Primer
GGGAGAGGl'.TITIMGGTTCGGGGAAICGCGGAC'.GTITcr..r'.JiTTITAGAMTTCGAGGTTTTMGTTTAGGTGTTTTMTAMTTTAGTGA
GAGTTAGTTTAGGITTTCGGTTTGTA TTCGTTGGTGTMGITTAGAGA TAAGTN:iGCGTTA TTTATGAGITTTTTTGCGGTTTTTTTTCGGGTT
TTATTTCGTAGGTTAGTTGGAGGGCGTGAITTTGGCGITTTTCGACGGTTTGGGGITTTMTTTAGAGGTTTGGGTGGGAGGGGATTAA
Figure 3.14: Diagram showing the location of PYCARD pyrosequencing primers. The upper sequence is
PYCARD genomic DNA sequence before bisulfite treatment. The sequence underlined is the sequence of
interest which is represented by the lower sequence after bisulfite treatment. The forward, reverse and
sequencing primers are represented by the arrow. The underline in the lower sequence represents the
sequence analysed by the pyrosequencing. CG in bold red represents the methylated CpG which are
maintained as CpG even after bisulfite treatment.
Selected GeT samples that had been bisulfite treated were subjected to 40
cycles of peR (95°e for 1min, 56°e for 1 min, 7re for 1 min). The peR products were
run on 1.5% agarose gel to make sure there were no contaminants (Figure 3.15). The
peR products along with the sequencing primer were then sent to Queen Mary
University for pyrosequencing analysis.
Figure 3.15: Representatltive gel showing amplification of PYCARD pyrosequencing peR products.
107
Completed pyrosequencing results were sent back in a form of a graph called a
pyrogram. Eachpyrogram represents an analysis of all 6 CpGsfor each tumour samples
which showed the percentage of methylation at each CpG of interest (Figure 3.16).
Data obtained from the pyrogram were then tabulated and represented on a graph.
From the graph, we saw that the YSTsshowed a higher methylation level compared to
the seminomas at all six CpG sites that were covered (Figure 3.17 A). When we
compared the one CpG site that was also included in the methylation array, the level
of methylation pattern was found to be similar between pyrosequencing and the array
(Figure 3.17 Bl. In fact from this same graph, it can be seen that pyrosequencing is
more sensitive than the array in picking up the methylation signal in places where the
array could not.
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Figure 3.16: PYCARD pyrogram. Representatitive pyrogram with CpG site of interest being highlighted in
grey and were given its percentage methylation value above the highlighted region.
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Figure 3.17: pyrosequencing showed that YST samples exhibit higher methylation at all PYCARD CpG
sites analysed. A) Methylation level at CpG sites included in the pyrosequencing in the tumour samples
which showed that YSTsamples have higher percentage of methylation level at all CpG sites compared
to seminoma samples B) Comparison between methylation level of CpG#6 that was included in both
pyrosequencing and the methylation array which suggests that pyrosequencing is more sensitive than
the array in picking up the methylation signal.
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3.2.4. : Methylation and gene expression
Since DNA methylation is generally considered to be influential in tumour
development when it affects gene expression, we used Reverse-Transcriptase (RT)PCR
to analyse gene expression. However, we could not obtain RNA for all the tumour
samples. Furthermore, the RNA that we did receive was often in low quality and we
could not obtain high quality eDNA out of it. This is illustrated in the figure below
(Figure 3.18) which showed that beta-actin could not be amplified in some of the
samples. Although this observation could also be due to an error in synthesizing the
cDNA, we had insufficient RNAto optimise and get good quality cDNA. For this reason,
it was not feasible to use the available RNAsamples to do RT-PCRon all the intended
genes.
NoRT
SSSyyy+SSSyyy+
APC
B-actin
Figure 3.18: RT-PCRof APe expression in the paediatric GCTsamples. It clearly shows that beta-actin
could not be amplified in some of the samples suggesting the possibility of RNA degradation. 5 indicate
seminoma samples, Y indicate YSTsamples.
Therefore, we instead referred to the Affymetrix expression array data from
our collaborators that used the same bank of tumour samples. By comparing this to
our Illumina GoldenGate methylation array data, we found that the majority of the
genes that were hypermethylated in our analysis were not differentially expressed
between YSTsand seminomas. Only 9 of the genes were found to be differentially
expressed (average LOOSvalue of more than 4) according to their methylation status.
Of these, 8 showed a significantly higher level of expression in seminomas (Table 3.3).
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Table 3.3: List of genes hypermethylated In YSTand differentially expressed In seminomas
3.3. : X-chromosome and GCTs
Before the exclusion of X-chromosome from our previous analysis, we observed
that some of our paediatric GeT samples features hypomethylation at some of the X
chromosome genes (Figure 3.19). Normally it is expected that the females will exhibit
50% methylation of all X-chromosomes genes while the males will show no
methylation. When analyse further, we found 19 out of 39 X-chromosome genes
included in the GoldenGate array were hypomethylated among six male and one
female GCTsamples. These hypomethylated X-chromosome genes are listed in Table
3.4.
Patients with an extra X chromosome, such as those with Klinefelter's
syndrome, have been found to have an increased risk of developing extragonadal germ
cell tumours (Aguirre et al., 2006, Gilbert et al., 2011). To investigate whether any
samples within our bank of tumours do have an extra X chromosome, we used
amelogenin assay to analyse our samples.
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Figure 3.19: Heatmap showing the presence of hypomethylated X-chromosome genes in our
paediatric GCT samples which are seen in the area marked in yellow circle.
List of X-chromosome genes found to be hypo methylated in the paediatric
GCT samples
ELKl VBPl DNASE1Ll IRAKl
ARAF SLC6A8 EFNBl MYCL2
GLA HDAC6 MECP2 TIMPl
G6PD DLG3 BGN FHLl
BIRC4 FMRl GPC3
Table 3.4: List of 19 X-chromosome genes hypomethylated In paediatric GCT samples
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The amelogenin assay is a PCR-based sex-identification assay based on the
amplification of amelogenin gene alleles. Amelogenin gene is known for its role in
enamel development and is homologous at both X and V sex chromosomes. Despite
being homologous, they are different in sizes which make this gene useful for sex-
identification. For this purpose we used a kit supplied by Promega that comes with a
labelled primer that will amplify a 212bp X-specific and 218bp V-specific product. Due
to the closeness of these two bands, we were unable to reliably distinguish them on a
gel (Figure 3.20). Therefore we subjected the samples to Genescan analysis using
PeakScanner software version 1.0. As illustrated in Figure 3.21, we determined the
number of X and V chromosome by calculating the ratio of height of peak at 212bp and
height of peak at 218bp.
Using NTlD1 cell line that are known to have an extra X-chromosome, we
found that some of our samples showed a presence of an extra X-chromosome (Table
3.5) and this includes tumours from gonadal sites. We also observed that the only
female sample included in the analysis showed a presence of V chromosome. The
reason behind this is still unclear although female caseswith V chromosome have been
reported before (Saavedra-Castillo et al., 2005, Schmid et al., 1992).
It is also unknown whether extra X chromosome observed in some of the
paediatric samples are due to the features of Klinefelter's Syndrome itself or the
features of the tumours on their own. To investigate this, we attempted to obtain
constitutional DNA from our collaborators in Cambridge. Unfortunately, none were
available. Therefore, this issuewas not pursued further.
113
YST
cs
..
..
'& c:
08
iii ~
~IISEM
Figure 3.20: Representative gel picture of amelogenin assay using paediatric germ cell tumour samples
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Figure 3.21: Genescan diagram showing the peak for X and Y chromosomes (blue peaks). Only one
peak (212bp) was observed in female lB infant control which corresponds to X chromosome. In male
MD infant control, two peaks (212bp and 218bp) represent X and Y chromosome respectively were
observed having a similar height of peak suggesting similar dosage of sex chromosome. In NT2Dl cell
line, a male testicular GCTcell line, were observed to have higher peak at X chromosome, almost double
in size than Y chromosome peak suggesting the presence of an extra X chromosome.
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Sample « Location
Heights' at
212bp (X-chr)
"' ,
Heights at
, '
218bp" . (Y-,
, ,
chr) , ''I''
, ,
Seminoma M Testis 496 421 01:01
NT2D1 M Testis 175 84 02:01
Table 3.5: Ratio of X chromosome to Y chromosome in paediatric GCT samples as determined using
amelogenin assay and measured using PeakScanner software. From this measurement, we observed
some of the paediatric samples showed a presence of an extra X chromosome.
3.4. Discussion
3.4.1. : Paediatric GCT'sglobal methylation
Our measurement of global methylation of LlNE-1 repeat elements as a means
of assessing global methylation level reveals that both of germinomas and yolk sac
tumours (YSTs)are significantly less methylated than the controls. This finding showed
similarity with the result found by Ushida et al. (2011) who used the same technique in
their study of patient with testicular germ cell tumours. In this study, the mean age of
patients involved was 3S years old for both seminoma and non-seminoma cohort.
However, our results showed that hypomethylation of LlNE-l repeat element can
occur even in a younger age patient, suggesting the phenomenon is not age
dependent. Furthermore, we also showed that this hypomethylation can be observed
regardless of sex and the location of the GeTs. looking at other global methylation
analysis approach done on other type of tumours (Baba et al., 2010, Daskalos et al.,
115
2009) it is clear that in all types of tumour hypomethylation of intergenic DNA is a
common feature.
From the Golden Gate array analysis, we did not find many genes showing
promoter hypomethylation despite the global intergenic hypomethylation. It seems to
suggest that there is no correlation between global hypomethylation and the state of
promoter methylation, which is in agreement with the current consensus (De Smet
and Loriot, 2010). Therefore, the most plausible contribution for this global
hypomethylation towards tumourigenesis is due to its effect on repeat elements. At
the moment, two mechanisms have been proposed to explain how repeat element
hypomethylation might be involved in tumouregenesis. The first is that
hypomethylation of repeat elements causes their mobilisation along the genome and
.creates genomic instability (Schulz et al., 2006).This was seen in an experiment using
Dnmtl hypomorphic mutation mice which only expressed 10% of wild-type Dnmt1.
These mice were found to develop lymphoma with a high frequency of chromosome
15 trisomy (Gaudet et al., 2003) which suggests an involvement of chromosomal
instability. Further experiment from this group also showed that among these mice,
there was evidence of an insertion of intracisternal A particles (lAP), a transposable
element, into the genomic locus of Notchl(Howard et al., 2008). This further suggests
that chromosomal instability in these mice was also accompanied with an activation of
the transposable elements.
Meanwhile, the abundant number of repeat elements in the human genome
and the fact that repetitive elements can be found at almost 30% of the transcription
start sites (Faulkner et al., 2009) suggests an involvement of repeat elements in some
gene regulation. For instance, human cMET, a proto-oncogene, contains an intronic
LlNE-l element between exon two and three (Weber et al., 2010a).This Ll-cMet gene
was found to be heavily methylated in normal cells but showed Significant
hypomethylation in bladder cancer (Wolff et al., 2010). This observation correlates
well with the high expression of the LlNE-l anti-sense promoter called LI-MET.
Furthermore, they also demonstrated that demethylation of this anti-sense promoter
in bladder fibroblast cell lines led to an increase in the expression of Ll-MET that is
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usually repressed in this cell line. This suggests an involvement of DNA methylation in
silencing this promoter. There is no doubt about the involvement of DNA methylation
in silencing the repeat element but how repeat element hypomethylation might
contribute to GCTsdevelopment still needs to be investigated.
3.4.2. YSTsamples showed higher methylation level at the gene regulatory region
From our genome-wide methylation analysis in two cohorts of paediatric GeTs
using lIIumina GoldenGate array, we found that seminomas showed an almost normal
methylation level when compared to controls while YSTsshowed a high methylation
level at many of the epG sites. This is in agreement with previous findings using
restriction landmark genome sequencing (RLGS)in adult testicular GeTwhich showed
almost no methylation at all epG site in seminomas (Smiraglia and Plass,2002). This is
interesting since similarity observed between seminoma and the normal controls
suggests that seminoma is a totally different type of tumour as compared to other
solid tumours. We also found that the CpGsof approximately 10%of genes included in
the array panel are hypermethylated in YSTsas compared to the seminomas. Unlike
previous studies that chose a candidate gene approach (Furukawa et al., 2009), our
data showed that the gene regulatory regions in the YSTsare more hypermethylated
than the seminomas across the genome. Interestingly, five of the genes (SCGB3Al,
HOXA91 AP~ RASSF1A1 HIC1) found to be methylated in our YSTsamples are among
the genes commonly found to be methylated in adult non-seminomatous testicular
GCTs(Koul et al., 2002, Koul et al., 2004, Smith-Sorensen et al., 2002, Honorio et al.,
2003, lind et al., 2006, lind et al., 2007, Manton et al., 2005).
Previously, SORBSl and GSTPl have been reported to be hypermethylated in
seminoma samples (Koul et al., 2002, Lind et al., 2006). However we found that none
of the seminoma samples (0/16) included in our Golden Gate analysis showed
hypermethylation of GSTP1. This is in agreement with the findings by (Kawakami et al.,
2003a) and (Honorio et al., 2003) who also showed no GSTP1methylation in their
seminoma samples. Given that previously only one out of 29 seminoma samples
showed hypermethylation of GSTP1(Koulet al., 2002), our current observation might
suggest that this hypermethylation could just be an isolated case. Unfortunately, we
117
could not assessthe methylation level of SORBSl in the paediatric seminoma samples
since this gene is not included in the array panel.
3.4.3. Hypermethylated genes in YSTsamples are not entirely silenced
It seems highly unlikely that all genes that are methylated could have a role in
tumour development, as seems to be suggested by previous study (Lind et al., 2007). It
is known that not all genes that are methylated will be silenced. At the moment, only
RASSF1A has been found to have any correlation between methylation and gene
Silencing in adult testicular GCTs (Koul et al., 2002). Therefore, we referred our
methylation result to the gene expression data performed on the same cohort of
paediatric GeT samples by our collaborators (Palmer et al., 2008). Interestingly, of 85
genes that are hypermethylated in YSTs,only eight genes were differentially expressed
in seminomas and strikingly RASSF1A was not one of them. It is also interesting to see
that only 13 out of 29 genes involved in TGF-~/BMP signalling that were found to be
differentially expressed in paediatric YSTs (Fustino et al., 2011) are differentially
expressed in our samples. However, only two out of these genes are included in our
methylation array and both of them (COLlAl and IGFBP3) are hypermethylated in YST.
Although we found only eight genes hypermethylated in our YSTssamples that show
differential expression, this small number has really narrowed down the search for
possible candidate gene involved in paediatric GCTsdevelopment.
3.4.4. : Genes hypermethylated in YSTand differentially expressed in seminoma
3.4.4.1. TFAP2C
Transcription factor AP-2 gamma, TFAP2C (other aliases AP-2 GAMMA, ERF1,
TFAP2G, hAP-2G) is a member of the AP2 transcription factor family known to be
involved in activation of many developmental genes. It has been found to be
methylated in chronic lymphocytic leukemia (Tong et al., 2010). In the same study,
treatment with a DNA methylation inhibitor could reactivate TFAP2C expression in two
leukemic cell lines which suggested involvement of DNA methylation in TFAP2C
regulation.
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Interestingly, TFAP2C was found to have a significant role in primordial germ
cells (PGCs), the cells thought to be the origin of germ cell tumours. Conditional
deletion of Tjap2c resulted in loss of primordial germ cells (PGCs) soon after
specification (Weber et al., 2010b). Besides losing a significant number of PGCsfrom
this knockout, the remaining PGCswere found to have impairment in their migration
ability. This might support the migration theory that suggests extragonadal GCTs
arising from PGCsthat fail to complete their migration into the gonad. In addition to
which, this deletion also leads to upregulation of markers related to mesoderm
differentiation. This fits well with the development of more differentiated germ cell
tumour such asYSTs.
While impairment of migration ability was found in PGCs after deletion of
Tjap2c, a recent study in a mouse model of melanoma showed a contrast observation.
In this study, silencing of Tjap2c with short-hairpin RNA caused an increase in cell
migration and extravasation (Penna et al., 2011) which fits well with the
aggressiveness of YSTs.This contrasting observation might be due to a different role
played by Tjap2c at different developmental stages and/or in different cell types.
3.4.4.2. PYCARD
PYD(Pyrin) and CARDcontaining domain, PYCARD (also known as ASCor TMS-
1) is an adaptor protein that has been shown to interact with CASP8and is involved in
apoptosis (Masumoto et al., 2003, Masumoto et al., 1999). A study done in prostate
cancer cell lines, LNCap,showed that PYCARD was fully silenced (Das et al., 2006). This
is due to DNA methylation since treatment with S-aza and not TSA, partially
demethylated and reactivated the gene.
Using methylation-specific PCR,Hervout et al. (2010) found that only 30% and
22% of their 27 glioblastoma multiforme patients showed methylation of PYCARD and
CASPB respectively. Interestingly, by measuring caspase 3 protease activity to
determine intra-tumor apoptosis levels and correlating them to the gene methylation
status, they found that there was no correlation between methylation level of these
two genes and the caspase activity. This might be due to low methylation of both
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genes and since no expression analysis was done, this low methylation might not have
had any effect on their expression.
3.4.4.3. HDAC9
Histone deacetylase 9, HDAC9 is a zinc-dependent HDAC class lJa located in a
chromosome region implicated in many cancers. Higher expression of HDAC9 has been
linked to poor prognosis for some tumour types (Moreno et al., 2010, Milde et al.,
2010); however the exact role played by HDAC9 in tumourigenesis is still not well-
studied. One study (Milde et al., 2010) showed that silencing of HDAC9 using siRNA
caused reduction in medulablastoma cell growth and viability.
3.4.4.4. ETV1.
ETSvariant 1, ETVl is a submember of the PEA3group of transcription factors
and it has been found to be overly expressed in many type of cancers either in their
full length or as a fusion with another gene (Tomlins et al., 2007, Gasi et al., 2011,
Jane-Valbuena et al., 2010). In melanoma, primary melanocytes were found to be
transformed and develop tumours in mice after overexpression of Etvl(Jane-Valbuena
et al., 2010). In addition to this, ETVl expression is essential in interstitial cells of Cajal
(ICC)development and this expression is regulated by KIT(Chi et al., 2010). In the same
study it was found that constitutive activation of KIT by mutation will cause
stabilization of ETVl protein which leads to ICC hyperplasia and gastrointestinal
stromal tumour development. It is interesting to see this strong relationship between
KIT and ETVl might also exist in GCTsdevelopment, particularly in seminomatous GCTs
since numerous studies have shown the presence of activating KIT mutations in
seminomas (Kamakura et al., 2006, Sakuma et al., 2003, Sakuma et al., 2004, Kemmer
et al., 2004). Indeed, preliminary sequencing experiments performed in our lab
revealed that some of the seminoma samples also exhibited KIT mutations. What is
more striking is that ETVl is among the genes that are differentially expressed in our
seminoma samples. This suggests the possibility that these two genes are involved in
seminoma development.
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3.4.4.5. CD2
C02 is an immune response gene but how its silencing affects tumour cells is
not well documented. However,C02 ligation has been shown to be one mechanism to
prime and subsequently activate resting NK cells (Bryceson et al., 2006). In addition to
that, a recent study in a leukemic cell line showed that blockade of C02 caused
inhibition of cell lysis (Sabry et al., 2011).This might suggest that C02 methylation and
its low expression in YSTmight provides the cell's with an ability to evade lysis.
3.4.4.6. CASPS
CASPS is a member of the caspase family and involved in the apoptosis
signalling pathways (Fulda, 2009, Kim et al., 2001), which could either be through the
death-receptor or the mitochondrial pathway. Beside its apoptotic function, CASPS has
also been shown to play other non-apoptotic roles such as in embry~nic development,
blood cell formation and immune response (Maelfait and Beyaert, 2008). In addition to
that, CASPS can play an important role in resistance to chemotherapy (de Vries et al.,
2007).
One study looking at the methylation of pS3 target genes in testicular GCTs
showed minimal methylation of CASPS in both seminoma and non-seminomatous GCT
(Christoph et al., 2007). Using quantitative methylation-specific PCR,they only found
one seminoma and two non-seminomatous samples to be methylated out of 26 and 20
samples respectively. This is much lower than the methylation level observed in our
YSTsamples (10% vs 70%). However, it should be noted that only one YSTsample was
included in their non-seminomatous group which might not reflect the true
methylation level of most YSTs. Furthermore, their method of using MYODl as a
reference gene might also have an influence in their measurement of the methylation
level. Nonetheless, they did not perform any expression analysis of CASPS due to this
low methylation level.
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3.4.4.7. EVI2A
The function of EVllA (ecotropic viral integration site 2a) remains unknown. It
is believed to be an oncogene and has been suggested to be involved in retrovirus
induced murine myeloid leukemia in BXH-2 mice (Buchberg et al., 1990). EVllA also
has been found in an intron of Nfl, a tumour suppressor, and is believed to have a role
in development of neurofibromatosis (Pasmant et al., 2011); however, the exact
mechanism is still unclear. Furthermore, how methylation affects EVllA function and
how this may contribute to GCTsdevelopment has yet to be investigated.
3.4.4.8. HLA-F
Major histocompatibility complex class 1 F (HLA-F) is important in the immune
response and has been found to be methylated in glioblastoma multiforme (Martinez
et al., 2009). However, how silencing of this gene might affect tumour development is
still unknown.
3.4.5. Paediatric GCTsassociated with an extra X-chromosome
We have found evidence of an extra X-chromosome present in some of our
paediatric GCTsamples. This extra X-chromosome suggests that these samples were
taken from Klinefelter's syndrome patients.However no clinical data or constitutional
DNA samples were available for these patients, so we could not be certain whether
such observation is due to Klinefelter's syndrome or it is the feature of the tumour
samples on its own.
Klinefelter's syndrome patients are at risk of getting extragonadal germ cell
tumours from mediastinal (Hasle et al., 1992) and to a lesser extent intracranial GCTs
(Kaido et al., 2003). From our analysis, we found that these extra X-chromosome can
also be seen in gonadal samples which have also been seen in a previous study
(Sandberg et al., 1996).
However, how an extra X-chromosome could initiate tumour development
especially in patients with Klinefelter's syndrome still needs to be investigated. Among
the X-chromosome genes that are hypomethylated in our paediatric GCT samples,
ELKl and ARAF,are known oncogenes (Nishigaki et al., 2005, Kawakami et al., 2003b).
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Therefore, activation of oncogenes on the X-chromosome might contribute to GCT
development. In addition to these two genes, the hypomethylation of FMRl and GPe3
genes in our samples have also been reported in a previous study in testicular GeTs
(Kawakami et al., 2003b) which seem to suggest common X-chromosome genes
hypomethylated in germ cell tumours. However, further research needs to be done to
ascertain the involvement of these X-chromosome genes in GeT development.
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4. METHYLATION CHARACTERISATION OF GERM CELL
TUMOUR CELL LINES
4.1. Introduction
From the Ilium ina GoldenGate methylation array, we saw that there are distinct
methylation properties between seminomas and yolk sac tumours with the latter
showing higher methylation at many genes' promoter regions. Nonetheless, we should
keep in mind that there are a few caveats around the Golden Gate methylation array.
First, the Golden Gate array only covers 807 genes, and these genes have been
pre-selected to be tumour-related genes such as tumour suppressors and oncogenes.
Therefore, we cannot really be sure whether such methylation patterns are also similar
in other types of genes. Furthermore, only 1505 CpG sites are analysed meaning that
only 1 - 2 CpGsare covered for each gene. The fact that such a small number of CpG
sites are covered, makes it quite difficult to generalise the methylation level to other
neighbouring CpG sites. In addition, CpG sites that were included in the Golden Gate
array were selected to be in the CpG islands. The reason behind this is that
hypermethylation of CpG islands at the promoter region has long been considered and
shown to contribute to gene silencing (Fernandez et al., 2011, Noushmehr et al., 2010,
Toyota et al., 1999). Contrary to this, recently Irizarry et al. (2009),ln their study on
colon cancer showed that instead of CpG islands, it was the CpG shores that were
usually differentially methylated and this methylation was seen to correlate with gene
silencing.
In order to fully understand this matter, we used the Infinium Methylation450
array. This array works on the same principles as the Golden Gate methylation but
with the addition of a newly designed assay called Infiniumll, which only uses one
probe rather than two for each CpG.The 3' terminus region of this probe will bind to
the query site, while the addition of a labelled G or A base that complements either
the methylated or the unmethylated site will result in the base extension (Figure 4.1).
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Infiniumll
bead type
5'5'
Bisulfite converted DNA Bisulfite converted DNA
Unmethylated locus Methylated locus
Figure 4.1: Infiniumll assaydesign which uses only one probe. The 3' terminus of the probes
complements the base directly upstream of the query site. Binding of either the methylated or the
unmethylated site depends on the addition of labelled G and A bases. Taken from Bibikova et 01.(2011)
The Infinium Methylation450 array panel covers a total of 485,577 sites where
the majorities (482,421 sites) are CpGsites which correspond to 21,231 RefSeq genes
in the University of California, Santa Cruz (UCSC)database. This includes an average of
17.2 probes per gene region. These sites are further subclassified according to UCSC
classification. Most of the sites (145,272 sites) are concentrated on the CpG islands
which is defined as 500bp DNA sequences that have a GCcomposition of greater than
50% and a CpGobserved/expected (O/E) ratio of more than 0.6 (Gardiner-Garden and
Frommer, 1987, Takai and Jones, 2002). In addition to this, sites that are adjacent to
the CpG islands were also covered. These were named CpG shores (two-kilobase
regions flanking up- and downstream of CpG islands) and CpG shelves (two-kilobase
regions flanking CpG shores). To ensure in-depth methylation assessment, sites were
also selected to include different gene elements such as S'UTR, the gene body, the first
exon and 3'UTR. Sites near the transcription start site (TSS)were also selected and
were labelled as TSS200 (sites 200bp upstream TSS) and TSS 1500 (sites 1500bp
upstream TSS).
It is not possible with tumour samples, to perform functional analyses such as
studying the consequences of demethylation on cell migration and survival, or studying
the role of genes identified to be silenced by methylation. We therefore decided to
move to the analysis of GCTcell lines for this array, where we could carry out such
follow-up functional studies. In addition, GCTcell lines are widely used; thus data on
these cell lines from other laboratories are easily accessible for comparison with our
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data. Furthermore, no previous GCTstudies have investigated methylation at regions
other than the CpG islands. Given that the Infinium array offers coverage beyond the
CpG islands, we believed this could provide a better understanding of GCT
methylation. However, the only available GCTcell lines at the moment are adult GCT
cell lines. Therefore in this chapter, methylation analysis were performed on fouradult
testicular GCT cell lines; TCAM2 (seminoma), NT2D1 (teratocarcinoma), GCT27
(embryonal carcinoma, EC)and GCT44 (yolk sac tumour, YST).TCAM2is a seminoma
cell line derived from aprimary lesion of testicular seminoma in a 35 years old male
patient (Mizuno et al., 1993). GCT 27 and GCT44 represent the ECand VSTcell lines
respectively (Pera et al., 1987). GCT27was derived from a primary teratoma testicular
tumour samples which formed embryonal carcinoma when inoculated into nude mice.
GCT44, on the other hand, was established from testicular tumour that has
metastasized into the para-aortic lymph node. This cell line was found to give rise to a
tumour that displayed endodermal sinus yolk-sac morphology when inoculated into
nude mice. Finally, the NT2D1 cell line was obtained as ateratocarcinoma cell line
(Boucher and Bennett, 2003, Pierce et al., 1999, Dahm et al., 2010, Vao et al., 2007)
derived from a 22-year old male patient. However, as I will discuss at the end of this
chapter, this cell line has also been considered as pluripotent embryonal carcinoma ,
cell line (Vestergaard et al., 2008, Milia-Argeiti et al., 2012, Caricasole et al., 2000).
4.2. Results
4.2.1. : Methylation analysis on GCTcell lines
The Infinium methylation450 array analysis on these four cell lines was carried
out at Queen Mary, University of London according to the manufacturer's protocol.
Basically, genomic DNA was first subjected to bisulfite modification before being
denatured into single-stranded DNA and neutralized. These denatured samples were
then isothermally amplified overnight at 3rC. They were then subjected to
fragmentation using a controlled enzymatic process. The fragmented DNA samples
were collected via isopropanol precipitation and subsequently resuspended in a
hybridization buffer. These DNA samples were then subjected to hybridization by
applying them to the BeadChip. Unhybridized and non-specifically hybridized DNA was
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then washed away. Hybridized DNA then underwent the extension process. BeadChips
were then scanned, and the fluorescence emitted from the single base extension
products was recorded. This data was extracted using Genome Studio Methylation
Module software where the fluorescence intensity values were measured and
represented as a l3-value ranging from 0 (not methylated) to 1 (fully methylated). Data
normalization was then performed by this software using the internal control present
in the BeadChip.
4.2.1.1. : Data exclusion
In addition to the l3-value, the software also measured the detection p-value
for the total signal intensity. According to the manufacturer, a high detection p-value
(>0.05), would indicate poor probe hybridization, which could affect the analysis. We
only had four samples and at anyone time, only one sample.could have a detection p-
value >0.05. Therefore, we measured the mean detection p-value for all four cell lines.
Since a mean detection p-value >0.01 would exclude any site where one cell line had a
detection p-value >0.05, we used this as a cut-off point. By taking this measure, we
excluded 4,813 sites from future analysis.
We also adopted a procedure proposed by Irizarry et of (unpublished data).
They calculated the intensities for both methylated and unmethylated probes. When
this was log2 transformed, they found that probes withsignals with a log2 intensity of
<10.5, indicating low signal intensity which could be due to poor probe binding, were
unable to discriminate the differences between samples. Therefore, we removed
probes with such low signals. Using this approach, we removed a total of 61,192 sites
from further analysis.
As with the GoldenGate methylation analysis, we also excluded all sites that
corresponded to the sex chromosomes. By doing so, we lost an additional 8,171 sites
(846 genes). We also noticed that quite a number of sites (100,446 sites) were not
represented by gene symbols which we believed would make it quite difficult to
identify differentially methylated genes. Therefore, we decided to exclude these sites
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for such purposes. After making all these exclusions, only 313,824 out of 422,440 sites
which corresponded to 20,444 out of 41,059 genes, were selected for future analysis.
4.2.2. Data Analysis
Unlike previous analysis in the GoldenGate array, currently there Is no software
or R script available to be used to analyse Infinium data in depth. Therefore, analysis
was carried out using an Excelspreadsheet.
The UCSCdatabase describes a standard in evaluating the methylation level
from the Infinium Methylation450 array. According to this database, a probe with a p-
value of 0.6 and above is considered fully methylated while a p-value between 0.2 and
0.59 is considered partially methylated and a p-value below 0.2 Is unmethylated.
Therefore, we used this as the criteria for the methylation state In our analysis.
4.2.2.1. Methylation features of GCTcell lines
Before we set out to characterise the methylation pattern In the GCTcell lines,
we wanted to determine the beta-value distribution across the entire GCT cell line
genomes. By counting the frequency of occurrence for each beta-value, we found that
all four cell lines shared a bimodal distribution of beta-values (Figure 4.2). Despite this,
we can clearly see that the distribution differs between all four cell lines. The
seminoma and the YSTcell lines showed a much higher distribution at beta-values
ranging from 0.2 to 0.7 (up to 0.8 in seminoma) but a low distribution at a beta-value
of 0.9 to 1.0 (except YSTwhich show high frequency at beta-value of 1.0). In contrast,
both the ECand the teratoma cell lines displayed higher distribution at beta-values
above 0.8, showing that higher methylation is a feature of ECand teratoma cell lines.
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Figure 4.2: Bimodal distribution of beta-values in A) all four GCTcell lines, and B) each of the cell lines.
This shows that probes' in ECand teratorml tend to concentrate at hilher methylation levels sugesting
these two cell lines feature higher methylation as compared to the other two cell lines.
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This was far more evident when we tried to determine methylation according to
chromosome region using a distribution plot. Using the SVSv7.0 software (Golden
Helix), we plotted probes' distribution according to their beta-value across
chromosome regions. In general we did not see any difference in methylation at any
chromosome region in all four cell lines. Strikingly however, we observed that there
were fewer probes distributed between beta-values of 0.2 and 0.6 (and to a lesser
extent between 0.6 and up to 0.8) in the ECand the teratoma cell lines as compared to
the seminoma and the VSTcell lines (Figure 4.3). Since beta-values ranging from 0.2 to
0.6 are considered partially methylated, it seems thatseminoma and VST cell lines
hadmore partially methylated sites as compared to the EC and teratoma cell lines.
Since the partial methylation observed resembles the expected properties of imprinted
genes, we investigated the methylation profile of all imprinted genes included in the
array for all four cell lines. Imprinted genes are expected to have one allele silenced by
methylation leaving only one allele functioning (50% methylated). However, there
could also be instances when both alleles are silenced (100% methylated) leading to
completegene inactivation. Therefore, we expected to observe these imprinted genes
to have beta-values of 0.2 to 0.59 or more than 0.6 which corresponds to partial
methylation or fully methylated respectively, as defined by theUCSCdatabase. Using
the Genelmprint database (www.geneimprint.com) which lists 84 known imprinted
genes in humans, we identified 34 that were included in our Infinium methylation
analysis. This low number is likely to be due to the exclusion of imprinted genes at the
X-chromosomes made earlier in the analysis. looking at the beta-value distribution of
all CpG probes for these 34 imprinted genes, we found that most of the probes in the
VST and seminoma cell lines accumulated at beta-values of 0.2 to 0.8, with more
probes in the VSTcell line than the seminoma cell line exhibitingat beta-value of 0.2 to
0.5, which fits with the partial methylation features of animprinted gene (Figure 4.4)
while many of the probes in the seminoma cell line displayed a beta-value of 0.6 to 0.8
as compared to the VSTcell line. Strikingly, for both ECand teratoma cell lines, the
majority of probes were concentrated at beta-values of more than 0.9, while only a
few exhibited a beta-value of less than 0.6. This might explain the lack of probe
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distribution between beta-values of 0.2 to 0.6 that was observed on the Manhattan
plot in both Ee and teratoma cell lines (Figure 4.3). However, when we performed the
same analysis across the (pG islands of the imprinted genes rather than for individual
(pG probes, we found that there was not much difference between partial and fully
methylated imprinted genes (Figure 4.5). But, it is obvious that many more imprinted
genes in the seminoma and E( cell lines were fully methylated (i.e. both alleles
methylated) while most of the imprinted genes in the YST cell line were partially
methylated, consistent with only one allele being methylated. Nonetheless, we realise
that the partially methylated imprinted genes only represent a subset of the partially
methylated loci. Therefore, there could be other reasons that could contribute to this
phenomenon and this may be worth investigating in the future.
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Figure 4.3: Distribution plots showing probe distribution at different chromosome regions
(represented by multicoloured channels) in A} seminoma B} teratoma C) EC and D}YST cell lines. In
general, no differences in methylation were observed at any chromosome region in all four cell lines.
However, fewer probes were found to be distributed between beta-value of 0.2 to 0.6 in teratoma and
ECcell lines as compared to the seminoma and YSTcell lines at all chromosome regions. A beta-value of
>0.6 (black line) is considered fully methylated; a beta-value <0.2 (orange line) is considered
unmethylated; while a beta-value between 0.2 and 0.6 is considered partially methylated.
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Figure 4.4: Beta-value distribution of the imprinted genes included in the Infinium methylation
analysis. Clearly most of the probes in the YSTand seminoma cell lines exhibited a beta-value of 0.2 to
0.8, with most of the probes in the YSTcell line exhibiting a beta-value of 0.2 to 0.5 which fits with the
partial methylation feature of the imprinted genes. In contrast, the majority of the probes in both EC
and teratoma cell lines displayed a beta-value of more than 0.9, which suggests that they were highly
methylated and probably silenced.
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Figure4.5: Bar graph showing the distribution of the Imprinted genes according to the average beta-
values across their CpG Islands. It is obvious from the graph that many more imprinted genes in the
seminoma and the ECcell lines were concentrated at a beta-value of 0.6 to 1.0, which implies that both
alleles were fully methylated and silenced. In contrast the majority of the imprinted genes in the YSTcell
line were partially methylated which fits with only one allele being methylated.
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CpG islands, especially those in the promoter region have long been considered
to have been affected by methylation (Noushmehr et al., 2010, Fernandez et al., 2011,
Toyota et al., 1999). However, recently CpG sites outside of CpG islands were also
found to be aberrantly methylated in colorectal cancer (Irizarry et al., 2009, Ushida et
al., 2011). Furthermore, these studies reported that these CpG regions called CpG
shores are the most differentially methylated regions. Since Infinium arrays offer wider
region coverage, this also gave us an opportunity to determine the methylation
pattern in GCT cell lines outside of CpG islands. For this purpose, we used an Excel
pivot table to calculate the average methylation level at different gene regions. As
expected, we found that in general, the methylation level was highest In the shelf
regions and decreased as it reached CpG islands in all cell lines (Figure 4.6). However,
when we compared all of the cell lines to each other, we found that both the ECand
teratoma cell lines showed a much higher methylation at most of the regions as
compared to the seminoma and the VSTcell lines. On the other hand, the VSTcell line
only showed a much higher methylation than the seminoma cell line at CpG islands
while at regions distal from CpG islands, the seminoma cell lines exhibited a higher
methylation than the VSTcell line.
Ogoshl et al. (2011) in their genome-wide methylation analysis of colon cancer
cell lines showed that the methylation level is lowest at the transcription start site
(TSS). This methylation level was found to increase as the location moves further
upstream or downstream of TSSand it is more pronounced when the location is more
than two kilobases from the TSS.Using the same approach as before, we calculated
the average methylation level in GCTcell lines at different gene elements. Indeed, we
found that in all cell lines, methylation was at its lowest near the TSSand started to
increase as it reached the 3'UTR (Figure 4.7). In addition to this, we found that there
was little variation in methylation level at the gene element (ie TSS,S'UTR,gene body,
3'UTR) as compared to the gene region (ie CpG shelf, CpG shores CpG islands). This Is
especially true between seminoma and VSTcell lines. Nonetheless as in methylation at
the gene region, ECand teratoma cell lines displayed a much higher methylation at all
gene elements as compared to the seminoma and the VSTcell lines.
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Figure 4.6: Methylation level across gene region. Average methylation across gene regions in GCTcell
lines which shows that EC and teratoma had a higher methylation at most regions as compared to
seminoma and VST. Meanwhile, VST only showed a higher methylation than seminoma in the CpG
islands region.
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Figure 4.7:Methylation levels at different gene elements showed much less variation between cell
lines. It is evident from here that methylation in GCTcell lines was at its lowest near TSSand increased
when it moved towards 3'UTR. Note that methylation level in teratoma and ECcell lines were higher
than the seminoma and the VSTcell lines at all gene elements, similar to the finding in the gene regions.
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4.2.2.2. Differentially methylated genes at CpGIslands and other gene regions
Previously we found that while EC and teratoma cell lines were highly
methylated in all gene regions, VSTonly showed a substantial increase in methylation
as compared to seminoma at CpG islands. Thus, we believe genes that are methylated
at CpG islands in VSTmight be important for VSTdevelopment. Our first attempt to
identify these genes was by selecting probes in the CpG islands with a beta-value
above 0.6 (considered fully methylated by the UCSCdatabase) and ranking them.
However, since each gene could have more than two probes for CpG islands, we found
that this method is not reliable, as sometimes a high methylation level in one probe
does not translate in the other probes.
Therefore, we used an Excel pivot table and calculated the average beta-value
at CpG islands, again using the cut-off point of above 0.6 to identify differentially
methylated genes in GCTcell lines especially in the VST.Comparing all four cell lines we
found that on average, ECcell line showed the highest methylation level at CpG islands
followed by the VST,the teratoma and lastly the seminoma cell lines (Figure 4.8A).
Interestingly when we looked at the number of genes uniquely methylated in
each cell line (defined as genes having an average beta-value >0.6 and a difference in
beta-value, or delta beta-value, >0.3), we found that the VSTcell line had the highest
number of uniquely methylated genes at CpGislands, followed by the EC,the teratoma
and lastly the seminoma cell lines (Figure 4.8B). In order to determine any similarities
or differences in the methylated genes in all four cell lines, we looked at the number of
overlapping genes in all four cell lines. We found that the majority (97-98%) of genes
methylated in the seminoma cell line were also methylated in the other three cell lines
(Figure 4.9). In contrast, only about half of the genes methylated in VST (50.1%), EC
(53.4%) and teratoma (62.6%) cell lines were also methylated in seminoma.
Analysis on the other gene regions (ie CpG shores and shelf) also displayed
similar features where, in accordance with the methylation level seen in Figure 4.6, EC
and teratoma cell lines displayed the highest percentage of methylated genes at all
regions. On the other hand, the VSTcell line only showed a higher percentage of
methylated genes at the islands and to a lesser extent in the shores as compared to
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the seminoma (Figure 4.10A). Nevertheless, the YSTcell line featured the highest
number of uniquely methylated genes at all regions as compared to the other cell lines
with the vast majority concentrated at island regions (Figure 4.10B)
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Figure 4.8: Bar graphs showing A) the frequency of genes methylated (average beta-value >0.6), and
B) the frequency of genes uniquely methylated (average beta-value >0.6 and have difference in beta-
value >0.3 to other cell lines) at the CpG islands in all four cell lines. It shows that EC had the highest
number of methylated genes at the CpG islands. Note that despite having lower number of genes
methylated as compared to EC, YSTdisplayed much higher number of uniquely methylated genes at the
CpG islands.
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Figure 4.9: Diagram showing the overlapping genes that were methylated in all four cell lines. It shows
that the majority of genes methylated in seminomas were also methylated in the other three cell lines.
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Figure 4.10: Graphs showing the frequency of A) methylated genes and B) uniquely methylated genes
across the gene regions in all four cell lines. They clearly show that VSTpossessed the highest number
of uniquely methylated genes at all regions although it did not display the highest number of methylated
genes as compared to ECand teratoma cell lines.
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4.2.2.3. Differentially methylated genes at the transcription start sites (TSS)and other gene
elements.
Previous methylation studies have focused on the CpG islands in the promoter
region, which can be found in the vicinity of transcription start sites. However, recently
non-CpG island regions have also been found to be methylated (Han et al., 2012).
Indeed, in our previous analysis, we focused on CpG islands such that we overlooked
almost 40% of genes where there was no CpG island in the region of the TSS.Since
methylation at TSSshas been shown to be important for gene regulation, we next
turned our analysis to this region.
Using the same approach as before, we tried to identify genes uniquely
methylated near the TSS regions. In our previous analysis we found that the
methylation levels at TSS200(region 200bp upstream of TSS)weremuch lower than
TSS1500(region 1500bp upstream of TSS).To determine whether such a difference in
methylation would have any effect on the number of genes methylated, we analysed
TSS200 and TSS1500 methylation separately. We found that both EC and
teratocarcinoma cell lines still displayed higher levels of methylated genes at both
TSS200 and TSS1500 as compared to the seminoma and the YST cell lines. It is
interesting to see that unlike in CpG islands, YST had the lowest percentage of
methylated genes at both TSSregions (Figures 4.11 A& B). Consistent with the higher
methylation level at the distal region (shown earlier in Figure 4.7), we found that the
number of genes methylated in all four cell lines at TSS1500was double that at the
TSS200 region (Figures 4.11 A&B). Despite this, the number of uniquely methylated
genes was much lower in the former region. Surprisingly despite having the lowest
percentage of methylated genes, we found that YSTdisplayed the highest number of
uniquely methylated genes at both TSSregions as compared to the other three cell
lines (Figures 4.12A & B).
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Figure 4.11: Graphs showing the percentage of methylated genes at A) TSS200 and 8) TSSISOO. It can
clearly be seen that at both T55200 and T551500 regions, ECand teratocarcinoma cell lines possessed
the highest percentage of methylated genes as compared to the seminoma and Y5T cell lines. In all four
cell lines, a higher percentage of methylated genes can be seen in T551500 as compared to the T55200
region and the number of genes methylated doubled in this region as well. Interestingly, Y5Tshowed the
lowest percentage and number of methylated genes as compared to the other three cell lines. The
percentage of methylated genes was calculated by dividing the number of genes with an average beta-
value >0.6 by the total number of genes. The values on top of each bar represent the gene count.
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Figure 4.12: Graphs showing the percentage of uniquely methylated genes at AI T55200 and BI
T551500.Uniquely methylated genes were determined by calculating genes that were methylated
(average beta-value >0.6) either at TSS200 or TSS1500 only and had a difference in beta-value (delta
beta-value) >0.3 in the other three cell lines. The value on each bar represents the gene count.
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Again when we looked into the similarities between all four cell lines in terms
of genes methylated at these two gene elements, virtually all genes methylated in
seminoma (more than 99%) constituted a subset of genes methylated in the other
three cell lines (Figures 4.13A & B). Similar to the findings at the CpG islands, more
than half of the genes methylated in EC (60%), YST (59.2%) and teratoma cell lines
(64.2%) at TSS200 were also methylated in the seminoma cell lines. However, at
TSS1500this percentage was slightly higher in the YST(72.1%) as compared to the EC
(67.7%) and teratoma cell lines (67.5%).
Focus on the CpG islands and TSSmethylation has recently shifted into other
regions outside of the TSS(Brenet et al., 2012, Ball et al., 2009). Therefore we also
analysed methylation at other gene elements (ie gene body, 3'UTR) besides TSSusing
the same approach. Indeed, we found that the body and 3'UTR regions featured the
highest percentage of methylated genes (Figure 4.14) which was in accordance with
the methylation level of individual CpG(Figure 4.7).
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Figure 4.13: Diagrams showing the overlapping genes in all four cell lines that were methylated at A)
T55200 and 8) T551500 regions. Again, genes methylated in seminoma represented a major subset of
genes methylated in the other three cell lines. At T551500, no methylated genes were overlapping
between ECand VSTcell lines only.
145
Frequency of rnethyl.ted lenes. different elements
100 ~
90 ~
til 80
.,
c 70 "t-.,
1ID 60
"! 50]- 40..
.,
30E
'#. 20 1
10 ~
0
T551500 T55200 5'UTR
• Seminoma • Teratoma
1st exon Body 3'UTR
EC • YST
Figure 4.14: Graph showing the frequency of methylated genes across gene elements. We can clearly
see that the gene body Ind 3'UTRhad the highest percentlge of methylated genes.
4.2.2.4.ldentifying genes silenced by methylation
As mentioned in the previous chapter, DNA methylation is considered to be
important as it can cause gene silencing. However, from our previous analysis of
paediatric samples, not all genes we found methylated were differentially expressed.
Therefore, we set out to identify target genes silenced by methylation focusing on the
YSTcell lines. We also narrowed down our list of genes to those that are methylated at
CpG islands because this is the region that we found differentially methylated to
seminoma. Therefore, we believe, that these genes are the most influential in YST
development.
Prior to receiving the Affymetrix data, we decided to select genes of interest via
two approaches. The first approach was by correlating the cell lines' methylation data
to the expression analysis done in the paediatric samples (Palmer et al., 2008). The
second approach was by screening all 264 genes uniquely methylated in YSTat CpG
islands and selecting those which are known to be methylated in other types of cancer.
The subsequent works were divided between my colleague, Martin Cusack, and me, in
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which I am using the first approach in identifying genes of interest while my colleague
used the second approach.
A total of 53 genes were identified from the first approach. 21 genes were then
selected based on the rank of the average beta-value at CpG islands and graphical
representations of the methylation level on these genes were made. At this stage we
realised that in some instances the CpG islands were separated into two or more
clusters (Appendix I). This we believed would make it quite difficult to be certain which
cluster might be involved in the gene silencing. Therefore, we only selected genes that
showed one cluster of CpG islands for easier analysis. Graphical representations of
these six genes (PYCARD, FUT4, CDX1, PRDM1, PARP12 and RPRM) were shown in
Figures 4.15 A to F. From these graphical representations we can clearly see that in
most of them, YSTdisplayed ~ striking difference in methylation at CpG islands as
compared to the other three cell lines.
In order to determine whether methylation at the CpG islands would cause
these six genes to be silenced, we performed 40 cycles of reverse-transcriptase PCR
(RT-PCR)on all four cell lines, using human neural stem cells (hNSCs) as a positive
control. As shown in figure 4.16, three genes (FUT4, PRDMl and RPRM) were not
silenced by methylation in the YST cell line. On the other hand, the other three
methylated genes (PYCARD, CDXl and PARP12) were found either to be fully silenced
or to have reduction in expression. To ensure that the silenced and reduced expression
was a prominent feature of YSTand not just due to late template amplification, we
performed semi-quantitative RT-PCRon these three genes. PCRwere performed for 45
cycles and PCR products were taken every five cycles starting from cycle 30. We
observed that CDXl still showed a reduced expression in YSTas seen previously even
at 45 cycles (Figure 4.17.A) while PARP12 and PYCARD were completely silenced in the
YSTcell lines (Figures 4.17B and 4.17C respectively)
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Figure 4.15: Graphical representations of methylation level across A) CDX1, B) FUT4, C) PARP12, D)
PRDM1, E) PYCARD and F) RPRM gene regions. For most genes, YST displayed a strikingly higher
methylation at CpG islands as compared to the other three cell lines. A beta-value between 0.6 and 1.0
is considered fully methylated, while a beta-value between 0.2 and 0.6 is considered partially
methylated. Beta-value below 0.2 is considered unmethylated. The numbers on the x-axis show the
location of the probe used in the human genome. Each uniquely coloured line graph represents a
different gene region analysed while the uniquely coloured boxes below the title represent the gene
elements analysed by the probes, details of which were summarized in the legend at the top of the
page.
148
A1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
IU 1
~
ii 0.8>.
~
0.6
sa 0.4
0.2
0
Leeends
TSS1500 TSS200 5'UlR IocIy S'UlR
N_shelf
-
S_shore
N_shore
-
S_shelf
Islands
CDXl
. .
II I I
II I I
II I. .. I I
I--
U
&1.1
1 ~ ~ ~ r- __
0.8+---~~--~H---------~~--~--------~--------~~--
0.6+---~~--___.jH---------~~--~--------~----~I--
0.4+----I-jl------fl-----------IH----I---------I----------U-
02+---~~--_4H--------.~-~----~-----~l-
o +-__~L_~~~-~--,LJ_._-L~-~-~-~-~~~
8
oD
~
~
...
0 0 0
~ ~
0 0
~
0 8 0 0rl N .., oD ....
'"
.... N
oD oD oD oD oD oD oD oD oD .... .... ....
N N N N N N N N
~
N N N
10 10 10 10 10 10 10 10 10 10 10
'"
m m m m
'"
m
'" '" '" '"
m
~ ~ ~ ~ ~ • • • ~ ~ • ~rl rl rl .... rl rl .... rl .... rl .... ....
Probe's location
149
B1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
., 0
:::J
1i
~
1
., 0.8
la
0.6
0.4
0.2
0
1
0.8
0.6
OA
0.2
0
TSS15CIO 1'SSZOO 5'VT1
-N ........
-N_"_'
- ......
s_.._.
5_sheIf
-
-
FUT4
Probe's IocMIon
150
c1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
II 0.4:s
"'ii 0.2
~ 0
II
la
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
Lepnds
1'551500 TSSlOO 5'UTR I'UTRBody
- N_shelf
N_shore
Islands
5_lho,.
5_lhelf
PARPU
_J
'I
_.
I ._
I I
•I I
§i
~§
a. a.
.., ..,
01 01
Probe's location
151
Lcends
1SS1500 1SS2OO S'UTa Iody J'UTa
N_sheIf
-
S_shoN
-N_shoN
-
S_sheIf
- ......
o
PROM1
1
0.8
0.6 :EW
0.4 en
0.2 _1
dl II I J0
1
0.8
G::
0.6
~
0.4
0.2
U III • ~ I:J 0fti
:r 1S
u
0.8ID
0.6 UW
0.4
0.2
dl .~ .0
1
0.8
0.6
0.4
0.2
0
~
0 0 0 0 :it 0 0 0 0 ~ 0 0 0 0 ~ 0.... s ... tot .... .. ... tot .... ~ ... tot ....0 0 ... ... ... ... ... rot rot rot ,... ,... tot tot tot tot.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
OD OD OD ... ... ... ... ... ... ... ... OD OD OD oD ... oD
! ! 8 8 8 8 ! 8 8 ! 8 8 ! ! 8 8 !
... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...
Probe's 100000n
152
E1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
., 0.2
~
ii 0
>,
~
1
la 0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
Lepncls
TSS1500 1SS200 5'UTR IocIy J'UTR
- "_Ihelf
-
S_shore
- N_shore
-
S_sheIf
Islands
PYCARD
• -t •I _l I I ,I I
,i
I 'I I I
u
w
Probe's loution
153
F1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
II
::s
1i 0
>.
! 1
ID 0.8
0.6
0.4
0.2
0
1
o.a
0.6
0.4
0.2
1SS1500 TSS20D S'UTIt Iody rUTlt
- M_shelf
_ S_shore
S_1heH
RPRM
I.
•II I 1_t II • • ... j I *
1 .1 iii '.!
•
• • • a
•I I J_t t II .•
.'
*
I • *
I
I
I
I
Ii
,
!
I
I
, I
I
I
Probe'llocMIon
154
Co)
w
E
~
Actin
FUT4
PRDMl
RPRM
Figure 4.16: Reverse-transcriptase peR performed on all four GCTcell lines for the selected genes that
showed differential methylation at CpG islands in YST. It clearly showed that despite being heaviiy
methylated, FUT4, PRDMl and RPRM expressions were not silenced in the YST cell line.
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4.3. A/fymetrix array expression analysis
In order to be able to determine the effect of methylation on gene regulation,
we performed expression analysis on the four GCT cell lines using Affymetrix
HumanGeneChip U133 Plus 2.0 arrays. This chip is an expansion from the previous
Affymetrix HumanGeneChip U133 and covers an additional 6,500 genes to the
previous coverage of 33,000 genes. This expression analysis was conducted at
Nottingham Arabidopsis Stock Centre (NASC)in Sutton Bonnington, Nottingham. RNA
from all four GCTcell lines was extracted. The eluted RNAwas then analysed using a
Bioanalyzer 2100 (Agilent). RNAwhich showed an RNA integrity number (RIN) of more
than 9.0 (refer subsection 2.7.2) was. selected for microarray, since this represents
good-quality ·RNA.
Initial analysis of the data was performed using GeneSpring GX (Agilent
Technologies) utilizing the software's default settings. By selecting these settings, all
genes with a fold change of more than 2.0 are considered significant. This is in line
with a previous study by Butte et 0/.(2001), which showed that Affymetrix gene
expression data with a fold change measurement of more than 1.7 are reproducible
and thus considered to be significant.
4.3.1. Correlation of methylation and expression data
Methylation of CpG islands (including those in the region near the transcription
start site) has been considered to playa role in gene silencing. Thus, it is not surprising
to see that many methylation studies have focused on CpG islands around the
promoter regions. However, recent advancement in genome-wide methylation study
has put these studies' findings into question since other gene regions/locations have
also been found to be methylated and silenced (Irizarry et al., 2009, Brenet et al.,
2012).
To understand further the correlation between methylation and expression in
the GCT cell lines, we compared our Infinium methylation data to the Affymetrix
expression array data. Our initial analysis was focused on the expression between the
157
VSTand seminoma cell lines. Due to time constriction, initial analysis was performed
only on genes that were methylated at the CpG islands and the CpGshores. We chose
CpG islands since this was the location which showed the highest difference of
methylation in the VSTcell line as compared to the seminoma cell line. Furthermore
our observation that the EC and teratoma cell lines displayed high differential
methylation at all regions as compared to just CpG islands in the VSTsuggests that the
methylation at CpG islands might be important in the VSTs.
On the other hand, we also observed a difference in the methylation level at the
CpG shores between the VSTand the seminoma cell lines albeit a smaller difference
than at the CpG islands. However recently Irizarry et al. (2009) in their study conducted
on colon cancer suggested that differential methylation at the CpG shores was more
strongly correlated with gene expression as compared to the CpG islands. Since CpG
shores methylation and its relationship to gene expression has not been mentioned in
any previous GCTstudies, we believed this was worth pursuing.
Out of 778 genes that were differentially methylated between seminoma and
VSTat the CpG islands, we obtained expression data for 67% of them (527 genes).
Meanwhile expression data was obtained for 74% (337 out of 454 genes) of the
differentially methylated genes at the CpG shores. This was not surprising given that
the Infinium methylation arrays offered wider gene coverage of the genome as
compared to the Affymetrix expression array. We also found that a gene could be
represented by just one or more than one probe in the Affymetrix array panels.
Therefore we categorized the expression data into three groups; one with no
difference in expression observed, while the other two could either have differential
expression in amajority of the probes (including genes with only one probe) or were
only differentially expressed in a minority of the probes. In the VST cell line, the
majority of genes (77.8% and 78%) that were represented in the expression analysis
and hypermethylated at the CpG islands or the CpG shores, respectively, showed no
difference in expression. Only 18.6% and 18.1% of genes that were hypermethylated at
the CpG islands and CpG shores, respectively, showed lower expression at a majority
of the probes (Figures 4.18A & B). Using Fisher's exact test, methylation at both CpG
islands and CpG shores was found not to be associated with gene expression (p-value
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of 0.9280). The top 30 genes that were hypermethylated at the CpG islands in the VST
cell line and differentially expressed in the seminoma cell line are listed on Table 4.1 (a
full list of genes is included in Appendix II).
Given that teratoma and EC cell lines displayed greater methylation than
seminoma at all regions, we wondered whether in these cell lines either of the two
regions (CpG islands or the CpG shores) could have a clearer association with gene
expression. Initial analysis performed on the teratoma cell line still showed that the
majority of genes differentially methylated at the CpG islands (82.7%) and the CpG
shores (79.5%) were not differentially expressed. Only 16.1% and 14% of differentially
methylated genes at the CpG islands and the CpG shores, respectively, showed
differential expression at a majority of the probes (Figure4 4.19A & B). Again, using
Fisher's exact test, methylation at both the CpG islands and the CpGshores turned out
not to be associated with gene expression (p-value of 0.5962).
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Figure 4.18: Graphs showing the percentage of differentially methylated genes at A) the CpG islands
and B) the CpG shores in the YST cell lines for whicht we obtained expression data. Clearly a majority
of the differentially methylated genes at both CpG islands and CpG shores did not show any difference
in expression.
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Genes Infinium Methvlation450K Array Affymetrix gene expression
Beta-value Delta beta-value Fold change (SEM/yST)
SEM YST
TMEM179B 0.07988 0.96112 0.881231782 5.288
NAAA 0.09695 0.9664 0.869453578 4.216,3.551,0.938
RCSD1 0.11676 0.96193 0.845172125 4.492
LGALS3 0.0465 0.87019 0.823685457 27.934,1.0
CYB5R2 0.1061 0.92785 0.82175694 17.977
PLEKHG4 0.08645 0.90034 0.813889264 7.164
C8orf42 0.11074 0.91336 0.8026243 26.467,21.137, 13.038
TNFRSF10C 0.08396 0.87102 0.787060766 6.821, 2.124, 1.686, 1.035
DDX43 0.09841 0.87273 0.774321444 22.838
C13orf27 0.15784 0.93144 0.773596226 16.081
CXCL14 0.10936 0.88044 0.77108022 16.011, 10.608, 1.048
PYCARD 0.15634 0.92655 0.770201975 19.669
TRIM59 0.1343 0.89473 0.760432096 26.334, 2.112
AMPD3 0.17016 0.92856 0.758400967 2.07, 1.142
PARP12 0.07193 0.82972 0.757787533 4.293
ABHD14A 0.14316 0.89501 0.751853917 2.084
ECHDC2 0.1369 0.88179 0.74489879 16.349, 1.0
C8orf41 0.12148 0.86509 0.743610235 2.022
OVOl1 0.13545 0.87859 0.743140737 8.465,2.08
C8orf84 0.21565 0.95544 0.739787541 3.005, 2.431, 1.0
HCGll 0.18361 0.91716 0.73355111 2.410, 1.674
HYLS1 0.15077 0.87805 0.727274774 15.174
PLD6 0.1701 0.8916 0.721497568 2.644
RBMXl2 0.13046 0.85041 0.719955922 43.16,1.0
FABP5 0.10154 0.81806 0.716519285 32.377
MYD88 0.13919 0.84068 0.701490237 3.357
PRDM14 0.20302 0.8985 0.695481061 3.187
ACOT4 0.13438 0.81011 0.67572599 3.192
TTYH2 0.2548 0.92609 0.67129675 2.630, 1.117
ELM03 0.26894 0.92462 0.65567793 2.188
Table 4.1: The top 30 genes that were differentially methylated in the YSTcell line at the CpG Islands
and found to be differentially expressed. Using the default setting recommended by the Affymetrix
gene expression array, expression with a fold change of more than 2.0 is considered significant.
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Figure 4.19: Graphs showing the percentage of differentially methylated genes at A) the CpG islands
and 8) the CpG shores in the teratoma cell lines for which we obtained expression data. Again, a
majority of the differentially methylated genes at both CpG regions did not show any difference in
expression.
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4.4. Discussion
4.4.1. : Methylation profile of GCTcell lines
From the Infinium methylation array, we found non-seminomatous cell lines
displayed a much higher methylation levels than the seminoma cell line which is in
agreement with previous studies (Zhang et al., 2005, Smiraglia et al., 2002) although
the levels we observed in both seminoma and non-seminomatous cell lines were much
higher. We believe that this was due to the technique used and the fact that our
coverage of genes was much wider than those studies.
We also showed that the ECand teratoma cell lines displayed a much higher
methylation across the gene region as compared to the seminoma cell line. This was
accompanied by a higher frequency of genes that were methylated as compared to
seminoma. This suggests aberrant methylation features of these two cell lines. It is
striking to see the similarity between these two cell lines even though ECis well known
to share pluripotent characteristics while teratoma represent more differentiated cells
(Oosterhuis and looijenga, 2005). However, this could be explained by the origin of
this teratoma cell line which was derived from a pluripotent stem cell population that
can differentiate into all three germ layers and is able to give rise to teratoma
(Andrews, 1984). Indeed, as mentioned earlier, the NT2Dl cell line used in this analysis
may in fact be derived from an ECcomponent of a teratoma.
Meanwhile, the VSTcell line displayed a quite unique methylation profile as
compared to the EC and teratoma cell lines. This is because in comparison to
seminoma, VSTonly showed a differential methylation at the CpG islands and to a
lesser extent in the shores. This might suggest that CpG island methylation is crucial in
VST development. In addition to this, our observation totally contrasted with the
finding by Irizarry et al. (2009) that the shores region was the most differentially
methylated regions in colon cancer cell lines. However, this contrast in findings might
be due to the different cell lines used and again implies that each cell line has its own
methylation characteristics.
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Nonetheless when we looked at the methylated genes in all four cell lines, we
found that majority of the genes methylated in the seminoma cell line were also
methylated in the other three cell lines. This similarity implies that EC,teratoma and
VSTcould have arisen from seminoma that undergone aberrant methylation. Despite
thegeneral idea that all germ cell tumours arise from carcinoma in situ (CIS),seminoma
has been found to share similar characteristics with CISin terms of histology (Sonne et
al., 2009), methylation level (Netto et al., 2008) and gene expression (Almstrup et al.,
2005). Therefore, aberrant methylation in seminoma could possibly give rise to the
differentiated GCTs.This might explain why GCTscould have a mixture of seminoma
and VSTcomponents(Looijenga, 2009) or how seminomatous GCTscould recur as VST
after therapy (Wong et al., 2010). Furthermore, a study suggested that repression of
BLlMPl as a consequence of inhibition of BMP/SMAD signalling in a seminoma cell line
could cause seminoma differentiation into mixed non-seminomatous lineages
(predominantly choriocarcinoma-like cells)(Nettersheim et al., 2011). This suggests
that repression of BLlMPl by methylation might result in the same consequences.
However, in our analysis, BLlMPl (also known as PROM1) was equally expressed in all
four GCTcell lines. Therefore, it is still inconclusive whether BLlMPl repression alone is
sufficient to drive seminoma into non-seminomatous lineages.
4.4.2. Methylation and gene expression
By correlating methylation and expression array data in VSTand teratoma cell
lines, we found that neither methylation at the CpG islands nor methylation at the CpG
shores had a strong influence on gene expression. Again, this finding is in contrast with
the finding by Irizarry et 01.(2009) which showed a strong correlation between CpG
shores methylation and gene expression. This could mean that such an observation
can be tumour- or cell-type specific. Indeed, methylation at CpG islands does not
necessarily result in gene silencing as shown in the RT-PCRdone on the selected six
genes methylated at CpG islands in VST.This is not surprising since methylation is not
the only factor that can contribute to transcription silencing. CpG islands have been
known to harbour binding sites for transcription factors (Deaton and Bird, 2011).
Studies have shown that human promoters, including those of housekeeping genes,
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tend to have a transcription factor binding motif (Rozenberg et al., 2008, Landolln et
al., 2010) with some of these factors have been shown to regulate methylation and
gene transcription aswell (Gebhard et al., 2010).
While many methylation studies have focused on CpG islands near the
promoter region, other studies have also pointed out the possibility of methylation
outside of this region that could also influence gene regulation (Eckhardt et al., 2006,
Irizarry et al., 2009, Ball et al., 2009, Brenet et al., 2012). Indeed, our analysis of
methylation across all gene locations showed that the highest methylation levels were
in the gene body and the 3'UTR. Numerous reports have shown high gene-body
methylation in fibroblast, induced pluripotent stem cell and even in the active X-
chromosome (Ball et al., 2009, Hellman and Chess, 2007). However, this high
methylation was associated with high gene expression suggesting that there might be
a dual function of methylation (Ball et al., 2009). Further analysis still needs to be
performed in order to find out whether the high gene-body methylation observed in
our analysis correlates with gene expression.
The finding that other gene regions/locations could also be methylated and
regulate gene transcription has sparked an interest in finding the right region/locations
behind this observation. Brenet et al. (2012) in their study using the Sequence Tag
Analysis of Methylation Patterns (STAMP) assay in human-derived leukemia cell lines
showed that methylation at the S'UTR and the first exon are important for
transcriptional silencing. On the other hand, a study of liver cancer showed that
methylation of just one CpG is enough to silence the TTP gene (Sohn et al., 2010)
suggesting that gene silencing does not require methylation of a cluster of CpG islands •
to be silenced. Our method of answering the same question using the Infinium
methylation array proved to be futile. Although Infinium reveals a clearer picture of
methylation across the gene region as shown in our graphical representation, it does
not really help in highlighting the crucial sites. Even though for one gene, PARP12,
since its CpG islands was only methylated and silenced in the YSTcell lines and not In
the other three cell lines, this would suggest a role was played by the CpG islands
methylation in PARP12 silencing. However, this still needs to be validated and we
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believe the only way to do that is by using a DNA methylation inhibitor such as 5-
azadeoxycytidine and comparing the methylation profile with the non-treated cell
lines.
4.4.3. Differentially methylated and expressed genes
We have identified 98 out of 528 hypermethylated genes in the YSTcell line
that showed lower expression as compared to the seminoma cell line. Using RT-PCR
and semi-quantitative RT-PCRanalysis on six of those hypermethylated genes, we
further validated that three genes (CDX1, PYCARD, and PARP12) were expressed in the
seminoma cell lines at a much higher level than the YSTcell line. It is interesting that
PYCARD in the YSTcell line showed similar methylation and expression features as in
the paediatric YSTsamples in our previous Golden Gate methylation array (Jeyapalan
et al., 2011).
Caudal-related homeobox protein 1 (CDX1) is a transcription factor normally
associated with the regulation of intestinal proliferation. In one study, overexpression
of Cdxl in a rat intestinal epithelial cell line led to cell cycle arrest and reduced the cell
proliferation (Lynch et al., 2000). The same observation was found in colon cancer cell
lines (Lynch et al., 2003). CDXl expression was found to be reduced in colorectal
carcinoma and colorectal cancer cell lines and this has been associated with promoter
hypermethylation (Pilozzi et al., 2004, Suh et al., 2002, Wong et al., 2004). Therefore,
hypermethylation and reduced expression of CDXl in the YST cell lines might be
contributing to the aggressive nature of YSTs.Functional analysis of CDXl still needs to
be performed to find out the exact role of CDXl silencing in the YSTcell lines.
On the other hand, not much is known about the function of the poly (ADP-
ribose) polymerase family, member 12 (PARP12). No study has been reported
regarding its function in any type of cancer or even in normal human development
although in cattle it has been associated with uterine receptivity during pregnancy
(Bauersachs et al., 2006, Forde et al., 2012). Interestingly, PARP12 has been found to
have an alternative promoter (Rauch et al., 2009) in the B-cell methylome. Using a
combination of the methylated CpG island recovery assay (MIRA) and whole-genome
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tiling array, this group found four genes including PARP12 that are expressed despite
having promoter hypermethylation. They then mapped the transcription initiation site
and found an unmethylated promoter in PARP12 and two other genes which they
believe is the promoter that controls gene expression. We did not determine whether
such an alternative promoter does exist in the GCTcell lines, but from our analysis,
promoter hypermethylation of PARP12 correlates with the gene silencing.
There are still 9S genes that are hypermethylated and have reduced expression
in the YST cell line that have not been validated by RT-PCR.Many of these genes
represent genes with biological functions that are possibly related to tumour
development. Therefore, future investigation of these genes is worth pursuing.
Korkola et al.{200S) in their analysis using Affymetrix microarrays, Identified a
list of genes uniquely expressed in each non-seminomatous GCTand suggested that
these genes could be used as a signature marker for each cell line. Comparing their
expression data on YSTsamples with our YSTcell line, we found that six out of nine
genes (APOA2, BMP2, FOXA2, EOMES, CYP26Al, and CCKBR) identified as uniquely
expressed in YSTby Korkola et al.{200S) were also highly expressed in the YSTcell line
in our analysis. We could not determine whether such expression is tumour-specific as
we used a seminoma cell line as the control and not normal testis tissue as used by
Korkola et al.{200S}. However, all six genes were found to be highly expressed as
compared to the other cell lines we analysed with most of them showing differential
expression between 10 and 100 fold. This supports the possibility of using these genes
as markers for YSTs.
Previously in the GoldenGate analysis, we showed that none of the paediatric
seminoma samples showed any hypermethylation of GSTPl which was in contrast to a
previous study (Koul et al., 2002). From the Infinium methylation analysis, we again
found that GSTPl was not methylated (beta-value 0.0883) in the seminoma cell line. In
addition to that, SORBS1, another gene previously found to be hypermethylated in
seminoma samples (lind et al., 2006), was also found to be not methylated in the
seminoma cell line (beta-value 0.1034). However, since no normal control was
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included in our Infinium arrays analysis, we could not determine whether these two
genes methylation level were high enough to be considered as hypermethylated.
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5. INHIBITION OF DNA METHYLATION AND ITS EFFECT ON GCT
CELL LINES' BEHAVIOUR
5.1. Introduction
In the previous two chapters, we observed that both paediatric YSTsand non-
seminomatous GCTcell lines were heavily methylated as compared to the seminomas.
Given that non-seminomatous GCTs display genome-wide hypermethylation, they
should in theory be able to respond to epigenetic therapy just like other tumours with
a similar methylation feature.
Many epigenetic modifiers have been shown to contribute to the
hypermethylation seen in cancer. Overexpression of DNA methyltransferase 3B
(DNMT3B) and its splice variants has been found In lung, breast and embryonal
carcinoma (Roll et al., 2008, Beaulieu et al., 2002, Gopalakrishnan et al., 2009, Van der
Auwera et al., 2010). Meanwhile, EZH2 and SUZ12, components of the Polycomb group
were found to be overexpressed in prostate and pancreatic cancer (Chen et al., 2010,
Karanikolas et al., 2010) and lymphoma (Martin-Perez et al., 2010) respectively.ln
order to identify the factor(s) behind the hypermethylation seen in our YSTsamples,
expression analysis of these three modifiers was performed using Real-Time
Quantitative PCR(RT-PCR).
5.2. Results
5.2.1. Factors contributing to YSThypermethylation
Quantitative PCRwas carried out using a SYBRgreen kit and 100ng of the
paediatric GCTcDNA sample. Samples were subjected to 40 cycles of quantitative PCR
using a Stratagene MXPro 300SP machine. For relative quantification, we used one of
the YSTsamples (#17) as a control (also known as a calibrator), which the expression of
the gene of interest is compared to. Both tumour samples and calibrator signal were
normalized with internal reference genes, in this case beta-actin and 18S RNA. These
normalizers function as an internal control that eliminates any variability In terms of
quantity and quality in the samples and the calibrator. Relative quantification of
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expression was then calculated by taking the average fold change of the samples to the
calibrator (Figure 5.1). Again, due to a limited amount of cDNA being available, we
could only manage to do duplicate analysis of some of the samples.
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Figure 5.1: Representative diagrams of SYBRGreen quantitative peR consolidation data. A) Diagram
showing the PCR cycle detail. B) Amplification plots which show that all samples were amplified at
almost the same cycles and there was no amplification of the negative control. C) Dissociation curve
which shows no irregular peaks suggesting the absence of contamination. D) Bar graph showing the
relative expression quantification ofthe samples according to the calibrator.
From the average log2 fold change, we found that in relation to human neural
stem cells, DNMT38 was more highly expressed in the majority of YST samples as
compared to seminomas (Figure s.2A) and this was significant (p-value of 0.035) when
we grouped the samples according to their tumour type (Figure 5.28). Meanwhile, we
observed that both EZH2 and SUZ12 expression was similar in both tumour types (p-
values of 0.556 and 0.5510 respectively) either as individual samples or as a group
(Figures s.3A and 5.38). This suggests that DNMT38 might be a contributing factor
towards the hypermethylation seen in YSTs.
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Figure 5.2: Bar graphs showing that VST samples had a higher level of DNMT38 expression than
seminoma samples. DNMT38 expression levels in A) tumour sampies which showed that VSTsamples
displayed higher expression of DNMT38 than seminoma samples, and B) tumour group which showed
significant difference of DNMT38 expression between seminoma and VST. * denotes p-value<O.OS using
Mann-Whitney Hest. Error bars represent standard deviation.
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Figure 5.3: Expression levels of A) EZH2 and B) SUZ12 in seminoma and YST samples. Both YST and
seminoma samples displayed almost similar levels of expression for both EZH2 and SUZ12. Dark grey
represents YSTswhile lighter grey represents the seminomas. Error bars represent standard deviation.
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5.2.2. DNMT3B expression in germ cell tumours (GCTs) cell lines
Since there are no GCT cell lines derived from the paediatric population,
analysis of the DNMT3B function in GCTs was carried out using cell lines derived from
adult testicular GCTs. Four cell lines were used, representing embryonal carcinoma
(EC), teratocarcinoma, yolk sac tumour (YST) and seminoma. Before further analyses
were performed, it was essential to know whether these cell lines have similar
DNMT38 expression, as seen in the paediatric samples. To investigate this, we
performed reverse-transcriptase QPCR using a Stratagene MxPro 300SP in duplicates.
As before, we used beta-actin as loading controls. However, since there was an
insufficient amount of sample #17 for the experiment, we switched to using human
neural stem cells as the calibrator. Relative quantification of the DNMT38 level was
determined by measuring the celilines'.foid change relative to the calibrator.
As illustrated in Figure 5.4, we found that the DNMT38 is more highly
expressed in the YST cell lines as compared to the seminoma cell line, which is similar
to the finding in the paediatric samples. Comparing to other cell lines, we observed
that EC cells expressed the highest level of DNMT38 followed by teratocarcinoma and,
YST, with the lowest level in seminoma.
DNMT 38 expression in GeT cell lines
9T-- ..···-·....····..·__ ..·_··-·..·.·-··· ..················.
a+-----------------
• 71...-· ..···--·--··-----~=L=..---···-
g' 8+------------,
~ 5 + - -.._ - -.-
~ 4 ·f-.._·_··---··-···..· ·--··-
2 3 j..-- ..--...-----..----..----
!~+---------
O+-------cl---
_1L---------------------------------------·
/
Samples
Figure 5.4: Bar graph showing the average log2 fold change of DNMT38 expression In all four GCTscell
lines. Clearly non-seminomatous GCTshad a higher DNMT38 level than seminomatous GCTs,with
embryonal carcinoma cell lines showing the highest level of DNMT38 expression. Error bars represent
standard deviation.
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5.2.3. Epigenetic modifiers' target gene among hypermethylated genes in YSTs
It seems, from the analysis above, that genes that are hypermethylated in both
paediatric YSTsamples and the YSTcell lines might be enriched for those targeted by
DNMT3B. In order to determine whether there is any such bias,we looked at published
articles related to the gene targets of DNMT3B, SUZ12and EZH2.Choi et 01.(2011), in a
recent study, looked at DNMT target sites by stably transfecting HEK293Tcells with
plasmids containing DNMTs and their isoforms. Using the lIIumina GoldenGate
methylation array, they found S04 loci showed changes in methylation level after
overexpressing each DNMT construct.
In order to compare our data to that of Choi et 01.(2011), we first focused on
those genes we found to be hypermethylated and differentially expressed in YSTs.
From the eight differentially methylated and differentially expressed genes identified
in the paediatric samples, we identified that three of them (HLA-F, TFAP2C and HDAC9)
are targets of DNMT3B (Table 5.1). We next looked at studies performed in epithelial
ovarian cancer (Li et al., 2012) and human embryonic stem cells (hESC) (Lee et al.,
2006), which looked into the target genes of EZH2 and SUZ12 respectively. Li et
01.(2012) identified 60 EZH2target genes through chromatin immunoprecipitation and
gene expression profile. Meanwhile, Lee et 01.(2006), in their experiment using DNA
microarrays, identified 1,893 annotated genes occupied by SUZ12 in hESC.Using these
data, we found that two genes that were differentially methylated and differentially
expressed in the paediatric YSTsamples (TFAP2C and PYCARD) are potential targets for
SUZ12and EZH2(Table s.i).
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Genes Epigenetic Modifier
DNMT3A DNMT3B SUZ12 EZH2
HlA-F No Yes Yes N/A
TFAP2C Yes Yes Yes Yes
CO2 No No N/A N/A
E1Vl No No N/A N/A
PYCARD No No Yes Yes
CASPS No No N/A N/A
HDAC9 Yes Yes N/A N/A
EVI2A No No N/A N/A
Table 5.1: Table showing epigenetic modifiers' targets Identified among the differentially expressed
genes In the paediatric GCTcohort based on three previous studies by Chol et 81 (2011), Lee et 81
(2006) and LI et al (2012). Most of the differentially expressed genes In the paediatric GCTcohort turned
out not to be a target for all three modifiers. N/A represents data that were not available from the
references.
We then expanded our analysis to all 85 genes found to be hypermethylated In
the YSTsamples. Using the same datasets as before, we found that eleven of the genes
found to be hypermethylated in the YSTsamples are target genes for DNMT3Bl and
only two are target genes for DNMT3A1. In addition to that, an additional22 genes are
target genes for both DNMT3Bl and DNMT3Al (Figure 5.5). On the other hand,38 of
these genes were found to be SUZ12 target genes while 27 genes were identified as
EZH2target genes (Figure 5.5). Strikingly, most of the genes are found to be the targets
of more than one modifier with seven of them targets for all four modifiers (Figure
5.5).
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Figure 5.5: Diagram showing number of target genes for DNMT3A, DNMT3B, SUZ12 and EZH2
identified from our list of 85 genes hypermethylated in YSTs. None of the genes were exclusively a
target of DNMT3B. Target genes were identified from previous studies (Choi et al., 2011, lee et al.,
2006, li et al., 2012)
Applying the same analysis on the Infinium Methyiation4s0K arrays data, we
found only two out of 98 genes (CDH1, WNT2B) found to be differentially methylated
and differentially expressed in the YSTcell lines were previously identified DNMT3B
targets (Table s.2). We believed this small number might be due to the different array
coverage used, because the Infinium methylation panel covers approximately 30 times
more genes as compared to the Golden Gate methylation panel used by Choi et
al.(2011}. In contrast, 18 genes that were differentially methylated and differentially
expressed in the YSTcell line were identified as targets for EZH2 and one gene was
found to be a target for SUZ12 (Table s.2).
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Genes EpigeneticModifier
ONMT3A ONMT3B SUZ12 EZH2
COHl No Yes N/A N/A
WNT2B No Yes N/A N/A
RASC1 N/A N/A Yes N/A
TTYH2 N/A N/A N/A Yes
TMEM163 N/A N/A N/A Yes
SHISA3 N/A N/A N/A Yes
RCSC1 N/A N/A N/A Yes
NPEPL1 N/A N/A N/A Yes
MEIS1 N/A N/A N/A Yes
MCFI N/A N/A N/A Yes
MAP7 N/A N/A N/A Yes
HYLSl N/A N/A N/A Yes
GAL N/A N/A N/A Yes
FAM162B N/A N/A N/A Yes
FAMISOB N/A N/A N/A Yes
COO N/A N/A N/A Yes
CYPllAl N/A N/A N/A Yes
C1QTNF4 N/A N/A N/A Yes
APIM2 N/A N/A N/A Yes
ACOXL N/A N/A N/A Yes
ACACL N/A N/A N/A Yes
Table 5.2: Table showing epigenetic modifiers' targets Identified among the differentially expressed
genes In the YST cell line based on three previous studies by Chol et al (2011),Lee et al (2006) and LIet
al (2012). It seems that none of the epigenetic modifiers share similar target genes, but this could be
due to the different array coverage used in these methods as compared to the Infinium
Methyiation450K arrays that we used. N/A represents data that were not available from the references.
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On the other hand, analysis performed on 1,195 genes found to be
hypermethylated in the YST cell lines showed that only 11 genes werea target for
DNMT3B while four genes were a target for DNMT3A. Only one gene, HIC1, was found
to be a target for both DNMT3A and DNMT3B. Meanwhile, ten genes were found to
be a target for SUZ12 with one gene, PDGFRA, also turned out to be a target for
DNMT3B. In contrast, 170 genes were found to be a target for EZH2.Although it would
seem that many more hypermethylated genes were targets for EZH2,we could not
make a conclusive statement on the possible epigenetic modifiers behind YSTs'
hypermethylation. This is because all three studies used different methods in
identifying the target genes, and each method has a big difference in the number of
genes covered in their analysis. Furthermore, all three studies were conducted on
different cell lines or cancer cells; thus it seems likely that their findings are specific for
particular cell types.
5.2.4. Expression analysis of differentially expressed genes in adult cell lines
As with DNMT3B, functional analysis on the differentially expressed genes in
the paediatric population can only be assessedusing cell lines that are entirely derived
from adult testicular GCTs.Thus, it is crucial to determine those genes' expression in
the cell lines. Again, we carried out reverse-transcriptase QPCR in duplicate to
determine the expression of one of those genes, CASP8, in seminoma and YSTcell
lines. Using human neural stem cells as a calibrator and beta-actin as a normalizer, we
found that CASP8 is significantly more expressed in seminoma (Fig 5.6). By comparing
both DNMT38 and CASPB expression, there seems to be an inverse correlation
between them where high DNMT38 expression links with low CASPBexpression.
To determine the expression of other differentially expressed genes in the cell
lines, we decided to use the Affymetrix gene expression array. Out of eight
differentially expressed genes in paediatric seminomas, only seven of them (PYCARD,
CASPB, HLA-F, TFAP2C, ETV1, EVI2A and HDAC9) were included in the array. The
expression levels of those genes in the seminoma and the YST cell lines were
compared using Gene Spring software. All except HLA-F were successfully analysed and
were expressed as a fold change. The initial results showed that four out of six genes
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showed more than a two-fold change in expression. This result is summarized in Table
5.3.
CASP8 expression
YSTs seminomas
Samples
DNMT3B expression
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~ 7 +------------------------------------
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~ 5 I··-··-,-"-- ..- - ..·· ·-J================~,·, -..,-" - -
o 4 -- -_-_._-,..+ -..-- , ,.." - -..- -,-,..- .,-",,,, ,,
'; 3 +.._ _ " ,
Cl
:! 2 -l----
~ 1+---
oc( 0 -'- __
YSTs Seminoma
Samples
Figure 5.6: Bar graph showing the average fold change in the expression levels of CASP8, and DNMT38
in YSTand seminoma celilines.TheDNMT38 expression level seems to correlate with their CASP8
expression level. * denotes p-value <0,01 while ** denotes p-value <0.001 using Mann-Whitney Hest.
Error bars represent standard deviation.
Table 5.3: Affymetrix expression array data of YSTand seminoma cell lines on previously identified
differentially expressed genes in the paediatric population. It clearly showed that most of the genes
differentially expressed in the paediatric samples were also differentially expressed in the cell lines.
LOOSvalue of more than 4.0 and fold change of more than 2.0 is considered to be significant.
179
5.2.5. Inhibition of DNA methylation and DNMT3B
To further understand the function of DNA methylation and DNMT3B in GCT
cell lines, we used two approaches to knockdown DNA methylation and DNMT3B. The
first approach used S-azadeoxycytidine (S-azadC) to inhibit DNA methylation while
knockdown of DNMT3B was performed by transfecting the GCT cell lines with the
microRNA-29b (mir-29b) plasmid.
5.2.5.1. S-azadeoxycytidine (S-azadC)
5-azadC is a nucleoside analogue that has been approved by the Food and Drug
Administration (FDA)as a treatment for myeloid malignancies. Importantly, it has been
shown to inhibit DNA methylation by incorporating into the DNA during DNA synthesis
(Christman, 2002, Chik and Szyf, 2010). In addition to that, S-azadC has also been
shown to inhibit methylation by triggering degradation of DNA methyltransferases
(Ghoshal et al., 2005). Thus, inhibition of methylation by S-azadC proves to be an
important tool in epigenetic therapy as it has been shown to be able to reactivate
silenced genes and improve cell behaviour, for example in sensitizing cells to
chemotherapy (Fulda et al., 2001, Siraj et al., 2011).
Among GCTs,previous studies using 5-azadC were only done in seminoma
(Wermann et al., 2010) and teratocarcinoma cell lines (Beyrouthy et al., 2009) which
used concentrations of 10 urn and between 100 and 1,000 nM respectively. Indeed
from works performed by my colleague, Safiah AI-Hazmi, it was found that the
teratoma cell line only showed toxicity towards S-azadCat concentrations above 1 urn,
However, the seminoma cell line was found to be able to tolerate up to 20 11m5-
azadC. By treating 3 X 104 cells with a range of s-azadC concentrations, she also found
that the ECcell line could only withstand up to 0.1 11M5-azadC, while the YSTcell line
started to show signs of toxicity at 20 11MS-azadC.Therefore, these concentrations
were used as a guide for the assays on cisplatin sensitivity and the wound healing
assay.
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5.2.5.2. MicroRNA 29b (mir29b)
MicroRNA-29b (mir29b) has been found to be able to knockdown both
DNMT3A and DNMT38, and reactivate genes that were previously repressed in many
tumour types (Fabbri et al., 2007, Garzon et al., 2009). Interestingly, members of the
microRNA-29 family have been found to be significantly upregulated in paediatric
seminomas as compared to YSTs in recent microRNA expression profiles which
correlates well with the lower expression of DNMT38 in seminomas (Murray et al.,
2010). This not only suggests a role for mir29b in regulating DNMT38, but also offers
us a means to manipulate the DNMT38 function in GCT cell lines.
To determine the DNMT38 knockdown efficiency in the YST cell lines, we
transfected 1 - 2 X 106 YST cell lines with 3 Ilg and 7 Ilg of plemiR plasmid containing
mir29b. For the controls, YST cells were transfected with GFP. Mediums were changed
6 hours after electroporation and cells were left to recuperate for 48 hours after which
cells were harvested for analysis.
Using reverse-transcriptase QPCR, the level of DNMT38 knockdown was
determined by normalizing the signal to beta-actin, and calibration to human neural
stem cells. We found that both transfection with three and seven micrograms of
mir29b achieved significant knockdown of DNMT38 (Figures 5.7 A and B) with seven
micrograms showing a much greater knockdown of up to an eight-fold change (Figure
5.7 B). Therefore, transfection with 7ug of mir29b was used in further experiments.
181
10 ··1..· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·.....
'81-----J ..
i 4 +---------
i 2 ·1··..·..· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·• · · · ··• ·
o +··········· ..·····r································
-2 --------------
hnsc 3 IlCmlr29b
12
10f 8
J 6
i 4
j 2
0
·2
hnsc
Figure 5.7: Bar graphs showingDMT38 expression level after transfection with A) 3ug and B) 7ug of
mlr29b. Both transfections significantly reduced DNMT38 expression level in the YSTcell line as
compared to the YSTtransfected with GFP. ** denotes p-value <0.001 using paired Hest. Error bars
represent standard deviation.
5.2.6. : Cell line sensitivity to cisplatin after inhibition of DNA methylation and
DNMT3B knockdown
Although germ cell tumours are considered to have a high cure rate, the cure
rate decreases substantially in patients with a more malignant form or who have
metastatic diseases (di Pietro et al., 2005). Cisplatin has been widely used to treat
GeTs, but despite having a good response to cisplatin (Duale et al., 2007, di Pietro et
al., 2005), resistance to this treatment has been reported in non-seminomatous GeTs
(Houldsworth et al., 1998). Furthermore, a higher dosage of cisplatin to counteract this
resistance has been associated with toxicity (Frazier et al., 2012, Travis et al., 2010).
DNA methylation has been implicated in cisplatin resistance, and the use of a
DNA methylation inhibitor such as 5-azacytidine (5-aza) and its analogue, 5-
azadeoxycytidine (5-azadC) has been shown to improve cell line and solid tumour
sensitivity towards cisplatin (Wermann et al., 2010, Koberle et al., 2010). To determine
whether inhibition of DNA methylation could improve the response of GeT cell lines
towards cisplatin, we utilized a clonogenic survival assay.The clonogenic survival assay
(also known as a colony formation assay) has been used to assessthe ability of a single
cell to form a colony after treatment with radiation or chemotherapy (Franken et al.,
2006). We replicated this method to determine whether GeT cell lines showed
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reduced resistance to cisplatin after those cell lines were exposed to the DNA
methylation inhibitor, 5-azadC,or transfected with mir29b.
5.2.6.1. : Clonogenic survival assay In cells pre-treated with 5-azadC
Cells were grown until they were 70% confluent before they were exposed to a
range of 5-azadC concentrations for 24 hours. Cells were then trypsinized and 100
single cells were plated in each well of a six-well plate. Once cells had adhered to the
well's surface, they were treated with 2.5 to 12.5 11Mof cisplatin for four hours. The
medium was then replaced with fresh medium without any drugs, and the cells were
left for 7-10 days. Cells were then fixed with 4% paraformaldehyde for 20 minutes
before they were stained with 0.5% crystal violet for five minutes (Figure 5.8). Under
the microscope, viable cell colonies (defined as having an excess of approximately 50
cells) were counted.
Plating efficiency (PE),defined as the ratio of the number of colonies formed to
the number of cells seeded, was calculated for each cell line, since each of them has a
different plating efficiency.
Number of colonies formed
PE=---------------------- Xl00
Number of cells seeded
After determining the PEfor each cell line, the number of colonies that survived
after the treatment (defined as a colony with at least SOcells), also called the surviving
fraction (SF),was calculated as follows:
Number of colonies formed after treatment
SF=
Number of cells seeded X PE
We found that only the EC cell line showed significant improvement In
response towards cisplatin after 5-azadC treatment (Figure 5.9B, left panel) with more
significant improvement seen in cells treated with a higher concentration of S-azadC
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(p-value <0.01 for 0.01 IlM 5-azadC, p-value<O.OOl for 0.05 and 0.1 IlM 5-azadC).
However, we also found that these concentrations of 5-azadC alone significantly
reduced the number of colonies formed in the ECcell line (Figure 5.9B, right panel).
Therefore, the observed improvement in response towards cisplatin in the ECcell line
might be confounded by the toxicity of 5-azadC treatment. The same toxicity was
observed in the teratoma (Figure 5.9A, right panel) and the seminoma cell lines (Figure
5.10A, right panel), although in both cases this toxicity did not seem to significantly
influence the cell lines' response to cisplatin (Figures 5.9 A and 5.10A). Only the VST
cell line was found not to be significantly affected by 5-azadC toxicity (Figure 5.10B,
right panel), but again, no significant improvement in response to cisplatin was
observed (Figure 5.10B left panel).
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5.2.6.2. : C/onogenic survival assay after DNMT38 knockdown In the GCTeel/lines
We next tried to determine whether inhibition of DNMT38 is enough to
improve the response of GCTcell lines to cisplatin. All four cell lines were grown until
they were confluent. They were then trypsinized and transfected with 7 ug pLeMiR
vector containing mir29b. Cells were left to recuperate for 48 hours before they were
trypsinized and assessedusing the clonogenic survival assay.
In contrast to s-azadC treatment, DNMT38 knockdown in general does not
seem to result In any improvement in response towards cisplatin in any of the cell lines
except in one treatment arm in the EC cell line. In this treatment arm of 7.5 J.lM
cisplatin, the EC cell line showed a significant improvement but with a weak p-
value<O.OS(Figure 5.11 B, left panel). Surprisingly, DNMT38 knockdown was found to
increase YST cell line's resistance towards cisplatin. A significant increase in the
number of surviving colonies was observed after being treated with 2.5 J.lM, 5 J.lM
(both p-value <0.05) and 7.5 J.lMcisplatin (p-value <0.01) (Figure 5.12 B, left panel).
This might be explained by an increase in colony formation after DNMT3B knockdown
in the cell line, although the Increment is not significant (Figure 5.12 B, right panel). On
the other hand, despite also showing a slight increase in the number of colony
formations after DNMT38 knockdown (Figure 5.11 A, left panel), no difference in
response to cisplatin was observed in the teratocarcinoma cell line (Figure 5.11 A, right
panel). Meanwhile, only the seminoma cell line showed a significant reduction in the
number of colonies formed after DNMT38 knockdown (p-value<O.Ol) (Figure 5.12 A,
right panel). However, this reduction does not seem to influence the cell line response
towards cisplatin as the response turned out to be similar to the control (Figure 5.12 A,
left panel).
Therefore, overall, DNMT38 knockdown does not seem to have any influence in
improving the response of most of the GCTcell lines to cisplatin.
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5.2.7. : Cell migration In GCTcell lines after Inhibition of DNA methylation
In order to analyze the role of DNA methylation, especially DNMT3B function,
in GCT cell lines migration, we used a scratch assay, also known as a wound-healing
assay. This assay determines cell migration rate by measuring the rate the cells move
and close a wound (scratch) made earlier. As in the cionogenic survival assay, this
assay also used cell lines that had been pre-treated with s-azadC or transfected with
mir29b.
5.2.7.1. : Wound healing assay In GCI' eel/lines treated with 5-azadC
All four cell lines were grown until they were 70% confluent, after which
theywere treated with a range of s-azadC concentrations for 24 hours. The next day,
cells were trypsinized and plated at 1 X 105densities into each well of a six-well plate.
Cells were left to grow until they were confluent before a scratch was made using a 10
~I filtered tip. After removing the medium, cells were washed with PBSto remove
dead cells. With new fresh medium added, cells were left in the incubator. Cell
movement was observed under the microscope every day until either the wound in
the control was closed or up to five days, whichever came first (Figure 5.13).
To measure the cells' movement, at least three locations were chosen for each
well. Pictures were taken every day and the measurement of cell movement from
these specified locations was calculated using ImageJsoftware.
One of the acknowledged drawbacks of this assay is the lack of uniformity of
the scratch in all replicates (Hulkower and Herber, 2011) which we also observed in
our cell lines. To compensate for this, we calculated the ratio between the distance on
day 1 onwards (Figure 5.18) to the distance on day O.
Distance on day 1 (2,3 etc)
Distance ratio =
Distance on day 0
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Figure 5.13: Representative diagram showing wound healing assay performed in ECcell lines. As
shown in the control Day 0, three locations were choosen for measurement. Scale bars represent
100nm in length.
5-azadC treatment was found to have a significant impact on the migration
ability of both the seminoma and the YST cell lines. In the seminoma cell line,
treatment with 30 ~M and SO~M S-azadCsignificantly impaired the cell lines' ability to
close the wound (p-value<O.Ol for 30 ~M and p-value<O.OOl for 50 ~M) (Figure S.lS
A). However by day 5, significant impairment in the migration ability only remained in
the cells treated with SO ~ 5-azadC. Meanwhile, a significant impairment in the
migration ability in the VSTcell line was observed in those cells treated with 2.5 "M (p-
value<O.Ol on day 2 and p-value<O.OOl on day 3) and 5 ~ (p-values <0.001 on both
day 2 and 3) (Figure 5.15 B). Given that the wound in the control healed on day 3, no
further observations were made beyond day 3.
On the other hand, 5-azadC treatment did not have any striking impact on the
migration ability of either the teratocarcinoma or the ECcell lines (Figures 5.14 A& B).
Although treltment with 0.75 ~ 5-azadC did show significant impairment in the
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teratocarcinoma cell line (p-value < 0.01), this was restricted to day 2 of treatment.
Beyond this day, no further significant impairment was observed.
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Figure 5.14: Wound-healing assay in 5-azadC pre-treated teratocarcinoma and ECcell lines. Bar graphs
showing the average distance ratio between the control and 5-azadC treated A) teratocarcinoma and B)
ECceil lines. Only 5-azadC treatment at 0.75 uM in teratocarcinoma showed significantly slower
movement. However, on the final day there were no significant differences seen in both 5-azadC treated
teratocarcinoma and ECceil lines .• • denotes p-value<O.Ol using paired Hest. Error bars represent
standard error of means.
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Figure 5.15: Wound-healing assay In S-azadC pre-treated seminoma and YSTcell lines. Bar graphs
showing the average distance ratio between the control and 5-azadC treated A) seminoma and B) VST
cell lines. Treatment at 30 and 50 uM significantly reduced the seminoma cell line's movement,
However, this only remained significant until day 5 in 50 uM treatment. In the YSTcell line, treatment at
both 2.5 and 5 uM signifICantly affected YSrs movement until day 3 when the control had closed up its
wound.·· denotes p-value<O.Ol while • • • denotes p-value<O.OOl using paired Hest. Error bars
represent standard error of means.
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5.2.7.2.: Wound healing assay In DNMT38 knockdown GCTcel/lines
We next asked whether DNMT38 knockdown alone is sufficient to affect GCT
cell lines' movement. Cell lines were grown until they were confluent. Once
trypsinized, they were subjected to transfection of 7 ug mir29b via electroporation at
2s0V for 10 milliseconds. Cells were left to recuperate for 48 hours before they were
trypsinized and plated at 1 X lOs densities into each well of a six-well plate in triplicate.
Once confluent, they were' subjected to a wound-healing assay as described
previously.
Significant impairment in the cells' ability to move and close up the wound as
compared to the control was only observed in the seminoma cell line (p-value<O.OOl)
(Figure 5.17 A). Migration ability in the ECand teratocarcinoma cell lines was found to
be similar for the control and the knockdown, as both were able to close the wound on
the same day (Figures 5.16 A& 8). There was a slight delay in the DNMT38 knockdown
VST cell line closing the wound as compared to the control, but this was not significant
(Figure 5.17 8).
195
A.2 1.2
i 1
B
c
• 0.1li
'V
'& 0.6
•r 0.4
•
~ 0.2
0
B
1.2
.2
i 1
S
c 0.1i
'V 0.Ii
'&
i 0.4
•
~
0.2
0
DJ D2 04
DJ D2
Figure S.16:Wound-healing assay in DNMT3B knockdown teratoma and ECcelilines.Bar graphs
showing the dist.nce ratio of A) ter~ocarclnoma .nd B) ECcell lines' movement after DNMT38
knockdown. It is clear that DNMT3B knockdown does not t\we any Imj)Kt on either cell lines'
movement. Error bars represent standard error of means.
_CadroI
-"*1",,
• CantraI
-"*1",,
196
A DIstancie ~ ___ IIound.ries.tler DfWBB IInocildown
.2 u
i 1
•u
c 0.8•
~ • • •
" 0.6
'1; • Control
••
.mlr7ug~
•
~
0
Dl D2 D3 D4
.,.
B
DIstancie be'-' YST bound8ria IItt.r DNMT38 lino clldown
u
.2
i 1
•.. 0.8c
•li 0.6
"
'1; .Control
• 0.4
.mlr7ugr
• 0.2
~
0
D1 D2 D3 D4
Figure 5.17: Wound-healing assay in DNMT3B knockdown seminoma and YSTcell lines. Bar graphs
showing the distance ratio of A) seminoma and B) YSTcell lines' movement after DNMT3B knockdown.
Only in seminoma did we observe a silnificant impairment in the cell's ability to move and close up the
wound after DNMT3B knockdown .• • • denotes p-value <0.001 using paired t-testand error bars
represent standard error of mean.
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5.3. Discussion
5.3.1. : DNMT3B as a contributing factor In YSThypermethylation
From 85 hypermethylated genes in VSTs,we identified quite a number of them
as a target for SUZ12, EZH2 and DNMT3. This is not surprising given that all these
modifiers have been found to have a role in methylation (Gopalakrishnan et al., 2009,
Karanikolas et al., 2010, Martin-Perez et al., 2010). However, by looking into the
epigenetic modifiers' expression, we found that hypermethylation seen in VSTseems
to correlate with high DNMT38 expression. This is in agreement with our collaborator's
Affymetrix expression array data done for the same cohort of samples (Palmer et al.,
2008), which showed significantly higher expression of DNMT38 in VSTs than in
seminomas. The same observation was seen in GCTcell lines where DNMT38 is highly
expressed in EC,teratoma and VST.This higher expression of DNMT38 has also been
seen in another expression array done in adult GCTs, although the majority of the
samples were ECand only two VSTcell lines were included in their analysis (Sperger et
al., 2003). This suggests that DNMT38 is the likely factor involved in hypermethylation
seen in VSTs.
In one study comparing EZH2and SUZ12protein expression in 69 tumour tissue
types, it was found that EZH2 was expressed in most of the tumours, while SUZ12
expression was restricted to a subset of tumours (Martin-Perez et al., 2010). In fact
they found that tumours which showed SUZ12 expression were usually positive for
EZH2 as well but not the other way around. Interestingly, seminoma, teratocarcinomas
and embryonal carcinomas were among the tumours which display high expression of
SUZ12. Although we did observe expression of SUZ12 In both paediatric seminoma
and VSTsamples, we did not see any significant difference between these two tumour
types in SUZ12 expression. However, this could be due to the small number of samples
Included In the assay, and furthermore we only managed to do duplicates on some of
the samples.
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5.3.2. Knockdown of DNA methyltransferase by 5-azadC and its effect on GCTcell
lines' behaviour
5.3.2.1.Cells' response towards cisplotin
Using a clonogenic survival assay, we found that in general, 5-azadC does not
have any significant impact in improving the response of GCT cell lines towards
cisplatin. Although we did see a significant improvement at a higher dosage of cisplatin
after 5-azadC treatment in the ECcell lines, we realised that this could be attributed to
5-azadC toxicity because 5-azadC treatment alone showed significant impairment in
the ability of the ECcell line to form colonies.
The same 5-azadC toxicity was also observed in the teratocarcinoma and
seminoma cell lines, although this did not have any influence on cells' response
towards cisplatin. However, we found that the teratocarcinoma cell line was the most
sensitive to cisplatin even without any prior treatment with 5-azadC or without
DNMT38 knockdown. This sensitivity towards cisplatin in teratocarcinoma cell lines
has also been reported in another study (Fenske et al., 2012). Using the MIT assay,
they found that teratocarcinoma viability is reduced to 50% after treatment with 0.7
~M cisplatin. Given that we observed total impairment in teratocarcinoma colony-
forming ability with 2.5 ~M cisplatin, this might be due to the high dosage of cisplatin
used. Adjustment to the cisplatin dosage maybe needed for future analysis.
Meanwhile, 5-azadC toxicity in the seminoma cell line leads to significant
impairment in its ability to form colonies. However this does not result in significant
improvement in its response to cisplatin. Treatments with both 2.5 IlM cisplatin alone
and 2.5 IlM cisplatin in combination with 5-azadCcaused more than a 50% reduction in
the fraction of the seminoma cell line that survived. This is in contrast to the finding by
Wermann et 01.(2010), who showed a 50% reduction in cell survival after 12 IlM
cisplatin alone or 8 IlM cisplatin in cells pre-treated with 5-azadC. This may be due to
the different method and cell density used in the experiment.
Only the VSTcell line did not show any toxicity from 5-azadC. This difference in
observation between the VST and the other GCT cell lines might have several
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explanations. First, the dosing of 5-azadC used in the experiment might be still low to
produce any toxicity in the YSTcell line. In this experiment we used the maximum
concentration of 15~M of 5-azadC. Indeed previous work performed by my colleague,
Safiah Al-Hazrnl, showed that 5-azadC toxicity in the YSTcell line was only visible after
treatment with concentrations beyond 20 11M.
The other factor that might have influenced such observations is the proportion
of replicating cells during 5-azadC treatment. 5-azadC needs to be incorporated into
the DNA before it can form a covalent bond with DNA methyltransferase and cause
DNMTs degradation (Stresemann and lyko, 2008), thus cells need to be in the S phase
to ensure optimal uptake of 5-azadC. Therefore, our method of treating the YSTcell
line with 5-azadCwhen they were 70% confluent might not provide enough replicating
cells for 5-azadC uptake. However, using the same method seems to work with the
other GCTcell lines although again this could be influenced by cells' doubling time. But
since the seminoma cell line displayed longer doubling time than the YSTcell line, we
can rule out this possibility.
lastly, the YSTcell line might be resistant towards 5-azadC. Many studies have
implicated many factors behind 5-azadC resistance. One such factor is the deficiencies
in deoxycytidine kinase (DCK). Mutation of this Dck gene has been implicated in 5-
azadC resistance in rat leukemic cell lines (Stegmann et al., 1995). Furthermore, low
DCK expression was found in five cell lines known to be resistant to decitabine (Oin et
al., 2009). Insertion of wild type DCK into one of these cell lines, Hl60, was found to
restore 5-azadCsensitivity. Although from the Affymetrix microarray data analysis, DCK
was found to be highly expressed in the YSTcell lines, we could not determine whether
gene mutation was present in the YSTcell lines. Other factors that have also been
implicated in 5-azadC resistance are a low level of the nucleoside transporter, hENTl
and hENT2(Oin et al., 2009) and a high level of cytidine deaminase (CDA) which
inactivate cytidine analogues (Rius and lyko, 2012). Although we could not get the
expression data on the nucleoside transporter, we found that the YSTcell line shares
low expression of CDA with other GCT cell lines suggesting it could not have any
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involvement in 5-azadC resistance in the YSTcell line. Therefore, further analysis needs
to be done to address this question.
Nonetheless, treatment with 5-azadC did not improve the response of the YST
cell line towards cisplatin. As mentioned before, paediatric YSTsamples and the YST
cell line showed reduced PYCARD and CASPS expression associated with promoter
hypermethylation. Indeed, reduced susceptibility to cell death has been suggested as a
mechanism of resistance to cisplatin in GCTs and other cancers (Kim et al., 2001,
Fenske et al., 2012). Furthermore, reexpression of these genes has been shown to
resensitize cancer cells to chemotherapy (Fulda et al., 2001, Ramachandran et al.,
2011). However, we did not manage to determine whether our 5-azadC treatment did
reactivate either one or both CASPS and PYCARD. Thus, it is possible that treatment
with 5-azadC did not reactivate these apoptosis-related genes which might explain why
no improvement in cisplatin response was observed in the YSTcell line. Furthermore,
Wu et al.(2010b), in their methylation analysis of four breast cancer cell lines, revealed
the down-regulation of CASPS expression due to promoter hypermethylation.
Interestingly, 5-azadC treatment could only caused CASPS demethylation in three out
of the four cell lines analysed. This suggests that the effect of S-azadCdemethylation
could be cell-type specific. It would be interesting to see whether the same
observation could be seen in the GCT cell lines, which might explain the different
effects of 5-azadCon each GCTcell line.
5.3.2.2. GCTcell lines' migration ability
In order to assess changes in the migration ability among the GCTcell lines
after 5-azadC treatment, we resorted to using the wound-healing assay. Using this
assay, we found that 5-azadC treatment leads to significant impairment in movement
in the seminoma and YSTcell lines. Neither teratocarcinoma nor ECcell lines showed
this kind of impairment after 5-azadC treatment. A previous study performed on a
choriocarcinoma cell line, BeWo, showed that 5-azadC treatment led to upregulation
of E-cadherin (CDH13) and resulted in the impairment of cell migration (Rahnama et
al., 2006). The same result was observed when forced expression of CDH13 was
performed on the same cell line. Although in our analysis there was no difference in
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the methylation levels of CDH13 in any of the four GCT cell lines, CDH13 expression
was found to be 10-fold and 13-fold higher in teratocarcinoma and EC cell lines
respectively, as compared to the seminoma and YSTcell lines. We did not analyze
whether 5-azadC treatment caused reactivation of COH13 expression in either the
seminoma or the YSTcell lines, which resulted in the migration impairment observed
in these two cell lines. However, we are currently planning to do Affymetrix gene
expression arrays on 5-azadC treated GCT cell lines. Hopefully this data will provide
some explanation of whether CDH13 or other genes might be involved in such
observations.
5.3.3. Knockdown of DNMT3B by micro RNA 29b and its effect on cell behaviour
5.3.3.1. Cells' response to cisplatin
Knockdown of DNMT3B does not seem to improve the response of any of the
four GCT cell lines towards cisplatin. Surprisingly, DNMT3B knockdown was found to
increase the resistance of the YSTcell line towards cisplatin. This is in contrast to the
finding that mir29b can up-regulate p53 levels and induce apoptosis in a p53-
dependent manner (Park et al., 2009a). Furthermore, in hepatocellular carcinoma,
McI-l and BcI-2 (anti-apoptotic proteins) were found to be direct targets for the mir-29
family (Xiong et al., 2010). In addition to that, overexpression of the mir-29 family
resulted in the release of cytochrome c, suggesting a role for the mir-29 family in
apoptosis. One possible explanation behind the increased resistance observed in the
YSTcell lines is that the effect of the mir-29 family could be cell-type-specific. Indeed,
previous miRNA expression microarrays performed on a cisplatin resistant breast
cancer cell line, MCF7/CODP, showed upregulation of the mir-29 family (Pogribny et
al., 2010). However, this study did not show whether such upregulation was directly
linked to cisplatin resistance. Therefore, it is still unclear whether overexpression of
mir-29b could also lead to increased resistance.
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5.3.3.2.GCT cell llnes' migration ability
Only the seminoma cell line showed significant impairment in its movement
after DNMT3B knockdown. Given that the seminoma cell line showed the lowest level
of methylation, knockdown of DNMT3B might have caused further hypomethylation
and caused this impairment. Indeed, DNMT3B knockdown by siRNA has been shown to
reduce cell growth and migration of the prostate cancer cell line, PC3 (Yaqinuddin et
al., 2008). However, why this observation is not seen in the other GCTcell lines is still
unclear. It could be that DNMT38knockdown alone is not enough to exert its
demethylation potential. Indeed, a study that looked at promoter demethylation after
knockdown of either DNMT1, DNMT3A or DNMT3B revealed that knockdown of all
three DNMTs gives a higher degree of demethylation as compared to single DNMT
knockdown (Chik and Szyf, 2010). Another possible explanation might be related to the
knockdown efficacy. We observed, during the course of our experiments, that the
knockdown reproducibility was inconsistent and we believe this might be due to
plasmid degradation.A recent study showed that a HDAC inhibitor, AR-42, could also
increase mir-29b level and down regulate mir-29b target genes such as DNMT38(Mims
et al., 2012). This might be another alternative approach to knockdown DNMT38 that
can be tried in the future.
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6. GENERAL DISCUSSION
6.1. YSTmethylator phenotype
Based on the data analysis performed on the paediatric GCT samples in this
study, we showed that VSTsdisplay hypermethylation at many of the gene promoter
regions analysed. Further analysis performed in a VSTcell line using a wider coverage
methylation array, Infinium 450K, validated this finding. In addition to that, this high
level of methylation displayed by the VSTcell line was found to be predominantly
restricted to CpG island regions. This finding seems to fit the criteria of CpG island
methylator phenotype (CIMP) reported in many types of cancer in the past decade
(Noushmehr et al., 2010, Weisenberger et al., 2006, Kusano et al., 2006, Marsit et al.,
2006, Toyota et al., 1999). However none of the genes identified previously as
consistent CIMP genes (MINTl, MINT2, MINT31, CDKN2A, MLH1, CACNA1G, IGF2,
NEUROG1, RUNX3, SOCS1) (lssa, 2004, Weisenberger et al., 2006) were methylated in
the VSTcell lines, while only RUNX3 was methylated in the VSTpaediatric samples. But,
since these genes were identified from studies performed in colorectal cancer; this
could mean that they were tissue specific. Instead, by correlating methylation and
expression data, we have identified six and 98 possible candidate genes in the
paediatric VST samples and the VST cell line respectively that were differentially
methylated and showed differential gene expression. Further functional analysis is
required before we can establish the function of these genes in VSTdevelopment. In
contrast to the VSTcell line, the other two GCTcell lines, the teratoma and ECcell
lines, showed different methylation at a" regions investigated. This suggests that there
might be a difference in the underlying mechanism disrupting methylation in the
development of the different GCTsubtypes.
We have identified DNMT38 as a possible factor behind the hypermethylation
observed in VSTsand other non-seminomatous GeTs, which is consistent with other
studies previously performed in GCTs.Indeed as mentioned before, DNMT38 has also
been implicated in the hypermethylation seen in other types of tumour (Beaulieu et
al., 2002, Gopalakrishnan et al., 2009, Roll et al., 2008, Van der Auwera et al., 2010).
However in our assay, DNMT38 knockdown alone does not seem to improve the
205
response of non-seminomatous GCTcell lines to Cisplatin or reduce their migration
ability. Although this still needs further analysis, we could not rule out that there might
be other factors that may contribute to the hypermethylation seen in the YSTcell lines.
Indeed, in recent years other possible candidates have been recognized to be
able to contribute to DNA hypermethylation. All these candidates (the TETfamily, AID
and the IDH family) are involved in the process of DNA demethylation. The ten-eleven
translocation (TET) family was found to modify 5-methylcytosine (5-mC) into 5-
hydroxymethylcytosine (S-hmC) in experiments performed in both human and mouse
(Ito et al., 2010, Tahiliani et al., 2009)a(Figure 6.1). Early developmental studies
performed in mouse showed that 5-mC was actively converted into S-hmC in the male
pronucleus upon zygotic development (Iqbal et al., 2011, Wossidlo et al., 2011). Given
.that Tet3 was found to be abundant during this stage, it is believed that Tet3 was
responsible for S-mCconversion into S-hmC. Furthermore, knockdown of Tet3 resulted
in an increase of S-mC, thus strengthening the role of Tet3 in the demethylation
process (Wossidlo et al., 2011). Indeed, loss of 5-hydroxymetylcytosine and TET
mutation has been reported in many types of cancer (Kudo et al., 2012, Lian et al.,
2012, Yang et al., 2012) which might implicate them in the hypermethylation
previously observed in these cancers.
Meanwhile, activation-induced cytidine deaminase (AID) is involved in DNA
demethylation by causing deamination of cytosine residues into uracil. This uracil will
then be converted into thymine by DNA repair mechanism such as base excision repair
(BER)or mismatch repair (MMR) (Figure 6.1). Although no direct involvement of AID
and methylation in cancer has been reported, a developmental study has shown that
the primordial germ cells (PGCs)of Aid mutant mice (Aid-I-)display an increase of
genome-wide hypermethylation of up to three times as compared to the wild-type
(Popp et al., 2010). In another study, rapid demethylation of POU5Fl and NANOG
observed upon fusion of mouse ESCand human fibroblast was blocked when AID was
knocked down with siRNA, which further supports the involvement of AID in
demethylation (Bhutani et al., 2010). However, given that Aid mutant mice did not
show any striking phenotype and the fact that some demethylation is still observed in
206
Aid mutant mice PGCs(Popp et al., 2010) suggest that AID may not be solely
responsible for demethylation.
P• • • in DNA Oemethyletlon Active DNA Oemethyletion
Figure 6.1: Diagram showing the process of DNA demethylation. Passive DNA demethylation occurs by
loss of DNA methyltransferases (DNMTs) activity. Active DNA demethylation could occur by two means.
The first is the conversion of S-methylcytosine (S-mC) into S-hydroxymethylcytosine (S-hmC) by ten
eleven translocation (TET) family (blue). This S-hmC could be further oxidized into S-formylcytosine (S-
fC) and S-carboxycytosine (S-caC). This modification will then be converted into cytosine by DNA repair
mechanism such as by thymine DNA glycosylase (TOG) or selective monofunctional uracil DNA
glycosylase q (SMUGl) (green). The second process of DNA demethylation involves the deamination of
S-mC or S-hmC into 5-methyluracil (S-mU) or S-hydroxymethyluracil (S-hmU) by activation induced
cytidine deaminase (AID) (purple). Again this modification will be repaired by TOG or SMUGl into
cytosine. Diagram adapted from Bhutani et al (2011)
In contrast to TETand AID, isocitrate dehydydrogenase (IDH) has an indirect role
in the DNA demethylation process. IDH produces a-ketoglutarate (a-KG) by catalyzing
the oxidative decarboxylation of isocitrate. However, when 'OH was mutated, this
activity was lost and replaced with a gain in the production of 2-hydroxyglutarate (2-
HG) (Dang et al., 2009). This 2-HG was found to competitively inhibit the activity of a-
KG-dependent dioxygenases which include the TETfamily demethylation activity. This
will result in reduced TET enzymatic activity and leads to DNA hypermethylation.
Indeed, IOH mutation has been reported in many types of cancer (Marcucci et al.,
2010, Turcan et al., 2012, Wang et al., 2012, Van et al., 2009) and was found to lead to
a CpG island methylator phenotype (CIMP) in leukemia, glioblastoma and glioma
(Figueroa et al., 2010a, Noushmehr et al., 2010, Turcan et al., 2012). However, to date
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no IDH mutation has been reported in GCTs,but given the YSTsshowed CIMP feature,
it would be interesting to see whether YSTsharbour IDH mutation that could lead to
such a feature.
A widely accepted current model of germ cell tumourssuggests that carcinoma
in-situ (CIS) are the progenitor cells for seminomas and EC, in which the latter can
further differentiate into teratomaor yolk sac tumour(looijenga et al., 1999)(Figure 6.2
A). However, our analysis using Infinium methylation arrays revealed that while ECand
teratoma cell lines share similar methylation profiles, the seminoma and YSTcell lines
displayed distinctly different methylation patterns. However, the similar methylation
profile observed between ECand teratoma cell lines could be because the latter cell
line is in fact an EC. Despite this, our data still clearly suggest a different lineage
relationship for these GCTsubtypes in which YSTis in a distinctly different branch from
ECand teratoma (Figure 6.2 B). Therefore, previous reports of seminomas recurring as
YSTor teratoma(Wong et al., 2010, Kamoshima et al., 2008), or teratoma recurring as
seminoma or YST (Czirjak et al., 1992, Utsuki et al., 2007) might be due to either
acquired or disruption of methylation in the tumour cells.
A G-G • 01 /1\0
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Figure 6.2: Model of GCTdevelopment. A) In the current model, carcinoma in-situ (CIS)is believed to be
the progenitor cell for seminoma and EC.EClater could differentiate into teratoma or YST.B) Distinct
methylation profile observed from our Infinium analysis suggests that each subtype of GCThave
different lineages. Therefore, subsequent methylation in the CIScould give rise to any subtype of GCTs.
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6.2. Clinical application 0/DNAmethylation
From our studies, it is possible to postulate that DNA methylation plays a role in
GCTsdevelopment. like many other tumours with aberrant methylation, application of
DNAmethylation in a clinical setting might also benefit patients diagnosed with a GCT.
Two areas of DNA methylation that have been widely studied are the use of DNA
methyltransferase inhibitors in cancer therapy and the application of hypermethylated
genes as therapeutic markers.
6.2.1. : DNA methylation in cancer therapy
As mentioned in the previous chapter, 5-azacytidine (5-aza) and 5-
azadeoxycytidine (5-azadC) have been well recognized for their use in epigenetic
therapy by inhibiting DNA methyltransferases. However, their early use in clinical trials
has been limited by toxicity '(Kantarjian et al., 2003, de lima et al., 2003) which is
believed to be due to high dosage of the drug used in these trials. Indeed, subsequent
clinical trials that adopted lower doses of 5-aza or 5-azadC elicited a much better
responses.
The better response seen at lower dose might be due to the interesting
pharmacodynamics of both drugs. In studies performed in acute myeloid leukemia
(AML) cell lines, both 5-aza and S-azadC showed depletion of DNMTl level at low
concentration (1 J,lMfor 5-aza and 100 nM for 5-azadC)and hypomethylation of repeat
elements at even lower concentration (300 nM for 5-aza and 30 nM for 5-azadC)
(Hollenbach et al., 2010, Qin et al., 2007). Furthermore, these groups also showed that
the hypomethylation effect of both drugs diminished at higher concentration (3-10
J,lM). This suggests that higher dosage of 5-aza and 5-azadC does not have any
therapeutic value and may expose patients to toxicity.
Both 5-aza and 5-azadC have been clinically proven to benefit myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML) patients. Clinical trials have shown
that treatment with S-aza or 5-azadC alone could benefit the patients as they require
less red blood cell transfusion and showed improvement in outcome and overall
response such as reduced duration of hospitalization and less severe side-effects as
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compared to the conventional therapy (Fenaux et al., 2010, Fenaux et al., 2009, Lyons
et al., 2009, Kantarjian et al., 2006, Kantarjian et al., 2007, Lubbert et al., 200B).
Meanwhile, clinical trials in solid tumours are mostly performed with a combination of
chemotherapy. There has been quite a mixed result from these trials. $chwartsmann et
al.(2000} in their combination of $-azadC and cisplatin trial in non-small cell lung
carcinoma showed no improvement in the antitumor activity with two patient
experiencing minor regressions. Recent trials using a much lower dosage (ranging from
10-90 mg/m2) however have shown quite a promising result with almost 30% of
patients showing partial response or stable disease for more than 4-6 months (Fang et
al., 2010, George et al., 2010, Appleton et al., 2007, Pohlmann et al., 2002).
Meanwhile, trials that used 5-aza or 5-azadC in combination with HDAC
inhibitors did not seem to produce a significant result. In one trial, addition of sodium
phenyl butyrate to 5-aza only showed a small benefit but with lower toxicity in patients
with refractory solid tumours (lin et al., 2009). In addition to this, a trial conducted in
acute myeloid leukemia showed that addition of valproic acid to 5-azadC therapy did
not contribute to patient improvement (Blum et al., 2007). In fact addition of low dose
valproic acid led to encephalopathy in three patients.
6.2.1.1. Genome-wide demethylating effect
One of the concerns of treatment using 5-aza or 5-azadC is that it might cause
the activation of unwanted genes or genome instability. Indeed, a previous study in
mouse NIH/3T3 fibroblast has revealed that demethylation at gene promoter regions
only occured at low concentration (0.1-1 j.lM) (lim et al., 20lO). In contrast,
demethylation of repetitive elements, minor satellite repeats and endogenous C-type
viruses occured at a wider concentration range (0.1 - 5 j.lM) which overlaps those for
gene promoter demethylation. Thus, there might be an increased risk of activating
unwanted elements while aiming for promoter demethylation. In addition to that,
studies performed in animal and cancer cells have shown that disruption of DNA
methyltransferase has the tendency to cause genomic instability and even induced
tumour formation (Gaudet et al., 2003, Karpf and Matsui, 200S).
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Myelodysplastic syndrome (MDS) patients treated with s-azadC was found to
display demethylation of chromosome 1 satellite 2 sequences (Mund et al., 2005).
Furthermore, in a clinical trial, patients treated with s-azadC were found to have an
increased level of demethylated MAGE1A after 8 days of treatment (Appleton et al.,
2007). However, this level returned to its initial level after 22 days.
Although all these studies imply the risk associated with the demethylating
agent, until now no study has been conducted to investigate whether such
demethylation effects will expose patients to an adverse outcome in the long term.
Furthermore, the animal study that showed hypomethylation induced tumour were
performed in Dnmtl hypomorphic mice which continuously expressed a low level of
Dnmtl. In contrast, the demethylation effect observed in the clinical trials were only
transient with methylation level returning to initial level within a month. Whether such
a short period of demethylation will have any prolonged effect in the patient still
needs to be investigated.
6.2.1.2. Stability issue
Meanwhile, other studies also highlighted another problem in delivering s-aza
and s-azadC. Both drugs are not stable at room temperature once dissolved in
aqueous solution. In one study, the half-life of s-aza and S-azadCsolution was found to
be reduced to 7 hours and 21 hours, respectively at 37 DC(Stresemann and Lyko,
2008). Thus, it has been recommended that these drugs have to be administered
within 15 minutes after reconstitution (Saba, 2007). Otherwise, they need to be
prepared with cold infusion solution and stored at 2-8DCfor a maximum of 7 hours.
Therefore, careful planning among practitioners is crucial to ensure optimal drug
delivery to the patient.
Another stability concern for these two drugs is their inactivation by cytidine
deaminase. This enzyme catalyze deamination of (deoxy-)cytidine into (deoxy-)uridine
and render inactivation of all cytidine analog drug which include both s-aza and 5-
azadC (Rius and lyko, 2012). In one study using a mouse model of myeloid cancer, 5-
azadC treatment managed to reduce the tumour burden in the spleen but not in the
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liver (Ebrahem et al., 2012). This observation is believed to be underpinned by the high
cytidine deaminase level found in the liver but not in the spleen. Furthermore, by
combining tetrahydrouridine, a cytidine deaminase inhibitor, with low dose 5-azadC, a
marked reduction of tumour burden was observed in the liver. This suggests the
involvement of cytidine deaminase in 5-azadCefficacy.
6.2.1.3. Development 0/new DNMTI
Given the issues surrounding 5-aza and 5-azadC in clinical settings, efforts are
being made to discover better and more tolerable demethylating agents. One of the
promising agents is zebularine. This drug is more stable than 5-aza and S-azadCsince it
can inhibit cytidine deaminase and has been shown to be well tolerated when given
orally in a mouse model (Cheng et al., 2003). In contrast to the mouse model,
zebularine oral bioavailability was found to be low when given to primates (Holleran et
al., 2005). To date, no clinical trials have been reported for zebularine, thus its clinical
value is still unclear. Another nucleoside analog beside zebularine that has been
developed is S,6-dihydroazacytidine (S,6-dihydroAza). However, despite showing
hypomethylation activity in cells, its potency is somewhat less than S-aza and this is
believed to be due to its poor incorporation into the DNA (Foulks et al., 2012).
Since nucleoside analog incorporation into DNA has been blamed for its
toxicity, researchers have tried to look into alternative demethylating agents in non-
nucleoside analogs. Among the available drugs that have shown demethylation activity
are the cardiovascular drugs, hydralazine and procainamide (Segura-Pacheco et a!.,
2003). However, since other study showed that this effect was not reproducible, the
role of both hydralazine and procainamide as demethylating agents remains
controversial (Chuang et al., 2005).
Other researchers have developed new derivatives of 5-aza as a way to
improve drug uptake and escape its inactivation by cytidine deaminase. Using a short
oligonucleotide containing an azapyrimidine called 5110, Yoo et 01.(2007) showed that
this drug could inhibit DNA methylation. Although it still has similar aqueous stability
and toxicity as 5-azadC, its main advantage is its ability to inhibit cytidine deaminase.
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Another group has developed an elaidic acid derivative of 5-aza called CP-4200
(Brueckner et al., 2010). It was found that this modified form of 5-aza uses a different
cellular uptake mechanism and was found to have higher efficacy than 5-aza when
tested in human acute lymphatic leukemia cells. Despite this promising result, we still
need to wait for clinical trial data to assessits clinical value.
6.2.2. : DNAmethylation as therapeutic markers
Using DNA methylation as biomarker has gained a lot of interest due to many
factors. First, DNA methylation appears to be an early event in tumour development
and often occurs at higher number of genes as compared to the mutated genes.
Therefore, it offers the potential for much higher detection sensitivity and might be
helpful for diagnostic purposes. Furthermore with the advancement of technology,
only a small amount of DNA is needed for analysis, thus eliminating the need to take
multiple samples at one time. In addition, excess DNA can be stored for a long time
due to the stability of DNA molecules. This proves to be useful when investigation of
prognosis or drug response needs to be done since both new DNA samples (taken after
therapy or in future follow-up) and the old samples can be analysed together, thus
eliminating ambiguous results. Another interesting characteristic of DNA is that it is
accessible from a variety of sources. Tumour DNA for instance can be released into the
body fluid such as blood and urine and this will provide a non-invasive approach to
epigenetic analysis (Heyn and Esteller, 2012). Therefore, this might provide an
alternative approach to help physicians in their decision making. Some of these
markers will be discussed further below.
6.2.2.1. Diagnosis Markers
Studies that showed the presence of methylation in early-onset cancer (Shim et
al., 2003, Jin et al., 2007) suggest that DNA methylation could be used for early cancer
detection or even to identify those at risk of developing cancer later in life. Indeed, a
study showed that p16 and/or MGMT genes were methylated in all sputum samples
taken from patients diagnosed with squamus cell lung carcinoma (SCC)(Palmisano et
al., 2000). Interestingly, in half of these patients, methylation of both genes was
observed in sputum samples taken three years before they were diagnosed with SCC.
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Methylations observed in the sputums were also found to be similar in most of the
tumour samples taken from these patients. However, when expanding their study in
123 samples of high-risk and cancer-free population, they found that only two SCCs
developed after two to six years. Even though the number was low, the author
suggests that this might be because the timing of the tumour is variable and a longer
follow-up period might uncover higher numbers of SCC in this population. Thus,
methylation of p16 and MGMT might still be useful in identifying a high risk population
for SCC.Another marker investigated for lung cancer was SHOX2. Methylation of this
gene was found to be helpful in lung cancer diagnosis in situations where no conclusive
evidence from histology and cytology were found (Schmidt et al., 2010). Furthermore,
this group also found that SHOX2 methylation detected from bronchial aspirates could
differentiate between malignant and benign lung cancer. Indeed, a kit detecting SHOX2
methylation from bronchial fluid is now available for early detection of lung cancer
(Mikeska et al., 2012). Besides bronchial aspirates, another group has also shown that
SHOX2 methylation could also be detected in the plasma of lung cancer patient with
90% specificity (Kneip et al., 2011).
In colorectal cancer (CRC),two genes (SEPT9 and VIM) were shown to have
potential in CRCdiagnosis (deVos et al., 2009, Chen et al., 200S, Itzkowitz et al., 2008).
In one study, detection of SEPT9 methylation using plasma samples taken from CRC
patients was found to be quite sensitive and specific (deVos et al., 2009). However its
application in the early detection of CRCis not yet established. On the other hand, VIM
methylation in the stool was found only in the CRCpatients but not in normal tissue
(Chen et al., 2005). A further study also found that VIM methylation was highly specific
in CRC identification (Zou et al., 2011) by identifying more than 80% of CRCswith a
specifity of 95%.
Meanwhile, GSTPl methylation was shown to be the most recognized marker
for prostate cancer diagnosis. In fact, GSTPl is the only DNAmethylation marker at the
moment that has been validated in a large number of studies. Meta-analysis
performed on 30 studies has recognized GSTPl as a marker for prostate cancer with a
specificity of 9S% (Van Neste et al., 2012). In addition to that, observation of GSTP1
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methylation in the precursor lesion of prostate cancer suggests that it can also be used
as an early detection marker (Nakayama et al., 2003). Meanwhile, this marker's
specificity to prostate cancer was also able to overcome the problem faced when using
serum prostate-specific antigen (PSA), which is the conventional marker used in
diagnosing prostate cancer. This is because PSA could also be elevated in other
prostate condition such as inflammation and benign prostate hyperplasia which could
lead to false-positive result (Mikeska et al., 2012). One study has shown that
combination of both PSA marker and GSTPl methylation could generate higher
sensitivity of both markers in diagnosing prostate cancer (Sunaml et al., 2009). Beside
GSTP1, studies using combination of markers (APe, RASSF1, PTGS2, MED15 and MDR1)
has also been shown to increase the sensitivity and specificity of up to 100% in
diagnosing prostate cancer (Bastian et al., 2005, Yegnasubramanian et al., 2004).
6.2.2.2. Prognosis Marker
Two types of DNA methylation profiling have been used to study the prognostic
value of methylation biomarkers that involve either single-loci approaches or genome-
wide profiling (Heyn & Esteller, 2012). Using a single-locus approach, elevated PITX2
methylation has been found to correlate with disease recurrence with distant
metastatis in node negative and estrogen receptor positive breast cancer patients
treated with tamoxifen (Maier et al., 2007). In another study by the same group, it was
later found that the same group of patients that have elevated PITX2 methylation
should be further treated with an adjuvant therapy since patients that were not
treated with any adjuvant therapy had a higher risk of getting early metastatis and
poor survival (Nimmrich et al., 2008). This clearly showed the usefulness of
methylation biomarkers in guiding the physician in their treatment plan. Meanwhile,
PITX2 methylation was also found to be the strongest prognostic predictor in prostate
cancer patients when compared with five other biomarkers (Weiss et al., 2009). In this
study, it was found that prostate cancer patients that underwent prostatectomy had a
higher chance of recurrence eight years after surgery if they displayed higher than the
median PITX2 methylation. This finding was further validated in a multicenter study by
the same group (Banez et al., 2010) further validating PITX2 methylation as a
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prognostic marker in this group of prostate cancer patients. On the other hand, a study
comparing 51 patients with non-small cell lung carcinoma (NSClC) that had undergone
resection and had a recurrence within 40 months with 116 patients treated with the
same procedure but had no recurrence within the same period showed a distinct
methylation signature (Brock et al., 2008). They found that methylation of four
(CDKN2A, CDH13, RASSF1A and APe) out of seven genes analysed was associated with
recurrence after surgery. However, further validation in larger samples is needed
before these markers could be used in a clinical setting.
Although the single-locus approach provides a list of promising candidates, it
has been restricted to certain genes relying on previous available data. To overcome
this, genome-wide profiling has recently entered the foray in determining possible
biomarker which may not have been identified before. In a study involving childhood
acute lymphoblastic leukemia (All), methylation analysis of 406 genes were found to
be able to discriminate between T-lineage All and B-cell precursor All patients
(Milani et al., 2010). Furthermore, this group also identified 20 promising genes which
can predict relapse in ALL. Meanwhile a study performed in 37 breast cancer patients
using the Infinium HumanMethyiation4S0K Array platform found two distinct groups
with one showing a methylator phenotype (CIMP+) (Fanget al., 2011). Further analysis
of three genes (ALX4, ARHGEF7 and RASGRF2) was found to be predictive for CIMP+
groups. They found that methylation of these genes was associated with lower risk of
metastatis and have a better survival rate as compared to the CIMP- group. The
authors did not rule out that there might be other methylated genes that might be
associated with poor outcome. However, their initial analysis of three genes previously
associated with poor outcome (CDKN2A, PTPRD and BRCA1) was found to be not
methylated in the CIMP+ groups. Thus, the authors suggest that methylation analysis
of the three genes (ALX4, ARHGEF7 and RASGRF2) might be useful in future metastasis
and survival prediction in breast cancer patient.
6.2.2.3. Markers 0/drug response
The other possible contribution of methylation biomarkers is in predicting
patient response towards certain therapies. This will help physician in tailoring therapy
216
to each patient. However, at the moment only methylation of the DNA repair gene,
MGMT, has been well-studied and shown to be a promising tool to predict response
towards alkylating agents in a clinical setting. In one study, glioma patients treated
with cisplatin and carmustine were observed to have a significant increase in overall
survival and progression-free survival if they showed methylation of MGMT(Esteller et
al., 2000a). The same observation was made by the same group when a similar
approach were applied in B-celllymphoma patients treated with multiple drugs which
included cyclophosphamide (Esteller et al., 2002). However, since both studies involves
multiple drugs, it cannot be certain whether the survival observed could also be due to
patient response to other drugs. Nonetheless, another study performed in
glioblastoma patients clearly showed the potential of MGMT methylation as a
response marker to alkylating agents (Hegi et al., 2005). In this study, glioblastoma
patients were randomized to receive either radiotherapy alone or radiotherapy with
temozolomide as an adjuvant therapy. They found that patients with MGMT
methylation and receiving both radiotherapy and temozolomide had significantly
higher median survival compared to those receiving only radiotherapy. On the other
hand, no different in response were observed in both arms of treatment in patient
with unmethylated MGMT suggesting no benefit in adding temozolomide to
radiotherapy in this group of patient.
Beside MGMT, BRCAl methylation in breast cancer patients which display lack
of expression of ERBB2, estrogen receptor and progesterone receptor was found be
associated with a better response towards cisplatin (Silver et al., 2010). Meanwhile,
methylation of WRN and UGT1Al were found to be associated with increased
sensitivity towards irinotecan, a topoisomerase inhibitor, in CRC patient and CRC cell
lines (Agrelo et al., 2006, Gagnon et al., 2006). However, unlike MGMT, further
validation needs to be conducted before the true potential of these genes can be
determined.
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6.2.2.4. Biomarkers In GCTs
In comparison to other tumours, methylation biomarkers in GCTsare still in
their infancy. Despite this, the contrast in the methylation pattern between seminoma
and non-seminomas shown in our data and others might be useful in current clinical
settings in distinguishing these two types of GCTs.However, for other clinical purposes
mentioned earlier, there is still a lot more work needs to be done. Our data and others
have identified a number of methylated genes that might be useful for these purposes,
but these selected genes need to be further validated in a larger number of samples
before they can be considered as promising biomarkers in GCTs.
Nevertheless, a recent study that used supernatant from testicular GCT(TGCT)
patient serum may provide an insight into a less invasive approach to current
technique that necessitates tissue biopsy. In this study that compared TGCTpatients
and healthy volunteers, CpG methylation was not only able to differentiate between
healthy volunteers and TGCTpatients, but could also identify TGCTpatients in which
conventional marker assessmentswere negative (Ellinger et al., 2009). Thus, this might
offer a better and tolerable diagnostic tool. However, this group did not find any
significant difference in methylation between seminomas and non-seminoma samples.
This contrast to our findings and other previous data might be due to their
methodology since they performed methylation analysis only on six genes (APe,
GSTP1, p14(ARF),p16{1NK),PTGS2 and RASSF1A).
6.2.2.S.lssues surrounding DNA methylation biomarkers
Despite the potential of methylation biomarkers in a clinical setting, there are
still unresolved issuesgoing from its discovery to its implementation. First, most of the
initial studies were performed in. cell lines which are known to often differ in
methylation levels as compared to primary tumours (Smiraglia et al., 2001). Thus,
genes identified from this type of study need to be validated using patient samples in
order to assesstheir reliability as a biomarker. As for those studies that used patient
samples in their analysis, most of them involved a small number of samples. Therefore,
validation needs to be performed in a larger set of samples and further validated using
a different set of samples by different laboratories. This is to ensure the reliability of
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the markers in its future usage in larger populations. In terms of GCTs,especially those
involving paediatric populations, this seems to be the major hurdle since GeTs in
children are quite rare, thus limiting the number of samples available for analysis.
Nevertheless, our analysis on the paediatric GCT samples was among the first that
incorporated both methylation and expression analysis. And of importance, through
this analysis we have identified six genes as possible candidate genes involved in YST
development.
Apart from the number of samples, available methylation data at the moment
was performed using a wide range of techniques. Since each method investigated
different region of epG islands, conflicting result might occur. In addition to that, CpG
island regions chosen in previous studies were based on the assumption that every
epG island region had a similar biological role which has been proven to be wrong
(Everhard et al., 2009). In their study, Everhard and his group found that the
methylation status of only two out of five CpG regions of MGMT analysed that
correlated well with its expression and were found to be reliable as a surrogate
markers for MGMT expression in the majority of glioblastoma patients. Indeed, a
recent study also adds to the complexity in choosing regions of interest. In their study,
Irizarry et al.observed that it was methylation at the CpGshores instead of CpG islands
that correlated well with gene expression in colorectal cancer cell lines (Irizarry et al.,
2009). Although the clinical value of CpG shore methylation is still unknown, this
finding should make researchers cautious in their interpretation of data. Furthermore
technical constraints, especially in designing peR primers, might affect decisions in
choosing the region of interest which could lead to selection of unreliable CpG regions.
However, we believe we overcome this uncertainty in our analysis by using the
GoldenGate and Infinium 4S0K methylation arrays that has been used and validated
countless times in many types of cancer (Bibikova et al., 2011, Bady et al., 2012, Clark
et al., 2012, Dedeurwaerder et al., 2011, Martin-Subero et al., 2009, McRonald et al.,
2009).
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As for GCTs, another technical issue that needs to be solved is the use of
controls. Indeed, contrasting results have been blamed on the use of different types of
control. Many studies resorted in using healthy testis samples as their controls.
However, since testes contain many different type of cells, this might have an effect on
the methylation level measurement. Others used carcinoma-in situ (CIS)samples as
the controls by arguing that CISis the precursor lesion of GCTsand thus supporting its
use as a control. However, due to low availability of CISand its inability to be grown as
a cell culture, it was not possible to use CISas a control in all studies. Furthermore,
most of the time CISis found adjacent to the tumour itself and there is the possibility
of contamination of tumour cells in the CIS,thus reducing its reliability as a control. In
our initial methylation study in the paediatric GCTsamples, we found that seminoma
methylation is similar to other somatic tissue such as the blood and buccal cells.
Indeed, previous studies have also shown that seminomas shares similar methylation
and gene expression characteristics with CIS (de Jong et al., 2008, Hoei-Hansen et al.,
2005, Eckert et al., 2008). Therefore, we used seminoma cell lines as the control for
the Infinium 4s0K methylation analysis.
6.3. Summary
In this project we set out to investigate the methylation profile of paediatric
seminomas and yolk sac tumours. The availability of a new and wider coverage
methylation array also prompted us to extend this investigation into GCTcell lines. This
was used as a means to investigate the methylation profile at regions outside of the
CpG islands which has never been reported before in GCTs. Furthermore, this study
also aimed to identify genes repressed by DNA methylation and the possible factor(s)
contributing to the hypermethylation features of the tumours.
With respect to the paediatric tumours analysed, seminomas and YSTsshowed
global hypomethylation of intergenic region, YSTswere found to be hypermethylated
at many gene promoter regions as compared to the seminomas. Strikingly, many of
these genes were found to be reproducibly hypermethylated in the YSTs,suggesting a
methylated gene signature that might be useful as a therapeutic marker in the future.
Interestingly only eight genes were found to be differentially methylated and
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differentially expressed suggesting these were possible candidates in paediatric YST
development. Meanwhile, methylation analysis performed in adult GCTcell lines also
revealed that non-seminomatous GCTcell lines are more highly methylated than the
seminoma cell line. Interestingly, different non-seminomatous GCTcell lines exhibited
distinct methylation features. While the teratocarcinoma and ECcell lines displayed
higher methylation than the seminoma cell line at all regions investigated, the YSTcell
line only showed higher methylation than the seminoma cell line at the CpG islands
and to a lesser extent at the CpG shores. This suggests a different mechanism
disrupting methylation in the different GCTsubtypes. In addition, we observed only a
weak correlation between methylation at the CpGislands or the CpGshores and gene
expression. Nonetheless, from this correlation we further identified 98 possible
candidate genes, potentially regulated by methylation that may influence YST
developments, among which are CDXl and PYCARD.
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Appendix I: Graphical representation of genes found to be differentially methylated In the VSTcell line
from the lnfinlum methylation analysis and showed differential expression in the paediatric
seminoma samples as reported by (Palmer et al., 2008). Bar graph showed probes' methylation level
for all of these genes in all four cell lines. They were ranked according to the coordinate ID given by
IIlumina Inc from smallest to the largest coordinate (left to right). Regions which these probes
correspond to were represented by colour-coded blocks at the bottom of the graph and the details were
listed in the legends.
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Appendix I: Graphical representation of the differentially methylated genes in
the YSTcell line
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Appendix II: List of 98 genes found to be methylated In the YST cell line at the CpG Islands from the
Inflnlum methylation analysis and showed differential expression In the seminoma cell line In the
Affymetrlx gene expression array. Genes with delta beta-value of more than 0.3 are considered to be
differentially methylated while genes with fold change of more than 2.0 in their expression level are
considered to be differentially expressed.
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Appendix II: List of 98 genes found to be differentially methylated and
differentially expressed at the CpG Islands in the YST cell line
Genes Infinium Methyiation450K Array Affymetrix gene expression
Beta-value Delta beta-value Fold change
SEM YST
TMEM179B 0.0798845 0.9611163 0.881231782 5.288
NAAA 0.0969456 0.9663992 0.869453578 4.216, 3.551, 0.938
RCSD1 0.1167558 0.9619279 0.845172125 4.492
LGALS3 0.0465027 0.8701882 0.823685457 27.934,1.0
CYB5R2 0.1060973 0.9278543 0.82175694 17.977
PLEKHG4 0.086451 0.9003403 0.813889264 7.164
C8orf42 0.1107351 0.9133594 0.8026243 26.467,21.137, B.038
TNFRSF10C 0.0839552 0.8710159 0.787060766 6.821, 2.124, 1.686, 1.035
DDX43 0.0984091 0.8727305 0.774321444 22.838
C13ori27 0.1578432 0.9314394 0.773596226 16.081
CXCLl4 0.1093593 0.8804395 0.77108022 16.011, 10.608, 1.048
PYCARD 0.1563432 0.9265451 0.770201975 19.669
TRIM59 0.1342966 0.8947287 0.760432096 26.334,2.112
AMPD3 0.1701624 0.9285633 0.758400967 2.07,1.142
PARP12 0.0719291 0.8297166 0.757787533 4,293
ABHD14A 0.143157 0.8950109 0.751853917 2.084
ECHDC2 0.1368952 0.881794 0.74489879 16.349,1.0
C8orf41 0.1214805 0.8650907 0.743610235 2.022
OVOL1 0.1354512 0.878592 0.743140737 8.465,2.08
C8ori84 0.2156512 0.9554388 0.739787541 3.005, 2.431, 1.0
HCG11 0.1836098 0.917161 0.73355111 2.410, 1,674
HYLS1 0.1507745 0.8780493 0.727274774 15,174
PLD6 0.1700991 0.8915967 0.721497568 2.644
RBMXL2 0.1304589 0.8504149 0.719955922 43.16,1.0
FABPS 0.1015446 0.8180639 0.716519285 32.377
MYD88 0.1391926 0.8406829 0.701490237 3.357
PRDM14 0.2030171 0.8984982 0.695481061 3.187
ACOT4 0.134381 0.810107 0,67572599 3.192
TTYH2 0.2547973 0.9260941 0.67129675 2.630, 1.117
ELM03 0.2689428 0.9246207 0.65567793 2.188
269
TNFRSFI0D 0.1472915 0.7953831 0.648091614 18.861, 1.114
GUCA1A 0.1933914 0.8300115 0.636620043 11.572,3.991,1.098
eST6 0.2872983 0.9233598 0.636061457 4.814, 1.207
TDRD12 0.3292812 0.9531206 0.62383946 84.861
SULTlAl 0.0861473 0.7074728 0.621325497 2.317, 2.150, 1.236
MEST 0.1683002 0.7882772 0.619977051 2.203
AIFM2 0.2132587 0.8161559 0.602897136 7.24,1.765
oxen 0.1427753 0.7452948 0.602519459 14.948,1.0
PPPIR14A 0.0831851 0.6819852 0.598800092 3.29
eLDN7 0.1059024 0.7034244 0.597521998 15.216
TNFRSFlOA 0.1634931 0.758585 0.595091897 7.703,2.294,1.631
RASD1 0.0932478 0.6784343 0.585186488 44.246
B3GNT7 0.3716875 0.9450635 0.57337601 12.449,8.771,1.0
SHISA3 0.0784321 0.6192666 0.540834478 42.467
LTBP2 0.3526378 0.8770516 0.524413841 3.995, 2.111
ARPelB 0.1346822 0.6525514 0.517869214 2.599
FAMl14Al 0.41635 0.9255086 0.5091586 2.23,2.049
UTFl 0.1665678 0.6748036 0.508235745 4.867
PPPIR14C 0.129667 0.6170103 0.487343291 5.908
HAS3 0.3837761 0.8696021 0.485825999 6.372, 0.921
MEl 0.1028691 0.574757 0.471887869 4.122, 2.121, 1.0
UHRF2 0.1194116 0.5886272 0.46921561 3.263
NPEPLl 0.4497619 0.9164939 0.466732 6.374,2.29,1.471, 1.073
BNCl 0.1602997 0.6189293 0.458629586 2.256,1.178
MDFI 0.1684365 0.6150566 0.446620102 2.697
INSL6 0.3001802 0.7433963 0.44321615 3.058
PLEKHGl 0.0926288 0.5329287 0.44029989 3.598
FAM150B 0.1410692 0.579992 0.438922883 2.976
ACADL 0.0815099 0.5183729 0.43686293 3.481, 1.388
CYPllAl 0.0716475 0.5045341 0.432886587 2.151
ACOXL 0.1863722 0.6179977 0.43162557 4.193,1.0
ABCA13 0.0656874 0.4961143 0.430426878 7.431,2.218,1.0
TMEM163 0.1017777 0.5205416 0.418763878 5.27,3.377
GAL 0.3242434 0.7337861 0.409542702 3.976,1.0
NAPRTl 0.5283096 0.9374048 0.409095171 3.985, 0.884
Clorf59 0.1263527 0.5338886 0.407535901 8.062
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-FAM162B 0.1573661 0.5601927 0.402826563 37.913
MEIS1 0.2153709 0.6169777 0.401606798 2.543,3.852,1.174
FHL2 0.1263811 0.52632 0.399938986 6.98
PLBD1 0.1163957 0.5158228 0.399427155 200.722, 1.131
C6orf132 0.3827052 0.7733776 0.390672384 4.84,3.14
MTLS 0.0904993 0.479908 0.389408718 3.406,1.0
AIM1 0.1596687 0.5404776 0.380808871 9.464
SECTM1 0.3139193 0.6940444 0.380125055 2.59
DLX3 0.125641 0.4989429 0.373301881 2.015
ADM 0.1110315 0.4784956 0.367464051 33.594
CPM 0.1804917 0.5473312 0.366839453 6.507,2.937,2.282, 1.249, 1.0775,
1.0
NSD1 0.3131123 0.6779757 0.364863373 3.871,2.663,2.357,1.897
GRHL2 0.1006928 0.4561325 0.355439643 13.451
RASGEFIA 0.1152567 0.47041 0.35515328 59.554, 8.652
CFD 0.2801656 0.6299344 0.349768867 2.453
NRIP3 0.1220335 0.47116 0.349126458 7.357,3.904
BASPl 0.3352765 0.6838573 0.348580787 41.935
SFN 0.5985111 0.9465868 0.3480757 15.734,5.463, 1.547 ..
ATP6V1B1 0.091879 0.437402 0.345523073 2.027, 0.999
NFE2L3 0.1316547 0.4658663 0.334211638 28.889, 20.526
CHODL 0.0760279 0.4087888 0.332760883 34.072
PGCP 0.0903661 0.4225412 0.332175078 5.643,3.188
THNSL2 0.111158 0.4407438 0.329585785 2.732,1.468
RAB11FIP4 0.1973342 0.5250608 0.327726567 3.193, 2.058, 1.636
AP1M2 0.1327458 0.4604457 0.327699879 3.119,1.616
NACAD 0.33309 0.6603458 0.327255808 2.944
WNT2B 0.126284 0.4524965 0.32621242 2.339,1.0
MAP7 0.2428566 0.5678175 0.324960939 36.396,5.695,5.561
CIQTNF4 0.4640128 0.7883627 0.324349896 3.023
LPAR2 0.273576 0.5902439 0.316667924 3.243, 1.589
CDH1 0.1036067 0.4076812 0.304074501 322.784,2.073
BSPRY 0.0792668 0.3833141 0.304047265 3.361, 2.043
FAM84B 0.1138834 0.4163967 0.302513294 3.179,1.412
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